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Background and Rationale: There is a well-documented practice gap in the rates at which evidence-
based smoking cessation treatments are delivered to patients in primary care settings. Multi-component 
intervention that combine practice, provider, and patient-level supports have been shown to increase the 
rates at which primary care providers deliver smoking cessation treatments to patients and increase rates 
of  smoking abstinence amongst patients. The incremental value of adjunct telephone-based smoking 
cessation counselling when delivered as part of a multi-component intervention has not been examined.  
 
Aim: The primary objective of this study was to determine whether adjunct telephone-based smoking 
cessation follow-up counselling (FC), when delivered as part of a multi-component intervention program 
within primary care clinics is associated with increases in (a) the delivery of evidence-based smoking 
cessation treatments, (b) patient quit attempts, and (c) patient smoking abstinence when compared to the 
provision  of practice and provider supports (PS) alone. The secondary objective of this study was to 
determine whether the introduction of a multi-component smoking cessation program is associated with 
increased delivery of evidence-based smoking cessation treatments by primary care providers and patient 
smoking outcomes, compared to pre-intervention rates. The study also sought to examine the association 
between patient, provider, clinic and implementation factors, and study outcomes.   
 
 Methods: A two-group, pre-post cluster randomized controlled trial was conducted. Eligible clinics were 
randomly assigned to the PS group or FC group. Both groups were supported with implementing a multi-
component intervention program that involved outreach facilitation visits, provider training, real time 




able to refer patients who smoke to a telephone-based follow-up support program for supplemental 
counselling support. An exit survey was completed with a cross-sectional sample of patients who smoked 
daily at each study clinic before and after the introduction of the intervention program, and all patients 
were contacted 4 months later to complete a brief telephone-based interview. Outcome measures included 
the rate at which evidence-based smoking cessation treatments (5As: ask, advise, assess, assist, arrange) 
were delivered to patients, the number of patients who made a quit attempt, and patient smoking 
abstinence at the 4-month follow-up. All data was analyzed using multi-level hierarchical modelling.  
 
Results: Seven family medicine clinics and 115 providers were enrolled in the study. A total of 12,585 
patients were screened, and 835 eligible patients (mean age 45.8 SD± 14.6, 41% male) who smoke 
participated in the study. Contrary to the study hypothesis, a higher and statistically significant 7-day 
point prevalence abstinence (OR 6.8, 95% CI 2.1-21.7; p=<0.01) and continuous abstinence (OR 13.7, 
95% CI 2.1-128.3; p=<0.05) rate was observed in the PS group compared to the FC group at the post-
assessment after controlling for differences in smoking cessation rates between intervention groups during 
the baseline period. The introduction of the multi-component intervention program was associated with 
higher rates of provider 5As delivery and patient quit attempts compared to baseline, with no differences 
between groups documented. The odds ratios (OR) and 95% confidence intervals (CI) for 5As delivery 
between the pre- and post-intervention assessments for both intervention groups combined were: “ask” 
(OR 1.5; 95% CI 1.1, 2.0); “advise” (OR 2.0; 95% CI 1.5, 2.7); “assess” (OR 2.1; 95% CI 1.6, 2.9); 
“assist” with cessation (OR 2.30; 95% CI 1.70, 3.12); “arrange” (OR 1.9; 95% CI 1.2, 3.0);  and “patient 
quit attempts” (OR 1.4; 95% CI 1.04, 1.94). Differences in 7-day point prevalence abstinence were not 
statistically significant between the pre- and post-intervention assessments (OR 1.5; 95% CI 0.94, 2.5). 




treatments are delivered to patients. Patient characteristics (readiness to quit, time to first cigarette, 
previous quit attempt in the last year), and the purpose of the clinic visit being for an annual health exam 
were associated with higher rates of 5As delivery.  
  
Conclusion: This is the first study to evaluate a multi-component smoking cessation intervention  within 
the primary health care setting in Canada. The study findings demonstrate that the introduction of a multi-
component intervention program in primary care settings was associated with significant improvements in 
the rates at which providers deliver evidence-based smoking cessation treatments, and increase patient 
quit attempts. The added value of adjunct telephone counselling was not evident at the 4-month follow-
up. The conclusions that can be drawn from the present study are limited by the study design and sample 
size. A larger trial is required to conclusively determine the impact of the program on long-term smoking 
abstinence and examine the importance of clinic-level variables in explaining observed differences 
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Chapter 1 Introduction to the Problem 
1.1 The burden of tobacco use in Canada  
Tobacco use in Canada has declined dramatically over the past 40 years, with the prevalence 
falling by 21% in the last decade alone to less than 19% in 2009 (CTUMS 2010). Much of the decline 
can be attributed to significant population-level policy interventions and changes in social norms 
associated with smoking in Canada. Despite the dramatic decline in tobacco use, an estimated 4.8 
million Canadians continue to smoke (18% of the population) (CTUMS 2010). This translates to 
almost one in five Canadians over the age of 12 who smoke (CTUMS 2010). 
Smoking remains the leading cause of premature morbidity and mortality in Canada 
(Makomaski Illing and Kaiserman 2004, 38-44). Each year, more than 37,000 Canadians die from 
tobacco-related illness, representing 22% of all deaths (Makomaski Illing and Kaiserman 2004, 38-44; 
Rehm et al. 2006). People who use tobacco have a 50-70% greater chance of dying from stroke or 
coronary heart disease than people who do not use tobacco (USDHHS 1984; USDHHS 2004;). 
Tobacco use is also a significant risk factor for other major causes of death in Canada including 
cancer, chronic obstructive pulmonary disease, and lower respiratory tract infections (USDHHS 2004; 
World Health Organization 2009a). Moreover, tobacco use exacts a large economic burden on the 
Canadian health care system. The total annual cost of tobacco use in Canada is estimated to be $17 
billion, which includes $4.3 billion in direct health care costs (Rehm et al. 2006). The excess lifetime 
medical costs resulting from tobacco use is estimated to range from $47,121 to $132,280 for low and 




1.2 Benefits of smoking cessation 
There is overwhelming evidence to support both health and economic benefits of smoking 
cessation. Quitting smoking reduces the excess risk of smoking-related coronary heart disease by 
approximately 50% within one year, and to normal levels within five years (USDHHS 1984; Benowitz 
2003, 91-111; Doll and Hill 2004, 1519; discussion 1533; Kenfield et al. 2008, 2037-2047). A 
significant reduction in fatal strokes is also observed within five years after cessation of cigarette 
smoking (Shinton and Beevers 1989, 789-794). Quitting smoking at any age has been shown to reduce 
the relative risk of developing lung cancer compared to continued smoking (Peto et al. 2000, 323-329). 
Doll et al. (2004) estimate that cessation at age 60, 50, 40, or 30 years will result in a gain of 3, 6, 9, or 
10 years of life expectancy, respectively, compared to continued tobacco use (Doll et al. 2004, 1519). 
Smoking cessation is also considered the “gold standard” among preventive interventions in terms of 
its cost-effectiveness (Gaziano, Galea, and Reddy 2007, 1939-1946; Kahn et al. 2008). The cost per 
life-year saved for smoking cessation is estimated to be between $2000 and $4000, thereby making it 
one of the more cost-effective preventative interventions available to clinicians (Tengs et al. 1995, 
369-390; Cromwell et al. 1997, 1759-1766; Franco et al. 2007, 71-79; Eddy et al. 2009, 241-249).   
1.3 Smoking cessation in clinical settings has superior cost-effectiveness than many 
common preventative interventions 
Smoking cessation interventions compare favourably against other preventative interventions. 
Franco et al. (2007) compared interventions for the primary prevention of heart disease using data 
from the Framingham Heart Study and found smoking cessation to be more cost-effective therapy than 
anti-hypertensives, aspirin, and statins (Franco et al. 2007, 71-79). The number needed to treat (NNT) 
to save one life among male smokers is estimated to be nine (Woolf 1999, 2358-2365). This is far 




percentage points (NNT=16), blood pressure control with dieuretics (NNT=34), mammography 
(NNT=205), papanicolaou smear (NNT=578), and pneumococcal vaccine (NNT=716). Smoking 
cessation has also been found to be of greater benefit than many secondary prevention interventions, 
including beta-blockers and aspirin use among patients with heart disease (Woolf 1999, 2358-2365). 
Kahn et al. (2008) evaluated the impact of preventative interventions on cardiovascular disease and 
found that smoking cessation is the only preventative intervention that provides a cost savings over a 
30-year follow-up period (Kahn et al. 2008, 1686-1696). 
1.4 Most people who smoke want to quit but are not accessing evidence-based 
cessation supports 
The majority (54%) of people who smoke in Ontario report intentions to quit smoking, and 
25% report serious intentions to quit in the next 30 days (Ismailov and Leatherdale 2010, 282-285; 
CTUMS 2005). It is estimated that each year, almost half of all people who smoke will make a serious 
quit attempt; however, only 4-7% are successful with long-term cessation (Zhu et al. 2000, 305-311; 
Fiore et al. 2008). There is strong clinical trial evidence that combining strategic counselling and first-
line smoking cessation medications, such as nicotine replacement therapy, bupropion, and varenicline, 
can double or triple long-term smoking abstinence (Cahill, Stead, and Lancaster 2007, CD006103; 
Hughes, Stead, and Lancaster 2007, CD000031; Stead et al. 2008a, CD000146; Cahill, Stead, and 
Lancaster 2008, CD006103; Fiore et al. 2008). However, few people who smoke are using these 
evidence-based cessation aids, with most (>80%) attempting to quit without assistance, therefore 
resulting in fewer successful quit attempts (Hammond et al. 2004, 1042-1048; Ismailov and 
Leatherdale 2010, 282-285; McIvor 2009, 21-26). Increasing access to and use of evidence-based 
cessation interventions among people who smoke is an important strategy for increasing long-term 




1.5  Family physicians are well positioned to enhance motivation to quit 
Seventy-five per cent of Canadians will visit a primary care practitioner at least once annually 
(Health Canada 1999; Jaakkimainen et al. 2006). These data are consistent with data from the Institute 
of Clinical and Evaluative Science (ICES) in Ontario, which found 76% of Ontarians under the age of 
65 and 90% of Ontarians 65 years and older saw a family physician in the last year (Health Canada 
1999; Jaakkimainen et al. 2006;). In Ontario alone, 140,000 residents will visit a primary care 
physician daily; suggesting primary care settings may provide access to a large number of individuals 
who smoke (Jaakkimainen et al. 2006; Health Canada 1999). Moreover, a family doctor’s advice to 
quit has been shown to increase the motivation to quit for a person who smokes (Pederson 1982, 71-
84; Ossip-Klein et al. 2000, 364-369; Eckert and Junker 2001, 521-526; Kreuter, Chheda, and Bull 
2000, 426-433; Fiore et al. 2008; Stead, Bergson, and Lancaster 2008b, CD000165). One large study   
found that over half of patients who quit smoking reported their practitioners’ advice to quit as having 
influenced their decision to quit “extremely” or “quite a lot” (Ossip-Klein et al. 2000, 364-369). Thus, 
physicians and other clinicians are uniquely positioned to intervene with patients who smoke and may 
play an important role in motivating a quit attempt and accelerating the quitting process.   
1.6 Smoking cessation interventions delivered in clinical settings increase long-term 
smoking abstinence 
Two meta-analyses have been published that summarize the evidence regarding the efficacy of 
practitioner advice and counselling on smoking abstinence. The United States Department of Human 
Health Service (USDHHS) Clinical Practice Guidelines for Treating Tobacco Use and Dependence 
reported the pooled odds ratio (OR) of long-term cessation (6 to 12 months) for physician advice to 




CI 1.2-2.0] for low intensity counselling (3 to 10 minutes); and 2.3 [95% CI 2.0-2.7] for higher 
intensity counselling (>10 minutes) (Fiore et al. 2008). This is equivalent to an increase 
in the rate of cessation of approximately 2.5%, 5%, and 11.2%, respectively, compared to controls.    
A second meta-analysis published by the Cochrane Collaboration, comparing physician advice 
to controls, reported on the efficacy of minimal advice and intensive cessation interventions delivered 
by physicians (Stead, Bergson, and Lancaster 2008b, CD000165). Within the review, minimal advice 
was defined as advice provided during a single consultation lasting less than 20 minutes with up to one 
follow-up visit. Intensive intervention was considered to involve a greater time commitment at the 
initial consultation, the use of additional materials other than a leaflet, or more than one follow-up 
visit. Similar to the USDHHS guideline, the review found a significant increase in the rate of quitting 
relative risk (RR) 1.66 [95% CI 1.42-1.94] for minimal advice and RR 1.84 [95% CI 1.60-2.13] for 
intensive intervention (Stead, Bergson, and Lancaster 2008b, CD000165).   
It is important to note that only a subset of these trials examined in both the USDHHS and 
Cochrane review were conducted in the primary care setting. A secondary analysis of only those trials 
conducted in the primary care setting found the pooled odds ratio of cessation advice was 1.85 [95% 
CI 1.64, 2.09].  
1.7 Evidence-based cessation interventions in clinical settings 
The USDHHS Clinical Practice Guidelines for Treating Tobacco Use and Dependence is a 
highly regarded and frequently cited reference manual concerning smoking cessation treatment in 
clinical settings (Fiore et al. 2008). The guideline clearly recommends five strategies as 
the basis for smoking cessation interventions in clinical settings. The so-called “five As” (5As) 
strategies are: ask (i.e., systematically identify all tobacco users at each visit); advise all people who 




making a quit attempt (i.e., set a quit date, provide self-help materials, prescribe medications); and 
arrange follow-up contact. The 5As strategies provide a structured approach for intervening with 
patients who smoke in clinical settings that are based on evidence (Fiore et al. 2008). 
 
1.8 Family doctors are not intervening with patients who smoke at optimal rates 
Despite the evidence supporting the importance of smoking cessation, there is a well-
documented practice gap in the rates at which smoking cessation is being addressed by practitioners. 
In Canada, between 40-57% of people who smoke report receiving cessation advice from their 
physicians in the previous 12 months (CTUMS 2006; McIvor 2009, 21-26). This is consistent with 
other international studies, which have reported rates at which patients are advised to quit are between 
36-95% (Gottlieb et al. 2001, 343-351; Young and Ward 2001, 14-20; Shaohua et al. 2003; Longo et 
al. 2006, 180-184; Tong et al. 2010, 724-733). Although advice to quit may be delivered at moderate 
rates, studies have shown clinicians are not as good at providing patients with assistance (i.e., 
counselling, providing self-help materials, prescribing quit smoking medications, and arranging 
follow-up) with quitting. The rates at which assistance with quitting is provided has been shown to be 
much lower at 3-20% (Gottlieb et al. 2001, 343-351; Shaohua et al. 2003; Longo et al. 2006, 180-184; 
Tong et al. 2010, 724-733). Thus, a key challenge remains to increase the number of practitioners 
adopting evidence-based cessation treatments (5As) and the degree to which these strategies are 




1.9 Strategies for increasing the rates of cessation intervention in primary care 
practice 
A systematic review and meta-analysis of the literature examining strategies for increasing the 
uptake of smoking cessation interventions in primary care practice settings was conducted to inform 
the design of the present study and recently published (see Appendix A). The meta-analysis identified 
several intervention strategies that play an important role in supporting the integration of smoking 
cessation interventions within the primary care setting (Papadakis et al. 2010, 199-213). These 
strategies include screening tools, real-time counselling prompts for providers, provider performance 
feedback, and extended adjunct follow-up counselling for patients, as well as multi-component 
interventions. 
1.9.1 Multi-component interventions are among the most promising strategies  
Multi-component interventions that combine two or more intervention strategies have been 
shown to be the most effective method for increasing provider performance in the delivery of smoking 
cessation treatments and have been shown to improve cessation rates among patients (Grimshaw et al. 
2001, II2-45; Anderson and Jane-Llopis 2004, 299-312; Fiore et al. 2008; Papadakis et al. 2010, 199-
213). Multiple large-scale controlled trials have demonstrated a significant impact of 
multi-component interventions in increasing the rates at which primary care providers deliver 
evidence-based smoking cessation treatments to patients as well as patient cessation rates. Among the 
seven trials that examined the effect of a multi-component intervention on smoking outcomes among 
patients identified in primary care settings, the pooled odds ratio compared to a control group was 2.2 




1.9.2 We do not know the optimal mix of intervention components  
 There has been considerable variability in the choice of intervention components used within 
evaluations of multi-component intervention programs. Interventions tested to date have included a 
combination of provider training (100%), screeners (40%), desktop resources (20%), performance 
feedback (40%), academic detailing (40%), adjunct counselling (50%), and cost-free pharmacotherapy 
(50%) (Papadakis et al. 2010, 199-213). Despite strong evidence to support the efficacy of multi-
component interventions, it is unclear which individual intervention components are necessary to 
produce the desired outcomes as well as the optimal mix of intervention components. Understanding 
whether higher-cost intervention strategies, such as extended follow-up counselling, are in fact 
necessary to produce increased rates of smoking cessation requires further investigation.  
1.9.3 Extended follow-up counselling 
The provision of extended follow-up counselling for patients making a quit attempt has been 
shown to increase success with quitting (Rigotti, Munafo, and Stead 2007, CD001837; Fiore et al. 
2008; Stead, Bergson, and Lancaster 2008b, CD000165; Papadakis et al. 2010, 199-213). Given the  
limited time  available in the primary care setting, linking patients to follow-up counselling conducted 
by individuals external to the practice can serve as a feasible method to “extend treatment” when 
delivered in conjunction with initial intervention provided by primary care providers (Zhu et al. 2002, 
1087-1093; Smith et al. 2009, 47-53). There is good evidence that linking patients identified in 
primary care settings to supplemental, external smoking cessation counselling is effective in 
increasing smoking abstinence, as well as increasing the frequency at which providers “arrange” 
follow-up counselling (Papadakis et al. 2010, 199-213). Borland and colleagues (2008) found referral 
of primary care smokers to a quit line doubled quit rates compared to the standard in-clinic primary 




extended adjunct counselling in addition to practice and provider-level intervention strategies; each 
trial was able to document a positive impact on smoking abstinence. However, these data are 
confounded by the fact that cost-free pharmacotherapies were also provided to patients in all but one 
of these trials.     
1.10 The Ottawa Model for Smoking Cessation (OMSC) in hospitals 
The Ottawa Model for Smoking Cessation (OMSC) is a systematic approach to the 
identification, treatment, and follow-up of hospitalized patients who smoke (Reid, Pipe, and Quinlan 
2006, 775-780).  The model was developed based on the experience of the University of Ottawa Heart 
Institute and reflects an application of a 5As approach to cessation (ask, advise, assess, assist, and 
arrange) customized for the hospital setting (Fiore et al. 2008). The aim of the OMSC is to increase the   
number of patient who smoke who achieve long-term abstinence following hospitalization. This is 
accomplished by systematically identifying and documenting the smoking status of all admitted 
patients; providing evidence-based, best practice clinical interventions for tobacco dependence, 
including counselling and pharmacotherapy; and ensuring post hospitalization follow-up. Patients are 
followed after discharge using a unique interactive voice response (IVR) mediated telephone follow-
up system (Reid et al. 2007a, 319-326). An evaluation conducted at the University of Ottawa Heart 
Institute found long-term quit rates increased by 15% (from 29% to 44%) among patients hospitalized 
for cardiovascular-related illness following implementation of the OMSC (Reid, Pipe, and Quinlan 
2006, 775-780). Based on the success of the OMSC, the program has expanded to hospitals across 
Ontario and Canada, and, in 2010, the OMSC was in place in nearly 70 hospitals in Canada. Reid et al. 
(2010) recently published an evaluation of the OMSC within nine hospitals in the Champlain District 
of Ontario. The evaluation found that the introduction of the OMSC in these community hospitals was 




month follow-up (Reid et al. 2010, 11-18). This evaluation included a more generalized patient 
population of hospitalized patients who smoke. A multi-component intervention program has been 
used to introduce the OMSC into hospitals that includes educational outreach visits, provider reminder 
systems and integration into institutional clinical processes, provider training, and ongoing audit and 




1.11 What new knowledge will be gained through the present study?  
In the present study, an adaptation of the OMSC, a multi-component intervention program 
was tested for use in busy primary settings. Similar multi-component intervention programs have been 
shown to be effective in increasing the delivery of evidence-based smoking cessation treatments by 
primary care providers as well as smoking abstinence among patients (Anderson and Jane-Llopis 
2004, 299-312; Fiore  et al. 2008; Papadakis et al. 2010, 199-213). Multi-component interventions 
tested to date have used a combination of intervention strategies to influence provider and patient 
behaviours and create supportive practice environments. Given that many primary care practices report 
relatively low rates of extended follow-up counselling to patients who smoke, it was hypothesized that 
creating stronger links to cessation interventions outside of the primary care setting, as part of a 
systems approach to cessation, may serve to increase the delivery of follow-up counselling and 
smoking abstinence among patients when delivered as part of a multi-component intervention 
program. As such, the aim of this study is to compare two interventions for integrating smoking 
cessation into routine primary care practice as measured by the proportion of patients receiving 
evidence-based smoking cessation treatments as well as patient quit attempts and smoking abstinence. 
More specifically, the study seeks to examine the incremental benefit of follow-up counselling (FC) 
for smokers compared to providing training and practice supports (PS) alone. To my knowledge, this 
will be the first randomized controlled trial that attempts to isolate the value of patient-level follow-up 
counselling in the primary care setting when delivered as part of a multi-level intervention. This study 
will also be the first published evaluation of a multi-component cessation intervention program for 
primary care tested within the Canadian health care system. The study will provide new knowledge 
that will assist with informing the design of future programs and policies related to the design and 







Chapter 2 Research Objectives and Hypotheses 
2.1 Study objectives 
1. The primary objective of this study was to determine whether adjunct telephone-based smoking 
cessation follow-up counselling (FC), when delivered as part of a multi-component intervention, 
is associated with increases in: 
a. the delivery of evidence-based smoking cessation treatments (5As) by primary care 
providers;  
b. patient quit attempts; and  
c. patient smoking abstinence compared to providing practice and provider supports (PS) 
alone. 
 
2. The secondary objective of this study was to compare before and after the introduction of the 
multi-component smoking cessation program increases in:  
a. the delivery of evidence-based smoking cessation treatments (5As) by primary care 
providers;  
b. patient quit attempts; and  
c. patient smoking abstinence.   
 
3. The study also sought to examine the association between patient, provider, clinic, and 





2.2 Hypotheses to be tested 
1. Compared to the PS group, clinics assigned to the follow-up counseling  group will: 
a. Have a greater increase in the rates at which follow-up support is arranged for patients 
compared with the PS group with no other changes in 5As delivery;  
b. an increase in the number of patients who report having made a quit attempt at the 4-month 
follow-up; 
c. a significant increase in patient smoking abstinence measured at the 4-month follow-up . 
2. The introduction of both multi-component intervention programs will be associated with increased 
provider delivery of evidence-based smoking cessation treatments, patient quit attempts, and 




Chapter 3 Considerations for the Design of Smoking Cessation 
Interventions in Primary Care  
3.1 Factors influencing patient behaviours and outcomes  
An understanding of the patient characteristics that are known to influence patient motivation 
to quit and success with smoking abstinence is relevant to the design and interpretation of findings for 
the present study. A brief summary of knowledge in this area is reviewed here.   
Older age and higher levels of education or income have been shown to predict greater success 
with smoking cessation (Coambs, Li, and Kozlowski 1992, 240-246; D'Angelo et al. 2001, 418-422; 
Hyland et al. 2004, S363-9; Lee and Kahende 2007, 1503-1509; Haug et al. 2010, 57-64). Mixed 
information has been published in regards to gender differences in regards to smoking abstinence, with 
several authors having reported greater cessation rates among males and other studies reporting no 
differences (Senore et al. 1998, 412-421; Monso et al. 2001, 165-169; National Center for Chronic 
Disease Prevention and Health Promotion. Office on Smoking and Health. 2001; Burgess et al. 2009, 
1439-1447; Haug et al. 2010, 57-64). On average, women smoke fewer cigarettes per day than their 
male counterparts and have reported greater sensitivity to adverse effects of quitting, such as 
withdrawal and weight gain (National Center for Chronic Disease Prevention and Health Promotion. 
Office on Smoking and Health. 2001; Burgess et al. 2009, 1439-1447; Haug et al. 2010, 57-64). 
Studies have also found cessation pharmacotherapies, such as nicotine replacement therapy, to be 
more effective in men than in women, which is likely associated with the lower levels of nicotine 
dependence reported by female smokers compared to male smokers (Cepeda-Benito, Reynoso, and 




literature with quit rates being higher among men who are employed and among women who are 
employed (Burgess et al. 2009, 1439-1447).   
The co-occurrence of smoking with anxiety, depression, and other mental health disorders is 
well known, with rates of nicotine dependence being three to six times higher in these individuals than 
in those with no mental health illness (Glassman et al. 1990, 1546-1549; Grant et al. 2004, 1107-
1115). A large U.S. population-based survey found that approximately half of those with drug abuse or 
dependence and 66% of individuals with alcohol abuse or dependence also smoked tobacco (Lasser et 
al. 2000, 2606-2610). Quit attempts and smoking abstinence among those with anxiety, depression, 
and other mental health illnesses, as well as substance related disorders, have also been shown to be 
lower than for the general population of people who smoke (Lasser et al. 2000, 2606-2610; Breslau 
and Johnson 2000, 1122-1127; Schorr et al. 2009, 347-354; Piper et al. 2010, 13-23).  
Nicotine dependence has also been reported as an important factor in predicting long-term 
cessation in smokers. Individuals with higher levels of nicotine dependence report fewer quit attempts 
and less success with quitting (Breslau and Johnson 2000, 1122-1127; Hyland et al. 2006, iii83-94; 
Piper, McCarthy, and Baker 2006, 339-351; Burgess et al. 2009, 1439-1447). Interestingly, those with 
higher levels of nicotine dependence or those who smoke a greater number of cigarettes have been 
shown in several trials to benefit from intervention, in particular pharmacotherapies, to a greater extent 
than those with lower levels of nicotine dependence in regards to success with quitting (Breslau and 
Johnson 2000, 1122-1127; Hyland et al. 2004, S363-9; Shiffman, Dresler, and Rohay 2004, 83-92; 
Piper, McCarthy, and Baker 2006, 339-351). The severity of withdrawal and cravings experienced 
when quitting are also associated with quit rates (Piper et al. 2008a, 94-105; Piper et al. 2008b, 747-




One of the best predictors of future smoking abstinence is a patient’s confidence (self-
efficacy) in his or her ability to quit smoking successfully (Haug et al. 2010, 57-64; Schnoll et al. 
2010). Past experience with quitting has been shown to be related to patient self-efficacy. Having 
made a quit attempt in the last year as well as the duration of past quit attempts has been shown to be 
positively correlated to success with quitting (Hyland et al. 2006, iii83-94). 
Finally, exposure to environmental smoking cues, such as others who smoke in the home, has 
been shown to be predictive of both fewer quit attempts and poorer cessation outcomes (Garvey et al. 
2000, 53-63; Lee and Kahende 2007, 1503-1509; Haug et al. 2010, 57-64). The behavioural cues, 
social persuasion, and access to tobacco products associated with regular contact with other 
individuals who smoke, tend to be associated with lower levels of self-efficacy for quitting and 
exposes the patient to a greater risk for relapse when they do quit.  
3.2 Populations reached in the primary care setting 
There has been some suggestion that primary care settings may offer exposure to only a 
limited segment of smokers most likely to seek medical advice (Jaakkimainen et al. 2006). The 
Institute of Clinical Evaluative Science (ICES) has documented important trends regarding the 
population of residents who visit a primary care physician annually. Older adults have been found to 
have more physician office visits than younger adults, with the average number of visits to a family 
physician for residents under the age 65 being four compared to seven for residents over the age of 65 
(Jaakkimainen et al. 2006). Individuals with a chronic disease, including diabetes mellitus, congestive 
heart failure, or history of heart attack, will visit general practitioners more often than the general 
population. (Jaakkimainen et al. 2006). There are also groups of residents that tend to access primary 
care services at lower rates. ICES found the lowest rates of primary care visits are reported among 




previous 12-months (Jaakkimainen et al. 2006). This is particularly significant given that men are 
smoking at higher rates than women, and in particular males aged 25-29 have the highest rates of 
smoking (39%) (CTUMS 2010). This data suggests that the primary care setting may be more likely to 
reach younger women and older adults, as well as those with an existing disease. Interestingly, there 
are relatively few differences noted in access to primary services across socio-economic groups 
(Jaakkimainen et al. 2006). Primary care clinics have access to approximately 64% of residents of any 
age, gender, or socio-economic grouping, at least once annually. There are limited data to assist with 
understanding if people who smoke are visiting primary care physicians at the same rate as people 
who do not smoke (CTUMS 2006).   
 
3.3 Factors influencing provider behaviours in primary care  
3.3.1 Mediators and moderators  
3.3.1.1 Patient-level  
Patient-level factors have been found to influence the rate at which evidence-based cessation 
treatments are delivered by providers in clinical settings. Studies have also found that patients who 
have been advised to quit smoking in the primary care setting are most often those with a smoking-
related illness (Wynn et al. 2002, 997-999; Martinson et al. 2003, 125-132; Steinberg et al. 2006, 405-
412; Azuri et al. 2009, 710-717), are older, (Lucan and Katz 2006, 16-23; Grandes et al. 2003, 101-
107), and have higher levels of education (Lucan and Katz 2006, 16-23). Patients who reported higher 
levels of nicotine dependence and previous quit attempts were also found to receive cessation advice 
more often (Grandes et al. 2003, 101-107). Advice to quit smoking has been found to be delivered less 




Increased age, higher socio-economic status, consuming more cigarettes, and having attempted to quit 
in the past 12 months are associated with receiving assistance with quitting (Browning et al. 2008, 55-
61). Steinberg and colleagues (2006) also found that women and older adults are less likely to receive 
prescriptions for cessation medications (Steinberg et al. 2006, 405-412).    
3.3.1.2 Practitioner-level 
The delivery of cessation advice has been found to occur at higher rates when the physician 
reports high levels of self-efficacy to counsel patients (ie., providers’ beliefs about their capabilities to 
effectively counsel patients and/or produce effects) (O'Loughlin et al. 2001, 627-638; Schnoll et al. 
2006, 233-239). There has been mixed information regarding the influence of a physician’s age on the 
delivery of cessation interventions, with some studies indicating that younger GPs perform better 
(Ulbricht et al. 2006, 232-238), whereas other studies have concluded that older physicians are 
delivering cessation counselling at higher rates (Schnoll et al. 2006, 233-239). Referrals for follow-up 
support were more commonly arranged by female primary care providers relative to male physicians 
(O'Loughlin et al. 2001, 627-638; Schnoll et al. 2006, 233-239). Prescribing smoking cessation 
pharmacotherapies is more common among younger providers with greater self-efficacy (O'Loughlin 
et al. 2001, 627-638; Schnoll et al. 2006, 233-239).  
3.3.1.3 Practice-level 
At the level of the practice, higher rates of provider delivery of some evidence-based smoking 
cessation interventions have been found in practices that have an identified champion (Bentz et al. 
2007, 341-349), high clinic volumes, and a higher case mix of patients who smoke (Bentz et al. 2007, 
341-349), as well as a higher number of patients in the contemplation stage of quitting  (Ulbricht et al. 




3.3.2 Barriers to the delivery of cessation treatments in primary care  
It has been reported that many practitioners find it difficult to deliver cessation interventions 
in busy primary care practice environments (Gottlieb et al. 2001, 343-351; Vogt, Hall, and Marteau 
2005, 1423-1431; Fiore et al. 2008). In a review of 19 studies, Vogt, Hall, and Marteau  (2005) 
reported several 
negative beliefs and attitudes associated with non-compliance with smoking cessation guidelines in the 
primary care setting (Vogt, Hall, and Marteau 2005, 1423-1431). These factors can be categorized into 
four main areas: patient, practitioner, practice, and system. The summary of barriers reported at each 
of these levels is further examined here.  
3.3.2.1 Patient-level  
  Several surveys have identified both patient resistance and a lack of motivation among 
patients as a frequent barrier reported by primary care providers to the delivery of smoking cessation 
interventions (Young and Ward 2001, 14-20; Vaughn et al. 2002, 17-31; Marcy et al. 2005, 479-487; 
Meredith et al. 2005, 929-934; Cantrell and Shelley 2009, 81).  
3.3.2.2 Practitioner-level 
Multiple surveys conducted in both Canada and internationally have documented low levels of 
knowledge (Marcy et al. 2005, 479-487; Kunzel et al. 2005, 1144-53; Twardella and Brenner 2005, 
140-145; Vogt, Hall, and Marteau 2005, 1423-1431) and self-efficacy (O'Loughlin et al. 2001, 627-
638; Vogt, Hall, and Marteau 2005, 1423-1431; Schnoll et al. 2006, 233-239) related to the delivery of 
smoking cessation counselling among physicians as barriers to the delivery of evidence-based 
treatments. In particular, a lack of skills and self-efficacy for dealing with low levels of motivation to 




efficacy and knowledge related to smoking cessation treatments reported by primary care providers 
may be the result of the lack of training provided in medical and other health professional training 
programs (Boily, Lavato, and Murphy 2006). A survey conducted by the Canadian Lung Association 
found that 18% of family physicians have had any formal training in smoking cessation counselling, 
which would be considered a low percentage (Canadian Lung Association 2003).  
Physician beliefs and attitudes are also important correlates of smoking cessation counselling 
(O'Loughlin et al. 2001, 627-638). In particular, it has been reported that many physicians consider 
smoking cessation peripheral to their role (Kunzel et al. 2005, 1144-53; Meredith et al. 2005, 929-
934; Tong et al. 2010, 724-733). Low expectations among physicians regarding the outcome of their 
counselling have also been identified as a factor limiting the delivery of cessation treatments 
(McIlvain et al. 2002, 114-119; Vogt, Hall, and Marteau 2005, 1423-1431). In addition, providers 
reported a concern regarding damage to their patient-provider relationship when addressing tobacco 
use (Vaughn et al. 2002, 17-31). 
3.3.2.3 Practice-level 
Surveys have found time constraints to be a consistent barrier to the delivery of smoking cessation 
interventions in the primary care setting (Marcy et al. 2005, 479-487; Twardella and Brenner 2005, 
140-145; Vogt, Hall, and Marteau 2005, 1423-1431). Meta-analysis data published by Vogt, Hall, and 
Martineau (2005) found 42% of physicians surveyed reported that discussions about smoking 
cessation are too time consuming (Vogt, Hall, and Marteau 2005, 1423-1431). Moreover, smoking 
cessation counselling often competes with other clinical tasks, and few organizational supports are 
typically found in primary care settings to support systematic interventions with patients who smoke 




2010, 724-733). Specifically, limitations of internal information systems for flagging, prompting, and 
performance measurement have been identified as rate limiting (Cantrell and Shelley 2009, 81). 
3.3.2.4 System-level  
Barriers have also been noted at the level of the health care system that can impede the 
delivery of smoking cessation treatments. First, primary care practice has been traditionally problem-
oriented with a focus on acute or episodic care rather than preventative care (Coleman and Wilson 
2000, 1001-1004). In this regard, smoking cessation interventions may be more frequently addressed 
when a patient presents with a smoking-related illness and/or symptoms rather than with seemingly 
healthy individuals, therefore detracting from the overall reach of cessation interventions. Second, 
many physicians report unrealistic expectations placed on them regarding the delivery of preventative 
health services (Yarnall et al. 2003, 635-641). A lack of smoking cessation experts to whom patients 
can be referred has also been cited as a barrier for involvement in tobacco treatments (Helgason and 
Lund 2002, 141-147). Furthermore, a lack of familiarity with the available community-based 
resources to help patients quit has also been cited in the literature as a barrier, and this has been 
correlated to low rates of arranging follow-up (O'Loughlin et al. 2001, 627-638; Marcy et al. 2005, 
479-487).  
The lack of provider incentives and accountabilities for the delivery of evidence-based 
smoking cessation treatments has been identified as potential impediments to the delivery of cessation 
services in primary care ( Okene et al. 1987, 237-340; Steinberg et al. 2006, 405-412; Curry et al. 
2008, 411-428; Rothemich et al. 2008, 60-68). In Ontario, where the present study was conducted, 
there are two health insurance plan billing codes to support the delivery of smoking cessation services 
by primary care providers (Ontario Ministry of Health and Long-Term Care 2009). This includes a 




$34.00 billing fee is available for follow-up smoking cessation counselling. Practices working in 
group-based models receive an additional bonus of $8.00 for smoking cessation counselling.    
 
3.4 Strategies to enhance provider delivery of smoking cessation treatments   
Several strategies have been tested with respect to their roles in increasing the uptake of 
evidence-based smoking cessation treatments by primary care practitioners as well as increasing 
smoking abstinence among patients in primary care settings. A systematic review and meta-analysis 
was undertaken to identify the impact of available controlled trial evaluations that reported on the 
impact of available strategies on the rates at which primary care providers deliver 5As treatments to 
patients as well their impact on patient smoking abstinence. The review methods and detailed results 
have been published elsewhere (see Appendix A) (Papadakis et al. 2010, 199-213). A synopsis of the 
findings are discussed here and presented in Table 1.   
 
3.4.1 Extended adjunct counselling  
Evidence was found to support the importance of linking patients who smoke, as identified in 
primary care settings, to supplemental smoking cessation counselling delivered outside of the standard 
medical appointments. Extended adjunct telephone counselling has been shown to increase smoking 
abstinence, as well as increase the frequency at which providers are arranging follow-up counselling 
(Rigotti, Munafo, and Stead 2007, CD001837; Fiore et al. 2008; Stead, Bergson, and Lancaster 2008b, 
CD000165; Papadakis et al. 2010, 199-213). The pooled odds ratio of long-term 
(> 6-months) smoking abstinence for adjunct counselling compared to controls was 1.7 [95% CI 1.5, 




Table 1: Pooled odds ratio of 5As delivery for patient-level, physician-level, practice-level, system-level and multi-




Ask Advise Assess Assist  Meds Assist Quit 
Date 
Assist   Arrange 
k OR [95%CI] k OR [95%CI] k OR [95%CI] k OR [95%CI] k OR [95%CI] k OR [95%CI] k OR [95%CI] k OR [95%CI] 
Patient-Level 
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2.9 [2.6,  3.3] 
Multi-Component 
 
7 2.2 [1.7, 2.8] 
 
6 1.8 [1.6, 2.1] 
 
7   1.6 [1.4, 1.8] 
 
3 1.9 [1.4, 2.7] 
 
5 3.5 [2.8, 4.2] 
 
4  9.3 [6.8, 12.8] 
 
1 1.2 (0.8-1.9) 
 
1 8.5 [5.1, 14.2] 
Source: Papadakis, S., et al. 2010. Strategies to increase the delivery of smoking cessation treatments in primary care settings: A systematic review and meta-analysis. Preventive 
medicine 51, no. 3-4:199-213. 
Includes studies published before January 1, 2009. 




Figure 1 presents a forest plot for the seven randomized controlled trials that reported on the 
efficacy of adjunct counselling delivered to patients identified in primary care settings on smoking 
abstinence. It is worth noting that several of these trials did not document a significant effect resulting 
from extended counselling. Many of the trials have varied in the intensity, format, and population of 
people who smoke involved. Additional research is required to strengthen evidence to support the 
value of adjunct counselling in enhancing 5As delivery; at present, the main impact appears to be on 





Figure 1: Forest plot for adjunct smoking cessation counselling delivered in the 
primary care setting compared to control group on smoking abstinence measured at 6 
or 12 months of follow-up  
 
Source: Papadakis, S., et al. 2010. Strategies to increase the delivery of smoking cessation treatments in primary care settings:  
A systematic review and meta-analysis. Preventive medicine 51, no. 3-4:199-213.  









3.4.2 Provider training  
Provider training has been shown to have limited influence on patient smoking abstinence 
when delivered in isolation (Kottke et al. 1989, 2101-2106; Lennox et al. 1998, 140). The two 
published controlled trials of training-based interventions delivered to primary care practitioners did 
not include 5As delivery as a study outcome. A review by the Cochrane Collaboration, which included 
quasi-experimental designs, found that practitioner training was associated with a positive effect on 
the rates of delivery of cessation interventions; however, only two of the eight trials were able to 
document an increase in smoking abstinence resulting from training-based interventions (Lancaster, 
Silagy, and Fowler 2000, CD000214). A second review found insufficient evidence to recommend 
provider education systems as stand-alone interventions, but did recommend provider education when 
delivered as part of other system changes such as system-prompts (Fiore et al. 2008). These findings 
are consistent with a review by the   
Cochrane Collaboration regarding the efficacy of educational meetings on a broader array of 
professional practice areas and health outcomes that found training-based interventions alone are not 
likely to be effective for changing complex behaviours (Forsetlund et al. 2009, CD003030). Thus, 
evidence would suggest training is necessary, but not sufficient to achieve meaningful influence on 
key smoking outcomes.  
3.4.3 Provider performance feedback  
Two trials evaluated the efficacy of audits and practitioner feedback on performance in the 
delivery of smoking cessation treatments as compared to peer-established benchmarks (Andrews et al. 




“asking” or “advising” compared to controls (Bentz et al. 2007, 341-349). Andrews and colleagues 
(2001) were not able to document an increase in rates or “asking” or “advising”; however, they did 
show an increase in rates of “assisting” and “arranging” follow-up compared to controls (Andrews et 
al. 2001, 415-421). A review that included a broader array of preventative interventions delivered in 
primary care settings documented a small to moderate benefit of performance-feedback on provider 
behaviours, with the greater effectiveness observed among providers with low baseline compliance to 
the recommended practice and among those trials in which feedback was delivered more intensively 
(Jamtvedt et al. 2006, CD000259). Further research is required to better understand the possible 
impact of performance-feedback on 5As delivery and also on rates of smoking cessation.  
3.4.4 Practice supports  
Screening systems such as waiting room screeners and the inclusion of smoking status on the 
clinic vital signs stamp have been found to be effective in increasing the rates of “asking” and 
“advising”, but no effect was documented in the rates at which other 5As strategies are delivered by 
primary care providers (Papadakis et al. 2010, 199-213; Rothemich 2010, 367-374; Seale et al. 2010, 
18). These findings suggest screening tools must be coupled with other strategies as part of any 
systematic approach to addressing smoking.   
Real-time provider prompts have been found to increase the delivery of evidence-based 
smoking cessation by primary care providers. Dubey and colleagues (2006) looked at the effect of a 
one-page reminder checklist that prompted practitioners to provide evidence-based recommendations 
for preventive interventions and found a significant increase in the rate at which cessation “assistance” 
was documented in patient charts (Dubey et al. 2006, 44). Milch et al. (2004) found that an expanded 
screener, which included five questions for assessing patient smoking status, readiness to quit, and 




abstinence (Milch et al. 2004, 284-294). Evidence from four trials found electronic medical-record 
(EMR) prompts increased the rates at which practitioners are “asking” about smoking status [OR 1.65; 
95% CI 1.4, 1.9] (Weingarten, Bazel, and Shannon 1989, 120-124; Bonevski et al. 1999, 478-486; 
Frank, Litt, and Beilby 2004, 87-90; Szpunar et al. 2006, 665-673). Furthermore, evidence from a 
smaller pool of trials was also found to support the value of EMR prompts on the delivery of the other 
5As strategies in primary care clinic settings. Further research is required to confirm the added value 
of EMR prompts in increasing smoking outcomes.  
3.4.5 Outreach facilitation and academic detailing 
Outreach facilitation or academic detailing is a form of educational outreach in which 
intervention is provided to practitioners in their offices by a trained health care provider to support 
quality improvement in a particular area of practice (Goldstein et al. 2003, 185-196). A single 
controlled trial has been published that examined the efficacy of an academic detailing intervention on 
smoking cessation in the primary care setting. The intervention included visits to the clinic during 
which support with developing a quality improvement plan, support facilitating changes to the 
practice, and feedback and monitoring during implementation of practice changes was addressed 
(Yano et al. 2008). The study documented a significant impact on rates of “advising”. A small 
observational pilot study involving four primary care clinics found an outreach facilitation intervention 
for supporting the uptake of tobacco control guidelines was acceptable to primary care providers and 
resulted in improvements in the delivery of smoking cessation treatments to patients (Swartz et al. 
2002, S38-S44). Although there is limited experience with outreach facilitation in tobacco control, 
there is a significant body of evidence to support the efficacy of outreach facilitation in increasing the 




Goodwin et al. 2001, 20-28; Lemelin, Hogg, and Baskerville 2001, 757-763; O'Brien et al. 2007, 
CD000409; Hogg et al. 2008, 40-48; Hogg et al. 2008, 40-48). 
3.4.6 Financial incentives 
Two randomized controlled trials examined the impact of financial incentives for practitioners 
within the primary care setting. Roski et al. (2003) found no effect on smoking abstinence rates was 
achieved by providing providers with a performance bonus for achieving performance targets for 5As 
delivery, but they did document a small increase in the rates at which providers “asked” patients about 
smoking status (Roski et al. 2003, 291-299). A second trial found incentives increased the rates at 
which providers referred patients to a quit line (An et al. 2008, 1993-1999). This finding supports 
reports by previous authors that financial incentives alone do not address the barriers to delivering 
cessation intervention in primary care practice and, as such, are insufficient to transform outcomes of 
interest (Coleman et al. 2001, 435-436; Coleman 2010).  
3.4.7 Cost-free cessation medications 
No published studies have examined, in isolation, the provision of cost-free medication to 
patients in the primary care setting. Several multi-component interventions included cost-free NRT in 
addition to other interventions and are described below (Grandes, Cortada, and Arrazola 2000, 803-
807; Katz et al. 2002, 293-301; Young, D'Este, and Ward 2002, 572-583; Katz et al. 2004, 594-603; 
Twardella and Brenner 2007, 15-21;). 
3.4.8 Multi-component interventions  
Multi-component interventions appear to hold the most promise for influencing practitioners’ 




controlled trials have demonstrated an impact on physician behaviours and patient cessation rates. Ten 
studies involving 13,831 patients were identified that evaluated multi-component interventions. The 
pooled OR calculated for multi-component interventions compared to control for provider 
performance showed significant increases in 5As delivery within intervention practices: “ask” [1.79, 
95% CI 1.6, 2.1], “advise” [1.6, 95% CI 1.4, 1.8], “assess” [1.9, 95% CI 1.4, 2.7], “assist” with 
medications [3.45, 95% CI 2.8, 4.2], “assist” with setting a quit date [9.3, 95% CI 6.8, 12.8], and 
“arrange” [8.5, 95% CI 5.1, 14.2] (Papadakis et al. 2010, 199-213). The pooled OR of smoking 
cessation calculated for a multi-level intervention compared to control is 2.2 [95% CI 1.7, 2.8] 
(Papadakis et al. 2010, 199-213). The forest plot for smoking abstinence among identified controlled 
trials of multi-component interventions in the primary care setting is presented in Figure 2. These 
findings are consistent with an earlier review that found that multi-component interventions, which 
combine education and practice-based supports, to be more effective than single component programs 
involving either education or practice-based approaches alone (Anderson and Jane-Llopis 2004, 299-
312).   
 
Figure 2: Forest plot for multi-component intervention program delivered in primary 
care settings compared to control group on smoking abstinence measured at 6 or 12 






Source: Papadakis, S., et al. 2010. Strategies to increase the delivery of smoking cessation treatments in primary care settings:  
A systematic review and meta-analysis. Preventive medicine 51, no. 3-4:199-213. 
Includes studies published before January 1, 2009 
 
            All of the multi-component interventions identified in the review employed between two and 
six sub-component strategies within the intervention. The two trials that used only two intervention 
components produced ORs for smoking abstinence of less than 2.0; those that employed three or more 
components resulted in ORs for smoking abstinence between 2.8 and 6.4. There was considerable 
variability in the components evaluated within the multi-component intervention models (see Figure 
3).  
Figure 3: Overview of the intervention components used within multi-component 




Source: Papadakis, S., et al. 2010. Strategies to increase the delivery of smoking cessation treatments in primary care settings: 
A systematic review and meta-analysis. Preventive medicine 51, no. 3-4:199-213. 




3.5  The role of behavioural theory in guiding intervention design  
Clinical practice is a form of human behaviour and, as such, theories of human behaviour may 
provide a basis for developing a scientific rationale for the choice of intervention that would be most 
useful in influencing primary care providers’ behaviours. Two behavioural theories (Socio-Ecological 
Theory and Social Cognitive Theory) and one adoption theory (Diffusion of Innovation) were selected 
to guide intervention design. These theories have been rigorously evaluated and assist with examining 
behaviour in terms of factors amenable to change (Glanz, Rimer, and Lewis 2002). Systems theory 
was also used to inform intervention design. Systems theory has been shown to be useful when 
designing interventions in complex settings such as that encountered in primary care practice (Plek 
2000, 309-17). These theoretical perspectives are examined here with respect to their roles in 
informing the design of interventions to influence primary care practitioners’ behaviour in the delivery 
of evidence-based smoking cessation treatments. 
3.5.1 Ecological theory  
Ecological theory suggests that behaviours are affected by multiple levels of influence, each of 
which can positively or negatively influence individuals (Bronfenbrenner 1976). Figure 4 depicts a 
multi-level perspective on key sources of influence on smoking cessation in primary care. This model 
has been adopted from the model originally introduced by McLeroy and colleagues (McLeroy et al. 
1988, 351-377). The figure depicts five levels of influence that affect a physician or other health 
provider’s behaviour. These levels include: (1) patient-level (interpersonal); (2) practitioner-level 




factors); and (5) socioeconomic and political factors (exo-system). It is hypothesized that a multi-level 
intervention will have greater impact on smoking behaviours than focusing on one particular level by 
itself (Emmons 2000, 242-266; Sallis and Owen 1999, 404-424). According to ecological theory, in 
order to maximize desired behaviours, interventions must be organized to positively affect the multiple 






Figure 4: Ecological model: Levels of influence on primary care provider behaviours 










3.5.2 Social cognitive theory 
Bandura’s Social Cognitive Theory (SCT) suggests that personal factors, behavioural factors, 
and environmental factors interact to produce human behaviour (Bandura 1986). SCT has an important 
role to play in the design of interventions that target individual level behaviour change and can be 
useful in identifying modifiable factors associated with the desired behaviour that should be targeted 
as part of the intervention program. According to SCT, physician and/or patient behaviour is mediated 
by cognition, and that important determinants of behaviour are: behavioural capabilities (knowledge 
and skill), outcome expectations (anticipated outcomes of a behaviour), expectancies (value one places 
on the outcome), self-efficacy (confidence in the ability to perform the behaviour), and perceived 
environmental facilitators and impediments (Bandura 1986; Glanz, Rimer, and Lewis 2002). Applying 
SCT to practitioner behaviours suggests that practitioners are most likely to engage in smoking 
cessation interventions if they believe it is important that they do so, if they believe they are capable of 
doing so, if they believe they will have a positive effect on patients’ smoking cessation, if they have a 
supportive environment, and if they are rewarded for doing so. Self-efficacy, one’s confidence in 
performing a particular behaviour, is considered within SCT to be the most important personal factor 
in behaviour change (Bandura 2004, 143-64). Self-efficacy is primarily determined by one’s personal 
experience with the behaviour or other similar behaviours. There are several suggested strategies for 
increasing self-efficacy for a desired behaviour: (1) skills training; (2) mastery experience (learning 
from doing); (3) setting incremental goals (breaking behaviours down into small steps to maximize 
success); (4) behavioural contracting (being specific about the behaviour change); (5) modelling or 
vicarious experience (learning from others); and (6) social persuasions and environmental supports 




3.5.3 Diffusion of innovation theory 
Roger’s diffusion of innovations theory provides insight into how best to support wide 
dissemination of an innovative program such as the delivery of smoking cessation interventions in 
primary care (Rogers 2003). Diffusion theory can serve to assist with designing the phases of the 
diffusion process from innovation development, through to matching interventions to environmental 
context, and integrating smoking cessation activities into the routines of practitioners (Oldenburg and 
Parcel G. 2002). The theory identifies the important factors to consider in the diffusion process as the 
characteristics of the intervention, messenger, adopter, system linkages, organizational context, and 
broader environmental context. Rogers also emphasized the importance between the fit between the 
intervention and the environmental context. According to the theory, there are several key factors that 
serve to influence the speed at which an innovation will be adopted and diffused. These factors can be 
used to guide the selection of possible intervention approaches to maximize appeal and speed of the 
innovation’s diffusion in the target population. Innovations that are most likely to be diffused rapidly 
are those that are least complicated to implement (complexity), provide an advantage over the existing 
practice (relative advantage), are most compatible with the intended audience’s needs and environment 
(compatibility), can demonstrate tangible results (observability), and can be tried on an experimental 
basis (trialability).    
3.5.4 Complexity Theory  
Primary care practices have been described in the literature as “complex organizations” 
because they consist of collections of individuals that have the freedom to act in ways that are not 
always predictable and whose actions are interconnected (Litaker et al. 2006, S30-4; Miller et al. 2001, 
872-878). This is particularly true amongst group practices in which a large number of independent 




processes (Plek 2000, 309-17). Moreover, the attitudes, skills, and self-efficacy of individuals may 
differ greatly among providers in a single clinic setting, and no two clinics may operate in the same 
way, therefore making it challenging for simple “one-size-fits-all” approaches to be effective in all 
primary care settings (Tallia et al. 2003, 45-59; discussion 60-1). Complexity theory emphasizes the 
importance of adapting to the context within which a practice is situated by encouraging flexibility and 
local adaptation (Hawe, Shiell, and Riley 2004, 1561-1563; Litaker et al. 2006, S30-4). This can be 
achieved by identifying characteristics that should be considered in tailoring an interaction to a clinic 
setting or individual provider within a clinic setting (Stange et al. 2003, 296-300). Having a menu of 
tools and approaches for achieving a desired outcome is suggested for complex organizations (Hawe, 
Shiell, and Riley 2004, 1561-1563; Litaker et al. 2006, S30-4). Community organizing and 
participatory models may also be useful in tailoring intervention to complex settings. Participatory 
models involve a process by which groups are helped to identify common problems, mobilize 
resources, and develop and implement strategies to achieve goals (National Cancer Institute 2005). 
The process focuses on building consensus and capacity and involves social planning and social 
action. The involvement of key opinion leaders, expert practitioners, and end users in this process has 
been identified as an important factor in influencing success in achieving intervention goals (National 
Cancer Institute 2005).  
3.6 How theory and evidence was used to inform intervention design 
The intervention program was designed using best available evidence regarding the delivery 
of cessation interventions in the primary care settings. The conceptual model for the intervention 
program is presented as Figure 5.  The model outlines the three levels (patient, provider, and practice) 
at which the intervention was designed to intervene. Consistent with ecological theory, the 




make the required behaviour changes. Social cognitive theory (SCT) was used to further define the 
intermediary behavioural targets at the level of the practitioner and patient by ensuring the required 
cognitive factors are in place to support the desired behaviour, including self-efficacy, knowledge and 
skill, outcome expectancies, goal setting, environmental cues, and social support. Intervention 
strategies were further informed by strategies known to be effective in introducing process change in 
complex organizations 
At the level of the practice, intervention strategies were informed by strategies known to be 
effective increasing the uptake of process change in complex organizations. Using the principles of 
complexity theory and diffusion of innovations, the practice-level strategies were selected to assist 
with simplifying the delivery of the 5As strategies as a part of routine practice at the clinic 
(complexity) and create a supportive practice environment. Outreach facilitation visits were used to 
tailor the 5As delivery to each clinic’s practice setting (compatability). This process involved the 
engagement of clinic staff in the problem solving process and setting behavioural goals for health 
professionals in supporting 5As delivery. Effort was made to simplify the responsibilities of the 
physician to advising and assessing readiness of patients to quit. Effort was also made to introduce 
practice-level supports to assist with the delivery of the remaining 5As (ask, assist, arrange follow-up 
support). This included specific roles and responsibilities for allied health professionals, flow charts, 
and the introduction of real time prompts and patient resources. Audit and feedback was provided to 
the clinic task force and staff as a call to action, and the feedback was provided during the early 
stages of implementation to assist with identifying gaps between targets and actual performance by 
clinic staff (observability and relative advantage).  
At the level of the provider, three strategies were used to support the delivery of the 5As. 




training, and audit and feedback. The intervention strategies were designed to enhance provider self-
efficacy, knowledge and skill, outcome expectancies, and provide both practice targets (goals) and 
environmental cues and supports for the delivery of the 5As tobacco cessation treatments to all 
patients at all scheduled non-urgent visits.   
At the level of the patient, the intervention aims to generate more supported quit attempts by 
patients identified in the primary care setting. This is achieved by having primary care providers 
systematically identifying and delivering cessation advice during teachable moments in order to 
motivate a patient to make a quit attempt and then link patients to evidence-based assistance with 
quitting (i.e. behavioural counselling and pharmacotherapy) so as to increase the likelihood of 
successful smoking abstinence.   
For practices assigned to the FC group, telephone follow-up counselling support aimed to 
support patient self-efficacy during the critical early quitting period in which risk for relapse is 
highest and assist with managing patient withdrawal and cravings. The delivery of this follow-up 
counselling support was hypothesized to result in more quit attempts and ultimately higher rates of 
smoking abstinence among patients. FC group clinics were also able to register patients not ready to 
quit smoking with the telephone follow-up program. The intent was to provide a cue to patients to 
make a quit attempt and provide more information on available supports to enhance self-efficacy. It 
was hypothesized that delivering follow-up contacts to patients not ready to quit when seen in clinic 
was to increase the likelihood that these patients would make a quit attempt relative to patients in the 
PS group.  
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• Outreach Facilitation Visits 
• Real Time Provider Prompts  
• Patient Tools  








• Training  
• Real Time Provider Prompts  












Assist with Quit Attempt 
 
i)   Provide self-help materials  
ii)  Set quit date   
iii) Discuss pharmacotherapy  
iv) Prescribe pharmacotherapy   
v) Behavioural counseling  
  
Arrange Follow-up Support 
FC Group 
Telephone Follow-up Counselling  
7 days before quit date, 3, 14, 30, 
60 days after quit attempt. 
FC Group  
Telephone Follow-up for Patients Not Ready to Quit at 30 and 60 days after visit to clinic 
Practice Level Intermediary Targets: ↑ social support, ↑ goal setting, ↑ self-efficacy, ↑ environmental cues 
 
 
Provider Level Intermediary Targets: ↑ self-efficacy, ↑ knowledge & skill,, ↑ goal setting,  
↑ outcome expectancies, ↑ social support, environmental cues 
 
 
Patient Level Intermediary Targets: 
 ↑ self-efficacy, ↑ goal setting, ↑ knowledge & skills, ↑ outcome expectancies,  





Instruction to arrange follow-up 
support for patients. No additional 
support provided.  
Active  
Smoker Use of Evidence-based Strategies Use of Evidence-based Strategies 
  








Patient Level Intermediary Targets: 
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Chapter 4 Methods 
4.1 Study design  
A two-arm pre-post cluster randomized trial design was used to compare two multi-
component interventions for integrating smoking cessation treatments into primary care practice 
routines among family medicine clinics in the Champlain District of Ontario. The study grant allowed 
for a maximum of eight clinics to be enrolled in the present study. Given that numerous trials have 
documented the efficacy of multi-component intervention programs compared to a standard-care 
control group, no control group comparator was employed in the present study. Pre-post 
measurements were used to document improvements in 5As delivery, quit rates, and smoking 
abstinence before and after the multi-component intervention program was implemented and 
comparisons between intervention groups made to isolate the incremental impact of follow-up 
counselling support delivered to FC study clinics. The study received ethics approval from the Office 
of Research Ethics at the University of Waterloo and the Human Research Ethics Board at the 
University of Ottawa Heart Institute. The Consort Flow Diagram for the study is presented as Figure 6.    
4.2 Clinic recruitment and sampling    
To be eligible to take part in the present study, clinics were required to be involved in a group-
practice (i.e., health team, family health group, or family health network) with a minimum of five full-
time physicians on staff and all physicians within the practice be willing to participate in the study. 
The criteria related to the minimum of five providers was selected to ensure adequate patient flow 
through the clinic to ensure data collection activities could be completed within the study timelines. 
Permission was granted from the Department of Family Medicine (DFM) at the University of Ottawa 
to access the distribution list for family physicians practicing in the Champlain District.  At the time of 
recruitment into the present study, the DFM was also recruiting clinics for another study in sub-
regions of the Champlain District. At the request of the DFM, only primary care practices from three 
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geographic sub-regions within the Champlain District which were not part of the DFM’s trial were 
approached about participating in the present study. A total of 15 group-based family medicine clinics 
from three sub-regions (Eastern Counties, South Ottawa, and Ottawa Central) in the Champlain 
District who had five or more physicians were invited to participate in the study in January 2009. A 
study-invitation letter and program summary was sent to the lead physicians of these clinics (see 
Appendices B and C).   
Of the 15 clinics invited to participate, two had less than five physicians practicing at the 
clinic during the study time period and were considered ineligible. An additional two clinics declined 
participation and no response was received from four of the invited clinics. Seven family medicine 
practices with 115 providers were enrolled in the study between January 2009 and April 2009. This 
represents an enrollment rate among eligible practices of 54% (7/13). All physician providers from 
participating clinics were asked to sign the study information sheet and consent form (see Appendix 
D). All practitioners at participating clinics were asked to complete a survey to assess variables of 
interest (see Appendix E). The following practitioner-level factors were evaluated: age; gender; self-
rated importance of smoking cessation; knowledge of evidence-based smoking cessation interventions; 
self-efficacy with delivering each of the 5As; and previous cessation training.   
4.3 Allocation to treatment and concealment 
Randomization occurred at the level of the practice (k) i.e., cluster. Eligible practices were 
randomly assigned (1:1) to one of two intervention groups: Practice Support (PS) or Follow-up 
Counselling (FC). Four practices were randomly assigned to the PS group, and three were assigned to 
the FC group. Randomization was performed with a table of random numbers generated by a 
researcher not involved in the study and who was blind to the identity of the practices. Randomization 
numbers were placed in a sealed envelope and opened by a representative from the practice site 
following the completion of the baseline data collection. The group assignment was verified by the 
third party researcher to verify that randomization occurred according to protocol. 
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Post-Intervention 16-week Telephone Follow-up 
k=4 Practices Completed Follow-up Assessment 
Patients Completed Follow-up Assessment (n=224/242, 93%) 
 
Loss to Follow-up, > 10 calls (n=12) 
Loss to Follow-up, contact information (n=1) 
Withdrawal (n=5) 
 
Analyzed (k=4), (n=242) 
Excluded from analysis (n=0) 
    
Post-Intervention 16-week Telephone Follow-up 
k=3 Practices Completed Follow-up Assessment 
Patients Completed Follow-up Assessment (n=155/177, 88%) 
 
Loss to Follow-up, > 10 calls (n=15) 
Loss to Follow-up, contact information (n=4) 
Withdrawal (n=3) 
 
Analyzed (k=3), (n=177) 
Excluded from analysis (n=0) 
    
Post-Intervention Follow-up Assessment  
Patients Screened (n=3241), Smokers (n=450, 13.9%) 
Excluded (n=273) 
Not meeting inclusion criteria (n=84) 
   Less than 18 years old (n=8) 
   Non-daily smoker (n=49) 
   No telephone (n=8) 
   Not able to read/write English or French (n=6) 
   Non MD/NP visit (n=13) 
Declined to participate (n=131) 
   Not Interested (n=72) 
   No Time (n=14) 
   Screener not returned (n=30) 
   Other (n=15) 
Survey not returned (n=58) 
     
 
Post-Intervention Follow-up Assessment 
Patients Screened (n=3190), Smokers (n=496, 15.7%) 
Excluded (n= 254) 
Not meeting inclusion criteria (n=66) 
   Less than 18 years old (n=9) 
   Non-daily smoker (n=25) 
   No telephone (n=5) 
   Not able to read/write English or French (n=9) 
   Non MD/NP visit (n=18) 
Declined to participate (n=129) 
   Not Interested (n=75) 
   No Time (n=20) 
   Screener not returned (n=19) 
   Other (n=15) 
Survey not returned (n=59) 
 
Patients Completed Post-Intervention Exit Interview (n=242) 
 
Patients Completed Post-Intervention Exit Interview (n=177) 
 
Pre-Intervention 16-week telephone follow-up 
Completed Follow-up (n=200/233, 86%) 
Loss to Follow-up, > 10 calls (n=15) 
Loss to Follow-up, contact information (n=7) 




Pre-Intervention 16-week telephone follow-up 
Completed Follow-up (n=166/183, 91%) 
Loss to Follow-up, > 10 calls (n=12) 
Loss to Follow-up, contact information (n=2) 
Withdrawal (n= 3), Deceased (n=0) 
 
 
Patients Completed Pre-Intervention Exit Survey (n=183) 
 
 
Patients Completed Pre-Intervention Exit Survey (n=233) 
 
Practice Support (PS) Group  
Received allocated intervention (k=4) 
Did not receive allocated intervention (k=0) 
 
Follow-up Counselling (FC) Group 
Received allocated intervention (k=3) 


































7 Practices Enrolled, 115 providers 
 
15 Practices Invited to Participate 
Randomized  
(k=7) 
Pre-Intervention Assessment  
Patients Screened (n=3573), Smokers (n=454, 12.7%) 
Excluded (n=271) 
Not meeting inclusion criteria (n=115) 
   Less than 18 years old (n=8) 
   Non-daily smoker (n=37) 
   No telephone (n=11) 
   Not able to read/write English/French (n=13) 
   Non MD/NP visit (n=46) 
Declined to participate (n=117) 
   Not Interested (n=60) 
   No Time (n=24) 
   Screener not returned (n=29) 
   Other (n=4) 














- Less than 5 physicians (n=2) 
No response (n=4) 
Declined to participate (n=2) 
 
Pre-Intervention Assessment  
Patients Screened (n=2581), Smokers (n=468, 18.1%) 
Excluded (n=235) 
Not meeting inclusion criteria (n =57) 
   Less than 18 years old (n=0) 
   Non-daily smoker (n=23) 
   No telephone (n=2) 
   Not able to read/write English/French (n=6) 
   Non MD/NP visit (n=26) 
Declined to participate (n=85) 
   Not Interested (n=64) 
   No Time (n=2) 
   Screener not returned (n=19) 
   Other (n=0) 
Survey not returned (n=93) 
 
Practice Support (PS) Group  
Allocated to intervention (k=4 practices) 
Provider (j =70) 
Follow-up Counselling (FC) Group 
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Patients and research assistants collecting data from patients were blinded to the clinic’s group 
assignment. It was not feasible to blind the outreach facilitator assigned to the clinic and members of 
the clinic staff to the intervention group assignment.  
 
4.4 Clinical framework used for the delivery of evidence-based (5As) smoking 
cessation treatments to patients  
All clinics were supported with the implementation of an adaptation of the “Ottawa Model for 
Smoking Cessation” designed for use in the present trial. Practices were encouraged to systematically 
deliver a standardized smoking cessation intervention that included:  (1) asking all patients at every 
visit about smoking status; (2) delivering clear, personalized advice to quit smoking to all patients who 
smoke and assess readiness to quit in the next 30 days; (3) providing assistance to patients ready to 
quit smoking in the next 30 days by conducting a quit plan consultation session during which a quit 
date is selected, options for quit smoking medications and instructions are discussed and prescription 
provided as appropriate, and strategic behavioural counselling to address cravings, withdrawal, and 
social-environmental factors related to quitting smoking; (4) offering patients ready and not ready to 
quit smoking follow-up support (arrange).  In order to increase feasibility of delivering all aspects of 
the Ottawa Model for Smoking Cessation, clinics were encouraged to integrate the protocol into 
existing clinic routines and to develop a team-based approach in which non-physician clinic staff 
would share the responsibility for delivering evidence-based smoking cessation treatments with 
physicians. Table 2 provides a description of the recommended intervention components to be 
delivered to patients as part of the clinics’ tobacco control protocol.  
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Table 2: Summary of the recommended patient-level intervention activities  








Ask and document 
smoking status of 
all patients  
 
30 seconds Reception or 
Triage Nurse 
-    All patients asked about current smoking status ateach 
visit, using the following two screening questions:      
     “Have you used any form of tobacco in last 7 days?”  
     “Have you used any form of tobacco in last 6 months?” 
- Recommendation to have asking and documenting of 
patient smoking status conducted by non-physician 
staff. 
 
Advise all smokers 
to quit   
  
1 minute Physician or 
Nurse 
Practitioner 
- Clear, personalized, non-judgmental advice to quit with 
offer of support with quitting delivered in 1 to 2 minutes 
by physician or nurse practitioner.   
 
Assess readiness 
to quit and support 
motivation  
 
1-3 minutes Physician or 
Nurse 
Practitioner 
- Readiness to quit assessed: “Are you willing to set a 
quit date in the next 30 days?” Yes or No 
- Provide brief 1 to 2 minutes of motivational intervention 
for smokers not ready to quit. 
- Schedule quit plan consult session for smokers ready 
to quit.  
 
Quit plan consult  
(Assist) 
 








- A 15-20 minute consult scheduled to develop a 
personalized quit plan with patients, including: 
- Select quit date;  
- Select pharmacotherapy;  
- Prepare environment and social supports;  
- Discuss management of cravings, withdrawal, 
triggers and temptation to smoke; 
- Discuss follow-up support. 
- Recommendation to have quit plan consult sessions 







Varies  Recommendation that provider arrange for follow-up 
support in accordance with best practice guidelines 2 to 4 




    
46 
4.5 Intervention comparators 
4.5.1 Practice Support (PS) Group 
 Clinics assigned to the PS intervention group were supported in implementing the 5As 
strategies using a multi-component intervention program that involved four components: (1) real time 
provider prompts and patient tools; (2) training; (3) audit and performance feedback; and (4) coaching 
and outreach facilitation visits. The intervention components were selected based on a review of the 
literature of evidence-based strategies for integrating smoking cessation into primary care settings (see 
Chapter 2). Each intervention component was designed to address a barrier that is known to limit the 
delivery of smoking cessation treatments in primary care settings. The conceptual model of the 
expected impact of each intervention component on the underlying behavioural constructs at the level 
of the patient, provider, and practice was presented as Figure 5. A description of each of the 
intervention components is provided here and summarized in Table 3.    
 
Real time provider prompts and patient tools: Practices were provided with five tools to support 
the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-
level strategy including: (1) a tobacco use survey; (2) smoking cessation consult form; (3) patient quit 
smoking plan; (4) booklet for smokers not ready to quit; and (5) clinic posters. The intervention tools 
were designed to minimize the amount of time required for clinicians to provide basic counselling on 
smoking cessation and provide real time prompts to guide the delivery of evidence-based smoking 
cessation treatments. All of the practice tools were developed for the present study and adapted from 
existing publicly available Canadian tools to meet the needs of busy primary care clinics. Clinics were 
able to adapt the tools to conform to the clinic’s tobacco control protocol. The Tobacco Use Survey is 
designed to assess the current smoking status of patients and to gather information regarding a 
patient’s smoking history and readiness to quit (see Appendix F). 
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Table 3: Summary of multi-component intervention program components  





PS FC Description 
Outreach 
Facilitation Visits  
X X -   Formation of clinic smoking cessation task force; 
-   Review of current clinic practices in the delivery of evidence-based smoking 
cessation intervention and needs assessment; 
-   Provide information and recommendations on the integration of evidence-
based smoking cessation strategies into clinical practice;  
- Facilitate development of clinic tobacco control protocol for integrating 
evidence-based smoking cessation strategies into all clinic appointments; 
- Define roles and responsibilities of clinic staff in delivering evidence-based 
smoking cessation treatments; 




and Real Time 
Reminders 
 
X X        -   Standardized smoker identification intake questions;  
-   Tobacco Use Survey;  
-   Smokers Consult Form; 
-   Patient Quit Plan for Smokers Ready to Quit; 
-   Booklet for Smokers Not Ready to Quit;    





X X - 1 to 3-hour training workshop on smoking cessation and the intervention 
program for all clinic providers (physicians, nurses, allied health 
professionals); 
- A 1-day workshop to designated clinic staff who will be responsible for 





X X - Feedback report on results of pre- and post-intervention assessments;  
- Audit and feedback of implementation activities 1 to 2 months following 













Practice Support (PS) Group:  
-   Clinics provided with guide for conducting follow-up visits with smokers 
ready to quit and recommendation made to provide 1 to 2 follow-up 
contacts over a 2-month period.   
-   No further support provided. 
 
Follow-up Counselling (FC) Group:  
- Ability to refer patients ready to quit smoking to the telephone-based 
Smoker’s Follow-up System which includes five triage calls over a 2- month 
period delivered by Interactive Voice Response System with support for 
patients struggling with their quit attempt by trained smoking cessation 
counsellors.  
- Ability to refer smokers not ready to quit to receive two automated 
Interactive Voice Response calls to reassess readiness to quit and link 
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The smoking cessation Consult Form (see Appendix G) is designed to provide clinicians with real-
time prompts for the delivery of evidence-based cessation strategies. The Quit Smoking Plan consists 
of an  
18-page booklet that is designed for clinicians to use when creating a quit plan with patients ready to 
quit smoking, including the selection of pharmacotherapy, the identification of a quit date, and 
behavioural counselling in preparation for the quit date (see Appendix H).  Posters for clinic waiting 
rooms were also provided to serve as environmental cues (see Appendix I).  
 
Provider Smoking Cessation Training: All clinic providers were invited to take part in a 3-hour 
training workshop on smoking cessation. One workshop was organized for each clinic and best effort 
made to have all or most providers who would be involved in the clinic’s tobacco control protocol 
attend.  The goal of the provider training was to increase knowledge, motivation, and self-efficacy 
regarding the delivery of evidence-based smoking cessation treatments within a busy primary care 
practice, including brief counselling and advice and pharmacotherapy. The workshop was delivered by 
the student investigator and a physician with expertise in smoking cessation who is considered a key 
opinion leader (A. Pipe). The training provided information on nicotine addiction, the importance of 
smoking cessation, an overview of available quit-smoking medications and indications for use, 
recommended methods for identifying and advising smokers to quit, assessing readiness to quit, and 
providing minimal intervention counselling for smoking cessation and follow-up support. All core 
training materials were standardized, and supplemental information was tailored to the unique needs of 
the clinic as required. During the workshop, representatives from the clinic smoking task force 
presented the clinic’s tobacco control protocol to participants and the roles and responsibilities of 
clinic staff. The workshop was accredited  
by the College of Family Physicians of Canada. Each clinic also identified one to six staff to attend a  
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one-day workshop on smoking cessation counselling. This workshop targeted staff designated to 
deliver the quit plan visits with smokers from their clinic who were ready to quit in the next 30 days. 
The training workshop provided participants with didactic training on counselling techniques using a 
motivational interviewing framework, first-line smoking cessation pharmacotherapies, and the use of 
the intervention practice tools. The workshop also provided practical experience in conducting 
counselling sessions with mock patients using a set of eight standardized patient case studies. Actors 
were used to play the role of patients who smoke during the mock patient interviews and all providers 
were guided through how to effectively conduct a quit plan visit and were provided feedback on their 
counselling techniques. A total of six 1-day workshops were delivered by the student investigator (S. 
Papadakis) and a nurse (S. Gocan) with expertise in smoking cessation.  
 
Audit and Feedback: All practices received feedback on the results of the pre-intervention 
assessment conducted within their practices (see Appendix J). This feedback included prevalence of 
smoking among clinic patients, patient-rated importance of provider advice to quit, characteristics of 
smokers, and baseline rates of 5As delivery by clinic staff. The goal of the audit and feedback was to 
increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of 
the current delivery of evidence-based cessation practices, identify areas for improvement, and 
motivate providers to deliver evidence-based treatments. The practices were provided with regular 
feedback on the design of the intervention protocol against known best practices and feedback on at 
least one audit of the practice implementation by the facilitator. Practices were also audited on 
implementation of the 5As on two separate dates during the first two months of implementation. The 
purpose of the audit was to identify any areas of the clinic protocol that were not implemented as 
planned or areas for improvement. All practices also received a feedback report on the results of the 
 
    
50 
clinic audits. Clinics also received the results of the post-intervention assessment at the conclusion of 
the study (see Appendix K). 
 
Coaching and Outreach Facilitation Visits: Each practice received one to five days of support over 
a three-to six-month period to support the implementation of the intervention components. A member 
of the investigative team served as the practice facilitator and conducted on-site visits with patients to 
support the implementation of the intervention components. The purpose of the outreach facilitation 
visits was to guide practices with the integration of evidence-based cessation practices into existing 
clinic routines, including a clinic specific tobacco control protocol. A seven-step workplan was used to 
guide the facilitation process (see Appendix L). Practices were first asked to complete a needs 
assessment that would be used to understand the profile and current activities of the clinic related to 
smoking cessation and clinical flow (see Appendix M). Practices were also asked to identify 
representatives from the clinic staff to sit on a smoking cessation task force to guide the adoption of a 
tobacco control protocol for the clinic and support implementation activities. The task force met with 
the outreach facilitator between three and six times. At the first meeting of the clinic task force, the 
facilitator delivered a brief presentation of evidence-based strategies for smoking cessation and 
reviewed the intended use of the practice support tools and the workplan for guiding implementation 
activities. At the second and third outreach facilitation meetings, the clinic task force was guided 
through the development of tobacco control protocol for their clinic based on the 5As strategies. The 
goal of the protocol was to define roles and responsibilities of members of the clinic staff in delivering 
the 5As strategies to all smokers at each visit. The task force members were responsible for 
implementing the agreed upon protocol into practice and working with the facilitator to coordinate 
communications to staff regarding roles and responsibilities and program logistics.  
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 Clinics assigned to the PS intervention group were asked to consider a process by which 
patients could receive one to two follow-up visits by phone or in person within the first 2 to 4 weeks of 
a quit attempt as per the USDHHS Clinical Practice Guidelines for Treating Tobacco Use and 
Dependence (Fiore et al. 2008). Clinics were provided with a written guide on how to 
structure the follow-up appointments. No further support was provided.   
4.5.2 Follow-up Counselling (FC) Group  
Clinics assigned to the FC group received the same multi-component intervention program delivered 
to the PS group. In addition FC intervention clinics were able to refer patients to a smoker’s telephone 
follow-up counselling program. The smoker’s follow-up counselling program was facilitated by the 
use of an interactive voice response (IVR)-mediated telephone follow-up system. The IVR system 
contacts registered patients via telephone 7 days before their target quit date and 3, 14, 30, and 60 days 
after their quit date. During the 7-day call, patients were asked to confirm they intended to quit on 
their scheduled quit date and rank their confidence with quitting. Patients received educational 
messages that reinforced the importance of quitting and strategies for staying quit, and the availability 
of support should they struggle with their quit attempt and require the assistance of trained smoking 
cessation counsellors. During all subsequent calls, the IVR system posed a series of questions 
concerning current smoking status, confidence in staying smoke-free over the time period until the 
next planned call, and the use of pharmacotherapy, self-help materials, and other forms of cessation 
support. Patient responses to the questions posed by the IVR system were monitored by a trained 
smoking cessation counsellor daily. If the patient indicated that his or her confidence in remaining 
smoke-free was low (less than 4 on a 5-point scale) or if he or she had resumed smoking, the smoking 
cessation counsellor contacted the patient to conduct a counselling session. The counsellors tailored 
counselling according to patient need and worked with patients to develop strategies to deal with high 
risk situations using cue control,  alternatives, pharmacotherapy and/or social support. A counselling 
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protocol with clinician scripts and protocols was used to guide all counselling contacts with patients. A 
modified version of the study consult form (see Appendix N) and patient quit plan (see Appendix O) 
were developed for FC clinics which included information of the smoker’s follow-up counselling 
program. 
Providers in the FC group were also able to refer patients who were not ready to quit in the 
next 30 days, but who reported a willingness to quit smoking in the next 6 months to receive two IVR 
follow-up telephone calls 30 and 60 days following their clinic visit to reassess readiness to quit. If a 
patient reported at the 30- or 60-day call a readiness to quit smoking in the next 30 days, he or she was 
linked back to the clinic to schedule a quit plan visit, or, if preferred, received a 10 to 20 minute 
counselling session with the smoking cessation counsellor in order to set a quit date and develop a 
personalized quit plan. The participant could then be enrolled in the 60-day IVR-mediated telephone 
follow-up and counselling program for patients ready to quit as described above. A Booklet for 
Smokers Not Ready to Quit was created for distribution to patients who indicated they were not ready 
to make a quit attempt in the next 30 days (see Appendix P). The booklet reinforced the importance of 
quitting and provided information about the Smoker’s Telephone Follow-up Program as well as 
available community-based cessation programs. 
4.6 Measures 
4.6.1 Provider performance in the delivery of cessation treatments  
Provider performance in the delivery of each of the 5As strategies (ask, advise, assist, assess, 
and arrange) was assessed via a self-administered survey amongst eligible consenting participants 
immediately following their clinic appointment. The survey asked participants to respond either “yes” 
or “no” or “don’t know” regarding whether their physician asked them about their smoking status 
(ask); advised them to quit smoking (advise); assessed their readiness to quit (assess); provided 
 
    
53 
assistance with quitting (assist); and arranged follow-up support (arrange). The exit survey is 
presented in Appendix Q. For the “assist” strategy, supplemental data was collected regarding the 
provision of self-help materials , setting of a quit date , discussing available quit smoking medications, 
and prescribing quit smoking  medications. Participants were also asked if any other member of the 
clinic staff (e.g., nurse) provided any of the 5As interventions identified above as part of their visit to 
the clinic that day. These questions have been previously assessed and found to yield reliable 
responses (Goldstein et al. 1997, 1313-1319). Previous research has also found patient exit surveys 
regarding 5As delivery to be well correlated with criterion measure of an audiotape assessment of the 
physician-patient interaction (r= .67, p< .001) (Pbert et al. 1999, 183-188). Several large trials of 
multi-component interventions in primary care have used patient exit interviews or surveys to assess 
rates of 5As delivery (Katz et al. 2002, 293-301; Katz et al. 2004, 594-603; Unrod et al. 2007, 478-
484). During the 16-week telephone follow-up assessment, participants were again asked about the 
delivery of 5As treatments since recruitment into the study to assess the delivery of cessation 
treatments to patients following their visit to clinic (see Appendix R). It is common practice for a 
separate visit to be scheduled with patients ready to quit to conduct the “assist” component of the 
intervention.  
4.6.2 Quit attempts 
The number of patients who made a quit attempt lasting greater than 24 hours between the 
completion of the exit survey and the 16-week follow-up was recorded (see Appendix R). The total 
number of days to relapse for participants who made a quit attempt and returned to active smoking at 
the time of the 4-month follow-up was also recorded. 
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4.6.3 Smoking abstinence 
Smoking status was assessed at 16 weeks (12 weeks after the estimated quit date) via 
telephone as defined by: (1) 7-day point prevalence abstinence; and (2) 12-week continuous 
abstinence. Seven-day point prevalence abstinence was defined as a self-report of not having 
smoked,not even a puff, in the past seven days measured at the four-month follow-up assessment 
(approximately 12 weeks after the estimated quit date). Continuous abstinence was defined as not 
having smoked, not even a puff,, in the previous 12 weeks (between weeks 4 and 16). The interview 
tool is presented as Appendix R. The NicAlert™ salivary cotinine test was used for bio-chemical 
validation of smoking status in patients reporting abstinence in the past 7 days. Cotinine is a major 
metabolite of nicotine and it has a relatively long half-life (10-40 hours). Cotinine has been shown to 
be more sensitive and specific than carbon monoxide (CO) testing for measuring smoking status 
(Benowitz 2003, 91-111; Jarvis et al. 1987, 1435-1438). The NicAlert™ salivary cotinine test has a 
sensitivity of 99% and a specificity of 96% compared to gas chromatography and can be self-
administered by study participants (Cooke et al. 2008, 607-612). For patients who reported current 
use of a Nicotine Replacement Therapy, a CO breath sample was used for biochemical validation 
using the Smokerlyzer EC50-Micro III. Participants with saliva cotinine concentrations greater than 
10ng/ml or a CO reading of <9ppm were considered smokers (Benowitz 2003, 91-111).  
4.6.4 Program implementation  
Implementation refers to the extent in which the program was implemented as intended (i.e., 
fidelity of program implementation). A pre- and post-implementation practice survey was completed 
with a representative from each of the intervention clinics to determine how successful practices were 
with implementing and maintaining intervention components, including number of providers who 
attended training, present use of practice tools at clinic, and adoption of the clinic tobacco control 
protocol. Descriptive data was analyzed and reported as the proportion of practices implementing each 
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practice strategy. For the FC clinics, data was collected on the number of patients referred to the 
telephone-based smoker’s follow-up program. This data was abstracted directly from the smoker’s 
follow-up system database.  
4.6.5 Mediating and moderating variables  
The role of patient, physician, and practice characteristics in mediating or moderating the 
delivery of evidence-based cessation treatments and smoking abstinence was examined. The selection 
of variables was determined a priori based on previously published research (See Chapter 2).  The 
following patient-level factors were examined: age, gender, education, number of cigarettes smoked 
per day, years of smoking, time to first cigarette, readiness to set a quit date, exposure to second-hand 
smoke, number of quit attempts in last year, purpose of visit to the clinic, presence of co-morbidities, 
and identifying information for the physician or nurse practitioner whom they saw while in the clinic. 
Patient self-efficacy related to quitting (“On a scale of 1 to 10, how confident are you that you would 
be able to quit smoking?”), importance of quitting (“On a scale of 1 to 10, how important is quitting 
smoking to you?”), and the importance of their primary care provider’s advice in motivating them to 
quit smoking (“How important is your primary care physician’s/other member of the staff’s advice in 
motivating you to want to quit smoking?”) was also documented. The following practitioner-level 
factors were evaluated: age; gender; self-rated importance of smoking cessation; knowledge of 
evidence-based smoking cessation interventions; self-efficacy with delivering each of the 5As; and 
previous cessation training.  Practice-level factors included the practice model type (family health 
team versus family health group), the size of the practice, the geographic location of the practice, 
presence of a nurse and physician champion, and baseline rates of asking and advising for the clinic.  
 
    
56 
4.7 Power calculations and sample size  
Power calculations were conducted to determine the number of patients to be sampled from 
each clinic at the pre- and post-assessments based on the recruitment of between six and eight 
practices. The primary outcome measure for the power calculation was 7-day point prevalence 
abstinence. Given the clustered design, the design effect or inflation factor was used to enlarge the 
total sample size to account for loss in statistical power. The design effect formula is: Design effect = 
1+ (n-1) * ICC (Donner and Klar 2000), where n is the mean sample size at the third hierarchical level 
(patient level) and ICC is the intra-class correlation. For the purposes of the power calculation, the 
intra-cluster correlation coefficient (ICC; between practice variation) was estimated to be relatively 
small (i.e., 0.01). Previously published data for primary care practices has found that the minimum and 
maximum ICC value for outcome measures was 0.01 and 0.05 respectively, and 0.05 and 0.15 for 
process measures (Baskerville, Hogg, and Lemelin 2001, W241-6; Campbell et al. 2004, 113-125). All 
calculations were based on a two-sided test, alpha level of 0.05, and the recruitment of between six 
and eight practices.  
The power calculations indicate that with seven practices and 55 patients per practice, there 
would be >80% power to detect a 10% or 15% difference between groups if the post-intervention quit 
rate in the PS group is 0.05 and 0.10, respectively. Appendix S presents a summary of the scenarios 
used for power calculations. The PASS (2008) software package by NCSS was used to conduct power 
calculations (NCSS 2008). Among published multi-component interventions that involved follow-up 
counselling, reported quit rates were between 4% and 21% compared to control practices (see 
Appendix T). As such, it was understood that the present study might be underpowered to detect 
significant differences in smoking abstinence between groups if differences between intervention 
groups were less than 10%. 
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4.8 Patient recruitment  
From each of the participating clinics, a cross-sectional sample of eligible patients was 
recruited pre- and post-intervention. Patients were eligible to participate in the study if they met the 
following criteria: currently smoking (≥1 cigarette per day on most days of the week); 18 years of age 
or older; have a scheduled appointment with a nurse practitioner or physician for annual exam or non-
urgent medical appointment; able to complete exit survey and telephone interview in English or 
French; and have a home or mobile telephone that can be used to receive follow-up telephone calls. 
All eligible patients were asked to complete an exit survey at the end of their clinic appointment to 
assess provider performance in 5As delivery. Participants were followed prospectively for four months 
to assess smoking cessation outcomes. 
 Across the seven practices, 12,585 patients were screened and 1868 smokers identified at the 
pre- and post-assessment, of which 835 eligible smokers took part in the present study across the two 
study periods: pre-intervention period (January 28, 2009 to June 12, 2009) and post-intervention 
period (July 20, 2009 to December 24, 2009). During each study period a new cohort of patients from 
each clinic site was enrolled in the study until the enrollment target for the site was reached. The pre-
intervention assessment was conducted prior to implementing the intervention program to establish 
pre-intervention rates of 5As delivery at the clinic and associated quit rates among patients, as well as 
allow comparisons to be made between intervention groups. The post-intervention assessment 
occurred approximately two months after the intervention program was implemented with patients at 
the clinic site. Table 4 presents summary data for study recruitment and data collection activities. 
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Table 4: Summary of recruitment and follow-up statistics for the pre- and post-








PS vs FC 
P= 
Pre-Assessment     
Patients Screened 
 
6154 2581 3573 - 
Smokers Screeneda 
 
922 (15.0) 468 (18.1) 454 (12.7) ** 
Eligible Smokers 
 
752  413  339  - 
Completed Exit Surveyb  
 
416 (55.3) 233 (56.4) 183 (54.0) Ns 
Completed 4-month Follow-upc 
 
366 (88.0) 200 (85.8) 166 (90.7) Ns 
Post-Assessment     
Patients Screened 
 
6431 3190 3241 - 
Smokers Screeneda 
 
946 (14.7) 496 (15.5) 450 (13.9) * 
Eligible Smokers 
 
796 430 366 - 
Completed Exit Surveyb 
 
419 (52.6) 242 (56.2) 177 (48.4) Ns 
Completed 4-month Follow-upc  
 
379 (90.5) 224 (92.6)  155 (87.6) Ns 
a Number of daily and non-daily smokers screened (percentage of patients who were smokers among all patients screened). 
b Number of eligible patients who returned survey i.e., study participants (percentage of patients who returned survey among all 
eligible patients screened). 
c Number of patients who completed telephone interview (percentage of study participants who completed telephone interview). 
FC Time 1 vs Time 2 p = .347 
PS Time 1 vs Time 2 p = .002 
*p < .05.     **p < .01.      ***p <.001.   
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4.9 Data collection 
A research assistant was located in the clinic waiting room and conducted all data collection 
activities. During the pre- and post-intervention screening periods, consecutive patients scheduled for 
an annual exam or non-urgent appointment with a physician or nurse practitioner were screened for 
eligibility upon check-in to the clinic. The clinic receptionist distributed an invite letter to patients and 
patients were asked to complete the eligibility screening questions and return the invite to the research 
assistant (see Appendix U). No information on the outcomes measures being assessed was provided in 
the invite letter distributed. Patients who were seen in the clinic for vaccination or for other services 
delivered only by a nurse or for urgent appointments were excluded. Urgent appointments were 
defined as medical appointments scheduled to treat serious acute illness such as bodily injury, severe 
illness, or transfer to hospital. The primary reason for ineligibility was non-daily smoking status (i.e., 
less than 1 cigarette per day smoked on average in last month), which was reported by 134 patients 
surveyed. Table 5 presents a summary of the reasons for patient ineligibility by study clinic. 
4.9.1 Exit interview 
Previous research has shown prompting patients prior to a clinic visit increases the likelihood 
of patient-provider discussions about smoking and, as such, all patient interviews were conducted 
upon exit from their clinic appointments (Coleman et al. 2007, 153). At the end of the patient visit to 
the clinic, the research assistant reviewed the study consent form and procedures with eligible patients. 
A copy of the patient information sheet and consent form is presented in Appendix V. Reasons for 
non-participation was documented by the research assistant. The most common reason for declining 
participation was the lack of interest or lack of time (74.2%). Table 6 presents a complete summary of 
reasons patients provided for declining participation in the study. 
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Patients willing to participate in the study were asked to complete a brief five- to ten-minute 
exit survey before leaving the clinic (see Appendix Q). Participants were provided with a gift card for 
a free coffee (value $2.00) as a token of appreciation for their time. Participants who indicated they 
were not able to complete the survey before leaving the clinic were provided with a copy of the survey 
and a stamped self-addressed envelope to return the survey. Up to three reminder calls were placed to 
patients who chose to take the survey home and did not return the survey within a week.  
 At the pre-assessment a total of 416 eligible smokers (233 smokers in the PS group and 183 in 
the FC group) completed the pre-assessment exit interview and were included in the study, 
representing 55.3% of all eligible smokers screened at study clinics. At the post-assessment a total of 
419 eligible patients enrolled in the study and returned the exit survey (242 in the PS group and 177 in 
the FC group), representing 52.6% of all eligible patients. There was no differential rate of 
participation between the intervention groups. A significant number of patients (23%) who agreed to 
participate in the study did not return the exit survey by mail after three reminder call attempts. These 
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in past 7 days 
Ineligible patients Eligible 
Smokers 
Invited 















n n % n n n n n n N n % n % 
Pre-Intervention               
Clinic 1 1887 230 12.2 5 6 9 22 40 148 82 66 44.6 56 84.9 
Clinic 2 872 118 13.5 0 2 0 6 8 102 28 74 72.5 58 78.4 
Clinic 3 689 120 17.4 0 3 2 5 6 104 29 75 72.1 55 73.3 
Clinic 4 883 114 12.9 0 2 0 7 6 99 18 81 81.8 70 86.4 
Clinic 5 623 115 18.5 0 1 0 10 2 102 22 80 78.4 56 70.0 
Clinic 6 803 110 13.7 3 5 2 8 0 92 17 75 81.5 57 76.0 
Clinic 7 397 115 29.0 0 0 0 2 10 103 6 97 94.2 64 66.0 
PS Group 2581 468 18.1 0 6 2 23 26 411 85 326 79.3 233 71.5 
FC Group 3573 454 12.7 8 13 11 37 46 339 117 222 65.5 183 82.4 
Total 6154 922 15.0 8 19 13 60 72 750 202 548 73.1 416 75.9 
Post-Intervention              
Clinic 1 1212 164 13.5 2 2 4 36 10 110 43 67 60.9 54 80.6 
Clinic 2 808 122 15.1 1 1 0 10 11 99 25 74 74.7 60 81.1 
Clinic 3 807 114 14.1 0 2 1 9 1 101 29 72 71.3 64 88.9 
Clinic 4 1169 141 12.1 4 1 4 1 1 130 42 88 67.7 63 71.6 
Clinic 5 890 103 12.0 1 1 4 2 4 91 19 72 79.1 52 72.2 
Clinic 6 860 145 16.9 2 3 0 12 2 126 46 80 63.5 60 75.0 
Clinic 7 685 157 22.9 7 5 0 4 2 139 57 82 59.0 66 80.5 
PS Group 3190 496 15.5 9 9 5 25 18 430 130 300 70.0 242 80.7 
FC Group 3241 450 13.9 8 6 8 49 13 366 131 235 64.2 177 75.3 
Total  6431 946 14.7 17 15 13 74 31 796 261 535 67.2 419 78.3 
 
    
62 
Table 6: Reason for refusal among eligible patients screened at the pre-intervention and post-intervention assessments 
 
















Pre-Intervention Assessment          
Not interested 31 21 18 15 19 14 6 124 
No time / Too busy 21 0 2 0 0 3 0 26 
Left without completing screener 27 7 9 2 3 0 0 48 
Leaving country soon, unable to complete follow-up 2 0 0 0 0 0 0 2 
Not feeling well enough to complete 0 0 0 1 0 0 0 1 
Will be leaving the country soon 1 0 0 0 0 0 0 1 
Total Pre-Assessment   82 28 29 18 22 17 6 202 
Post-Intervention Assessment           
Not interested 20 10 12 30 15 22 38 147 
No time / Too busy 3 6 4 5 1 6 9 34 
Left without completing screener 0 5 4 6 2 8 8 33 
Screener received after patient left 14 0 0 0 0 2 0 16 
Leaving country soon, unable to complete follow-up 0 1 0 0 0 5 0 6 
Participated at baseline, not interested in repeating 0 0 3 1 0 0 1 5 
Participating in another study 1 0 2 0 0 0 0 3 
Confidentiality issues 0 1 0 0 0 0 0 1 
Reason not provided 5 2 4 0 0 3 1 15 
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4.9.2 Four-month telephone follow-up interview 
 All consenting participants were contacted by telephone approximately 4 months (+/-2 weeks) 
after their clinic visit. The 4-month telephone follow-up assessment was completed with 89.2% of 
study participants. Table 7 provides a summary of the 4-month follow-up interview statistics for 
patients involved in the post-assessment sample. There were no significant differences in the rates of 
recruitment or loss to follow-up between intervention groups or between the pre- and post-assessment 
samples. During the telephone interview, smoking status (7-day point prevalence and 12-week 
continuous abstinence) and number of quit attempts since their visit to the clinic was assessed (see 
Appendix R). Supplemental smoking cessation services received at the clinic were also documented as 
part of the telephone follow-up assessment. For participants who reported active smoking, the current 
number of cigarettes smoked was recorded. For participants who reported an unsuccessful quit 
attempt, the primary reason for relapse was recorded. Participants who did not complete the 16-week 
exit interview were included in the analysis and coded as currently smoking for both 7-day point 
prevalence abstinence and continuous abstinence and responses for all other 16-week data was coded 
as missing. Biochemical validation of self-reported smoking abstinence was completed with 53.3% of 
patients who reported a smoke-free status. Participants were mailed the NicAlert™ test, instruction 
sheet, and a package for returning the kit. Participants were asked to return the kit to the research 
office in a sealed pre-paid stamped box. If a participant reported at the 16-week follow-up assessment 
that he or she was currently using nicotine replacement therapy, arrangements were made by the 
research assistant for a carbon monoxide (CO) breath sample to be taken. Forty-five percent of 
patients who agreed to provide a biochemical sample did not return the sample following multiple 
reminder contacts (see Table 8). No differences were noted in the completion of the bio-chemical 
validation at the pre- and post-intervention assessments nor were differences noted between 
intervention groups.  
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Lost to FU  
> 10 calls 
Lost to FU  
contact information Deceased 
Total 
n % N % n % n % n % n 
 














200  85.8 10 4.3 15 6.4 7 3.0 1 0.4 233 
Sub-total 
 
366  88.0 13 3.1 27 6.5 9 2.2 1 0.2 416 
 























































Post Pre Post 
Validation Completed 
 
38/71 (53.4) 15/29 (51.7) 23/42 (54.8) 2/4 (50) 11/20 (55) 13/25 (52)  11/22 (50) 
Patient Refused to Provide Sample  
 
  1/71 (  1.4)  0/29 (    0)    1/42 (  2.4) 0/4 (  0) 0//20 (  0)   0/25 (  0)    1/22 (4.5) 
Sample Not Returned  
 
32/71 (45.0) 14/29 (48.3) 18/42 (42.9) 2/4 (50) 9/20 (45) 12/25 (48)   9/22 (41) 
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4.10 Statistical analysis  
 Data from all seven family medicine clinics and the 835 patients who completed the pre-and 
post-assessment data collection activities were included in the intention to treat analysis.  
Differences in the distribution of provider and clinic characteristics between FC and PS groups 
were determined using the Pearson chi-square test for categorical variables and Student’s t-test for 
continuous variables using SPSS 17.0 (SPSS Inc., Chicago, IL). This analysis was repeated to 
compare patient characteristics between the FC and PS groups at the pre-assessment and post-
assessment. A three-level hierarchical model was used to compare patient characteristics between 
groups at the post-assessment, controlling for baseline differences and the cluster randomized design. 
A second three-level model was used to examine differences in patient characteristics between the pre-
and-post assessment overall (i.e., both intervention groups combined).    
Multi-level (or hierarchical) modelling was used for all statistical analysis using MLwiN 
version 2.02 (Institute of Education, London, UK) (Institute of Education). Individual patients were 
grouped by individual intake clinicians (who were grouped by clinic). A three-level model was 
constructed to fit for each outcome measure: the individual patients (level 1), provider (level 2), and 
clinic (level 3). Para-meters in the model were estimated using iterative generalized least squares 
method for model fitting  
with binomial structure for binary data and the logit link function. Wald tests were used to obtain  
p-values. P-values were calculated using two-sided tests and a 5% significance level for fixed effects. 
One-sided tests were calculated for variance components.  
The formulas used to examine the three-level logit model are presented below. In the models 
that were fit , there was more than one covariate at each level. The models given below contain only a 
single covariate to simplify the presentation.  
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Level 1  
If πijk is the probability of the outcome for patient i of provider j in clinic k is then the patient 
level model is: 
Logit (πijk) = ß0jk + ß1jkxijk…+…βmxijkm 
where:    
ß0jk is the intercept for provider j in clinic k.  
ß1jk is the effect of xjk1 (fixed patient level variable 1) for provider j in clinic k, with other 
parameters defined similarly.  
Level 2  
At level 2 (provider level), the regression parameters in the level 1 model are assumed to be 
related to covariates at the level of the provider through the models: 
ß0jk = γ00k + γ10kwjk1 + ….. + u0jk;     
ß1jk = γ10k + γ11kwjk1 + …….+ u1jk;  
where:  
γ00k is the intercept for clinic k in predicting provider level differences in outcomes.  
γ10jk is the effect of wjk1 (e.g. fixed provider variable 1), etc.  
u0jk is the random effect of provider j in clinic k.  
γ10k is the intercept for clinic k the model describing how the effect of individual level 
predictor 1 depends on provider. 
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γ11jk is the effect of the interaction between individual level predictor 1 and provider level 
predictor 1.  
u1jk is the random effect of provider j in clinic k in the model relating the effect of individual 
level variable 1 on the provider level 2 covariates. 
 
Level 3  
At level three, the level two regression parameters are modeled in terms of practice variables 
through the models: 
γ00k= δ000 + δ001zk1+ … + v00k;  
γ01k= δ010 + δ011zk1 + … + v01k;   
γ10k= δ100 + δ101zk1 + …+ v10k;  
γ11k= δ110 + δ111zk1 + … + v11k;  
where: 
δ000, δ010, δ100 , δ110  are the intercepts in the clinic-level models for the γ at the provider-
level.  
δ001, δ100, δ110 and δ111 reflect how the effects of individual–level variables and practice-level 
variables, and their interaction depend on z, a clinic characteristic.  
v00k, v01k, v10k, v11k are the random effects reflecting deviation of clinic k from the overall 
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Combined Model 
To illustrate the combined model, assume we have a single covariate (independent variable) at 
each of the three levels.  Then putting the three equations above together gives:  
Logit (πijk) = Yijk = δ000 + δ001zk + δ010wjk1 + δ100xijk1  + δ011zk1wjk1 + δ101zk1xijk1 + 
δ110wjk1xijk1 + δ111zk1wjk1xijk1 +v00k + v01kwjk1 + v10kxijk1 + v11kwjk1xijk1 + u0jk + 
u1jkxijk1           
 
Odds ratios and 95% CI were used to summarize the effects of each explanatory variable in 
explaining variance in individual level effects, with similar definitions for the provider and practice 
level effects, giving the ratio of the odds of the outcome for two individuals whose value of the 
relevant co-variable differ by one unit, with all other co-variables held constant. For the random 
effects, variance components and their estimated standard errors are listed.         
The intra-class correlation coefficient (ICC) was calculated to compare the variation between 
clusters to the total variation; this was measured on a scale from 0 to 1, with a value close to 0 
indicating the clusters were all “similar”. An intra-clinic and intra-provider ICC was calculated for 
each of the outcome variables examined. Given the present analysis used logistic models for binary 
outcomes, patient level variance was estimated to be equal to π2/3 = 3.29 (Snijders and Bosker 1999). 
 
Intra-Clinic ICC     =  clinic variance / total variance  
  =  σ 20k  / (σ 20k + 3.29)           
Intra-Provider ICC  =  clinic variance + provider variance / total variance  
            = (σ 20k + σ 20j )/(σ 20k + σ 2u0 + 3.29)                                   
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The first study objective was to compare the efficacy of the follow-up counselling group and 
practice support group on study outcomes. Modelling for each variable at baseline began by entering 
the random effects at the clinic and provider level (which are required because of the cluster design) 
along with three fixed effects: an “intercept” term, “dummy” variables for intervention group (FC vs. 
PS) and time (pre- vs. post-assessment), and an interaction effect for group x time. Again, a separate 
model was constructed for 7-day point prevalent abstinence, prolonged abstinence (weeks 4 to 16), 
quit attempts, and provider performance in each of the 5As strategies.    
The second objective of the study was to examine the efficacy of the multi-component 
smoking cessation intervention program at the post-assessment on 5As delivery, quit attempts, and 
smoking abstinence compared to pre-assessment rates. The proportion of patients (# patients received 
strategy/total # patients) receiving each of the 5As (ask, advise, assess, assist, arrange) strategies was 
calculated for the pre-assessment and post-assessment. Pre- and post-intervention assessment rates 
were calculated for 5As delivery and smoking abstinence for all seven study clinics. The coefficients 
and standard errors for the three-level models constructed (as described above) were examined to 
assess the effect of time (pre- vs. post-assessment) on study outcomes when controlling for clinic and 
provider level clustering. A separate model was constructed for 7-day point prevalent abstinence, 
prolonged abstinence (weeks 4 to 16), quit attempts, and provider performance in each of the 5As 
strategies.    
 To understand the patient-provider and clinic-level factors associated with each outcome, a 
separate multi-level logistic regression analyses was performed. A multi-step modelling procedure was 
used for each outcome. Step (1), the model fit for each outcome variable of interest began by entering 
random effects for clinic and provider. The modelling of the fixed effects proceeded in blocks until a 
final model in which all fixed effects were significant was obtained. Possible mediating and 
moderating factors at the level of the practice and provider were entered as variables in the analysis. 
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Step (2), study design variables were entered for time, group, and the interaction between time and 
group. Step (3), level-3 practice-level factors (practice model, geographic location) and 
implementation factors (availability of nursing support; use of dedicated staff for cessation 
intervention) were entered. Step (4), level-2 practitioner-level factors were then entered for the 
clinician most responsible for patients’ care in two blocks. The first block included demographic 
variables (age, gender, type of provider), and the second block included smoking-related variables 
(previous smoking cessation training, importance of smoking cessation, self-efficacy in the delivery of 
smoking cessation counselling). Step (5), level-3 patient variables were entered into the model and in 
three blocks. The first block included demographic variables (age, gender, education), followed by 
medical history (presence of a smoking-related illness, self-reported anxiety or depression), then 
smoking-related variables (time to first cigarette, number of cigarettes smoked per day, years smoking, 
presence of another person who smokes in the home, self-efficacy related to quitting smoking, 
importance of quitting, readiness to quit in the next 30 days), and, finally, purpose of visit to the clinic. 
Only significant variables (p<0.05) were retained. Step (6), a final model was then developed to 
examine the direct effects of only the significant (p<0.05) clinic, provider, and patient characteristics 
on outcomes (Final Model). Interaction effects were also examined between significant variables at 
each level. No adjustment to the significance value was made to account for the number of outcomes 
being assessed.  
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Chapter 5 Results 
5.1 Descriptive characteristics  
5.1.1 Clinic characteristics  
A summary of the characteristics of clinics who participated in the study is presented in Table 
9. The study sample included clinics from urban, suburban, and rural communities from within the 
Champlain District of Ontario. Approximately half of the practices had 10 or more physicians on staff. 
Four of the seven participating clinics were family health teams that receive funding from the Ministry 
of Health and Long-Term Care for allied health professional and administrative personnel.  
 
Table 9:  Characteristics of pilot clinics 
 















16 Urban FHT 12.7  Y Y Y 
Clinic 2 
 
7 Urban FHT 14.3 N N N 
Clinic 3 
 
40 Urban FHT 15.6 N N Y 
Clinic 4 
 
14 Suburban FHT 12.4 Y-N Y-N N 
Clinic 5 
 
9 Urban FHG 14.4 Y Y Y 
Clinic 6 
  
11 Suburban FHG 15.3  N N N 
Clinic 7 
 
11 Rural FHG 25.1 Y N N 
a FHT = Family Health Team, FHG = Family Health Group. 
b Percentage of total patients screened who reported being an active smoker (“used a tobacco product in previous seven 
days”). 
c A “clinician champion” was defined as a key opinion in the clinic who was actively involved as a member of the task force that 
was established at each clinic to support program implementation   
. 
 
    
72 
Table 10 provides a comparison of the clinic characteristics by intervention group assignment. 
Intervention groups were well balanced in regards to practice size (i.e., number of physicians), practice 
type, geographic location, and presence of a physician champion for the study. Smoking prevalence 
rates varied significantly between study clinics ranging from 12% to 29%. The highest rate of smoking 
(25%) was documented in the single rural clinic. This pattern is consistent with previously reported 
rates of smoking for sub-regions within the Champlain District, which range from 14.1% in the City of 
Ottawa to 26% in surrounding public health regions (Statistics Canada 2009). There was a 
significantly higher rate of smoking among patients in the PS group at both the pre- and post-
assessment, which can be attributed to the high rate of smoking in the single rural clinic assigned to 
the PS group. The overall rate of smoking prevalence documented at the post-assessment for each 
study group was similar to the pre-assessment (14.7% vs. 15.0%).    
Clinics assigned to the PS group had a higher baseline rate of asking and advising patients to 
quit as compared to the FC group. These differences were not statistically significant.  
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Number of Physicians 
<10 Full TimeEquivalents 





























Family Health Team  


















































Baseline Smoking Prevalence 
 
15.0 18.1 12.7 
Baseline Rate of Ask  
 
52.2 53.7 47.6 
Baseline Rate of Advise, Today 
 
39.2 43.0 34.3 
Baseline Rate of Advise, Last 12 months 
 
70.0 72.4 66.7 
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5.1.2 Provider characteristics   
Provider surveys were completed by 74/115 (64.3%) of clinic providers who saw at least one 
patient during the pre- or post-assessment periods. Responding providers had a mean age of 45.2 
(SD±11.3) years and 44.9% were male. No significant differences were found between intervention 
groups in regards to provider demographic characteristics. Table 11 provides a summary of the 
demographic characteristics of responding providers as well as an assessment of the self-reported 
importance of smoking cessation and self-efficacy of providers as it relates to the delivery of each of 
the 5As for smoking cessation treatments in clinical settings.   
Significantly more providers in the FC group compared to the PS group reported receiving 
previous smoking cessation training (28% vs. 54% p=0.023). Self-reported participation in previous 
smoking cessation training ranged from 25% to 80% of providers among the participating clinics. The 
highest rates of participation were found in three of the four participating family health teams.  
A significantly greater number of providers in the FC group were physicians compared to the 
PS group which had a higher number of medical residents. Despite these differences, the overall 
number of patients screened by residents during the course of the study was small (n=48 patients, 
6.4% of study sample).  The majority of providers reported smoking cessation was either extremely 
important or very important to both the clinic as well as to the providers’ own practices. There were no 
differences between groups in the self-reported importance placed on smoking cessation with patients 
among clinic providers. The highest scores for self-efficacy were documented for advising patients to 
quit, the provision of brief counselling and prescribing of medications (all mean scores were greater 
than 8 on a 10-point scale). Slightly lower levels of self-efficacy were documented for other activities, 
such as setting a quit date with patients, the provision of extended smoking cessation counselling, and 
arranging follow-up. There were no significant differences between intervention groups in provider 
self-efficacy related to 5As delivery.     
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Type of Provider, % 











  3.6 
 
76.5 




Age, Mean (SD) 
 
45.2 (11.3) 44.5 (11.9) 46.4 (10.6) .514 
Male, % 
 
44.9 50.0 38.2 .300 
















How would you describe the importance placed on 
smoking cessation within your clinic setting?, % 
Extremely important  
Very important 
Important   



























As a practitioner, how would you describe the 
importance you place personally on helping your 
patients quit smoking?, % 
Extremely important  
Very important 
Important   









     0 







     0 






  9.7 
            0 





Self-efficacy (1 to 10 scale), Mean (SD) 
Advising patients to quit  
Brief counselling  
Prescribing medications 
Set quit date  
Extended counselling to quit  
Arrange follow-up support 
 
 



























Survey data was received from 74/115 (64.3%) clinicians who saw patients during one of the assessment periods. Data were 
missing for those intake clinicians who were employed as “floating” (or locums) staff and those clinicians who did not return 
surveys after three reminders. 
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5.1.3 Patient characteristics  
5.1.3.1 Demographics 
Table 12 presents the demographic profile of patients at the pre- and post-intervention 
assessments. Study participants ranged in age from 18 to 85 years with a mean age of 45.8 years 
(SD±14.6). Forty-one percent of participants were male, with an average of 14 (SD±3.2) years of 
formal education. More than half of participants reported the presence of one or more smoking-related 
illnesses. At the pre-assessment, a larger proportion of patients reported the presence of a smoking-
related illness relative to the post-assessment sample. A significant proportion of patients from the pre-
post assessment samples reported the presence of anxiety (29%) or depression (27.5%). Significantly, 
more patients in the PS group identified themselves as depressed compared to the FC group at the pre-
assessment (33.8% vs. 22.7%, p=0.041). A similar trend was observed at the post-assessment; 
however, observed differences were not statistically significant. The majority (83.8%) of patients were 
recruited when visiting the clinic for a follow-up appointment or visit other than the annual physical 
exam.    
The unadjusted analysis documented significant differences in the mean age of participants 
(48.2 vs. 43.5 years, p=.001) between intervention groups at the pre-intervention assessment. 
Significant differences were also documented between intervention groups for the number of years of 
formal education reported by participants at both the pre- and post-assessment. However, after 
controlling for the cluster design and baseline differences between groups, there was no statistically 
significant difference noted in any of the demographic variables between intervention groups across 
time.  
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Pre-Intervention Assessment a 
 



















p=    p= p= 
Age, mean (SD) 
 
46.2 (14.7) 48.2 (14.5) 43.5 (14.7) .001 45.3 (14.5) 46.1 (14.1) 44.2 (15.0) .203 ns ns 
Male, n (%) 
 
169 (40.6) 89 (38.4) 80 (44.0) .250 167 (41.1) 92 (38.3) 75 (45.2) .168 ns ns 
Years of formal education, 
mean (SD) 
 
14.2 (3.2) 13.8 (3.0)   14.7 (3.3) .007 14.1 (3.2) 13.8 (3.1) 14.6 (3.1) .007 ns ns 









High blood pressure 
High cholesterol 
 
 317 (67.2) 
  35 (  8.6) 
  25 (  6.2) 
    2 (  0.5) 
  20 (  5.0) 
  58 (14.3) 
   10 (  2.5) 
  49 (12.2) 
  28 (  6.9) 
113 (27.8) 
  95 (23.5) 
 158 (67.8) 
   24 (10.6) 
     18 (  8.1) 
     2 (  0.9) 
     14 (  6.3) 
   41 (18.2) 
     3 (  1.7) 
   34 (15.2) 
     20 ( 8.9) 
  78 (34.5) 
   63 (28.3) 
159 (66.5) 
 11 (  6.0) 
   7 (  3.9) 
   0 (  0.0) 
   6 (  3.3) 
 17 (  9.4) 
   7 (  3.1) 
 15 (  8.4) 
   8 (  4.4) 
  35 (19.3) 













  20 (  4.9) 
  17 (  4.2) 
   4 (  1.0) 
  11 (  2.7) 
  41 (10.0) 
  10 (  2.5) 
  39 (  9.6) 
  23 (  5.7) 
  73 (17.8) 
  70 (17.1) 
139 (57.7) 
  12 (  5.1) 
   9 (  3.8) 
   3 (  1.3) 
   8 (  3.4) 
 28 (11.9) 
   7 (  3.0) 
 26 (11.1) 
    14 (  5.9) 
 51 (21.4) 
 42 (17.7) 
  79 (45.7) 
    8 (  4.7) 
    8 (  4.7) 
    1 (  0.6) 
    3 (  1.7) 
  13 (  7.6) 
    3 (  1.7) 
  13 (  7.6) 
    9 (  5.3) 
  22 (12.9) 


































Mental health history, n (%) 
Anxiety  
Depression  









    21 ( 9.7) 
 
  55 (30.6) 
  41 (22.7) 








  29 (  7.3) 
 
  76 (32.5) 
  73 (30.8) 
  22 (  9.6) 
 
 38 (22.1) 
 39 (22.5) 










  ns 
  ns   
  ns                         






  58 (16.1) 
 124 (34.4) 
178 (49.4) 
 
 37 (15.9) 
 87 (37.3) 
  109 (46.8) 
 
  21 (16.5) 
  37 (29.1) 








  47 (19.7) 











  ns 
ns=non-significant. 
a Comparisons are based on the Pearson chi-square test for categorical variables and Student’s t-test for continuous variables.   
b Comparisons are based on hierarchical logistic regression models (adjusted for clinic and provider level variance). 
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5.1.3.2 Smoking history  
A profile of the smoking history of respondents at both assessments points is presented in 
Table 13. Smoking history variables indicate that participants were relatively heavy smokers who had 
smoked for an extended period of time, consuming an average of 16.8 (SD±9.5) cigarettes per day for 
an average of 26 (SD±15) years. The majority of respondents reported smoking within 30 minutes of 
waking. Most respondents reported making one or more quit attempts in the last year. More than 40% 
of patients reported another person who smokes in their home.   
A statistically significant difference between intervention groups was documented for both the 
number of cigarettes smoked per day, years of smoking, exposure to second-hand smoke, and self-
efficacy at the pre-intervention assessment. There was a statistically significant difference between 
intervention comparators at the follow-up with respect to the average time to first cigarette, with PS 
participants more frequently reporting smoking within 5 minutes of waking, an indication of higher 
levels of addiction to nicotine. However, after controlling for the cluster design and baseline 
differences, there was no statistically significant difference noted between the smoking-related 
characteristics of patients between intervention groups.  
5.1.3.3 Readiness to quit  
Thirty-four percent of participants sampled reported they were ready to quit in the next 30 
days at both assessment points. An additional 40% of participants reported that they were ready to quit 
smoking in the next 6 months. There were no differences between groups in the self-reported readiness 
to quit at either assessment point or between the pre- and post-assessment samples.  
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5.1.3.4 Self-efficacy and importance of quitting 
Two questions assessed patient self-efficacy related to quitting smoking and importance of 
quitting on a 10-point scale. The mean level of confidence related to quitting was relatively low at 4.6 
(SD±2.8) and 5.1 (SD±2.9) at the pre- and post-assessments, respectively. Patients in the FC group 
ranked self-efficacy for quitting higher than patients in the PS group at baseline with no differences 
noted between groups at the post-intervention assessment. The average score for the importance of 
quitting was 6.7 (SD±3.2) and 7.0 (SD±3.1), respectively, at the pre- and post-assessment, with no 
differences between groups.    
5.1.3.5 Importance and satisfaction related to a health professional’s advice to quit  
Table 14 presents a summary of participant responses regarding the importance of their 
provider’s advice on patient motivation to quit as well as patient satisfaction regarding the assistance 
provided by the clinic with quitting smoking. Approximately half of respondents indicated the advice 
of their primary care physician was either an “extremely important” or “important” factor in 
motivating them to quit smoking at the baseline assessment. This proportion increased to 60% at the 
post-assessment and was higher in the FC group relative to the PS group. At the post-assessment, 
approximately 45% of patients indicated they were either “extremely satisfied” or “satisfied” with the 
assistance they received at the clinic on that day related to smoking, and 27% indicated the assistance 
they received was “extremely helpful” or “helpful”. 
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  p=    p= p= 
Cigarettes/day, mean (SD) 
 
15.6 (9.0) 16.5 (9.0) 14.4 (8.8) .02  15.5 (  9.4)  16.3 (  9.6) 14.4 ( 8.9) .05   ns ns 
Years smoked, mean (SD) 27.4 (15.2) 29.9 (14.6) 24.3(15.3) .00  25.7(14.7)  25.9(14.3)  25.5 (15.3) .77   ns ns 
Time to first cigarette, n (%) 
After 60 minutes  
31-60 minutes  
6-30 minutes  
Within 5 minutes 
 
  89  (21.4) 
  71  (17.1) 
  145  (34.9) 
































  ns 
 
ns 
Readiness to quit, n (%)c 
Ready in next 30 days 
Ready in next 6 months 
Not Ready 































     ns 
 
ns 
Quit Attempts in last year, n (%) 
No attempts 
1-2 attempts 





 82 (19.7) 
 
105 (45.1) 
 86 (36.9) 












  66 (16.6) 
 
101 (42.8) 
 97 (41.1) 








     ns 
 
ns 
Other smokers in the home, n (%) 
 
200 (48.4) 117 (50.9)  83 (45.4) .27 166 (41.6) 98 (41.0)  68 (42.5) .77       ns ns 
Exposed to second-hand smoke, n (%) 
 
   190 (45.9) 117 (50.4)  73 (40.1) .04 136 (36.0) 90 (39.5)  46 (30.7) .08       ns ns 
Self-Efficacy, mean (SD)d 
 
4.6 (2.8) 4.4 (2.7) 4.9 (2.9) .04 5.1 (2.9) 5.0 (2.7) 5.2 (3.1) .38       ns ns 
Importance of quitting, mean (SD)e 
 
6.7 (3.2) 6.7 (3.2) 6.7 (3.3) .84 7.0 (3.1) 7.1 (3.0)  6.9 (3.1) .65       ns   ns 
ns=non-significant. 
aComparisons are based on the Pearson chi-square test for categorical variables and Student’s t-test for continuous variables.  
bComparisons are based on hierarchical logistic regression models (adjusted for clinic and provider level variance). 
cWhich of the following best describes your feelings about smoking right now? 
dOn a scale of 1 to 10 how confident are you that you would be able to quit smoking at this time? (1=not at all confident, 10=extremely confident)  
eOn a scale of 1 to 10 how important is it to you to quit smoking at this time? (1=not important at all, 10=extremely important) 
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Table 14: Self-reported importance of physician and clinic staff advice to quit and satisfaction with smoking cessation 













































  49 (11.8) 
 
72 (29.9) 
72 (29.9)  
74 (30.7) 












Not at all important 
 
 
 70 (17.3) 





































Not at all satisfied 
 
     
79 (22.4) 
78 (22.1) 
     133 (37.7) 






        12 (  6.0) 





       14 (  9.2) 








Not at all helpful 
 
















       13 (  8.9) 
54 (37.0)  
 
.040 
aComparisons are based on the Pearson chi-square test for categorical variables and Student’s t-test for continuous variables. 
bHow important is your doctor’s advice to quit smoking in motivating you to want to quit? 
cHow important is the advice of other clinic staff (e.g., nurse) in motivating you to want to quit smoking? 
dHow satisfied were you with the support provided to you on smoking cessation while in clinic 
eHow helpful were the clinic staff to you 
today? 
today as it relates to addressing smoking? 
 
    
82 
 
5.1.3.6 Comparison of study sample with provincial and national data   
Table 15 provides a comparison of the characteristics of study participants with available data 
on the population of people who smoke in Ontario and Canada. Overall, 13.8% of patients screened 
during the two study assessment periods reported using a tobacco product in the 7 days prior to their 
visits to the clinic. This rate is in line with rates of daily smoking in Ontario (14%) and Canada 
(13.5%) (Statistics Canada 2009).  
Among study participants, the greatest proportion of smokers identified were men and women 
between the ages of 45 and 64. In Ontario and Canada, the largest overall number of smokers is also in 
the 45- to 64-year-old age category (CTUMS 2010; Ontario Tobacco Research Unit 2010). Among 
females, a relatively similar distribution of people who smoke was identified in the present study for 
all age categories relative to available provincial and national data. There was, however, a smaller 
proportion of males who participated in the study relative to the reported prevalence of males who 
smoke in Ontario, Canada. Study participants also tended to report higher levels of education than the 
known population of smokers in Ontario.  
Participants recruited into the study consumed a similar number of cigarettes to that reported 
for people who smoke in Ontario. There were, however, several differences in the characteristics of 
study participants noted compared to available data for individuals who smoke in Ontario and Canada. 
For example, a larger proportion of patients in the present study reported a readiness to quit smoking 
in the next 6 months and the next 30 days compared to provincial and national data. Study participants 
were more likely to have made a quit attempt in the last year compared to data available for smokers in 
Ontario and Canada. Data also suggests a trend towards higher rates of nicotine dependence among 
people who smoke, screened as part of this study, relative to national data.  
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Table 15: Comparison of the demographic characteristics and smoking history of 
study participants with individuals who smoke in Ontario and Canada  
 
Variable % Pilot Study % Ontario % Canada 
Daily Smoking Prevalence 13.8 14.0 13.5 
Males 
     20-34 years 
     35-44 years 
     45-64 years 












     20-34 years 
     35-44 years 
     45-64 years 












    <High School 
    High School 
    Some Post-secondary                 
















Number of Cigarettes 15.6 15.7 14.9  
Readiness to Quit  
     Next 6 months 
     Next 30 days 
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Time to first cigarette 
        >60 mins 
        31-60 mins 
        5-30 minutes 
















Quit Attempt in last year 58.4 49.0 49.4 
Advised to quit in past 12 months 69.9a 64.0            54.0 
Source: Ontario Tobacco Survey 2010; Canadian Tobacco Monitoring Survey 2008. 
a Non-daily smoking rates should be interpreted with caution as only patients who reported smoking in last 7-days were 
screened for the present study. Provincial and National data is based on a broader definition for occasional smokers. 
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5.2 Comparison between PS and FC intervention groups 
5.2.1 Provider delivery of evidence-based smoking cessation treatments (5As) 
The comparison between the PS and FC intervention groups for provider performance in 5As 
delivery is presented as Table 16. Summary statistics generated for the multi-level models for the 
interaction between group (PS vs. FC) and time (pre- vs. post-assessment) are presented as Table 17. 
As hypothesized, there were no significant differences between intervention groups in 5As delivery at 
the follow-up when controlling for the cluster design and baseline rates of 5As delivery. The intra-
class correlations coefficients calculated indicate the majority of variation in 5As delivery was at the 
level of the providers. The intra-clinic ICC for “ask”, “advise”, “assess”, and “assist” was 0, indicating 
no variance attributable to the cluster design. An ICC of 0.01 was documented for “discuss 
medications” and “arrange follow-up” indicating less clustering at the level of the clinic than expected. 
A slightly larger intra-clinic ICC value of 0.05 was calculated for the “prescribing medications” 
component of assist. 
Table 18 presents the rates at which other clinic staff delivered evidence-based smoking 
cessation strategies for each of the intervention groups. No significant differences were found between 
groups in the rates at which other clinics staff delivered cessation support.  
5.2.2 Support with quitting received between clinic visit and 4-month follow-up  
Table 19 presents data by intervention group regarding smoking cessation services received 
between the exit survey and 4-month follow-up interview. In the PS group, there was a 16% increase 
in the number of patients who were recommended pharmacotherapy, with a 10% increase observed in 
the FC group.  
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Table 16: Provider delivery of tobacco treatment strategies (5As) between intervention groups  
 
Parameter                     PS Group                   FC Group  P= 
Pre Post ∆ Pre Post ∆ ∆ FC - ∆PS  
Ask  
Today’s Visit 








































  60/175 (34.3) 
120/180 (66.7) 
 








































Today’s Visit  



















































































18/233 (7.7) 30/239 (12.6) +4.9 23/177 (13.0) 18/173 (10.4) -2.6 -7.5  
Self-Help Material 
Today’s Visit 





























17/232 (7.3) 35/241 (14.5) +7.2* 20/182 (11.0) 29/176 (16.5) +5.5 -1.7 ns 
Comparisons between PS and FC groups are based on hierarchical logistic regression models (adjusted for clinic and provider level variance). 
*p < .05.     **p < .01.      ***p <.001.  
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Table 17: Outcome estimates for multi-level models examining differences between groups in 5As delivery when controlling 





























    Ask 
 
1.03 0.58 1.84   0.03 0.297 0.01 0.00 0.04 
Advise 
 
0.89 0.49 1.59  -0.122 0.299 0.17 0.00 0.04 
Assess 
 
0.82 0.45 1.48   -0.201 0.302 0.44 0.00 0.07 
Assist  
 
1.18 0.64 2.17   0.163 0.312 0.27 0.00 0.05 
Assist – Quit Date 
 
2.42 0.95 6.21   0.885 0.480 3.40 0.00 0.13 
Assist – Self-help 
 
1.23 0.50 3.06   0.210 0.463 0.21 0.00 0.10 
Assist – Discuss Medications 
 
1.60 0.83 3.09   0.473 0.334 2.01 0.01 0.05 
Assist – Prescribe Medications 
 
1.21 0.57 2.59   0.191 0.388 0.24 0.05 0.06 
Arrange 
 
1.56 0.63 3.87   0.444 0.464 0.92 0.01 0.11 
Controlling for clinic and provider level factors  
CI= confidence interval 
*p < .05.     **p < .01.      ***p <.001.  
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Table 18: Staff performance in the delivery of tobacco treatment strategies (5As) between intervention groups 
 
Parameter                     PS Group                    FC Group Diff 
Pre Post ∆ Pre Post ∆ ∆FC - 
∆PS 
Ask  
Today’s Visit  
Last 12 months 
 
 





















Today’s Visit   
























Today’s Visit   
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Table 19: Use of smoking cessation treatments and support reported at the 4-month follow-up interview by intervention 
group 
Parameter PS Group 
 
FC Group Diff 
Pre 
 
Post ∆ Pre Post ∆ FC-UC 
Has your family doctor or another 
member of the clinic staff advised you to 

















Have you sought/received counselling for 
smoking cessation from your primary 

















In the last 12 months has your doctor or 
another member of the clinic staff 
recommended you use one of the 

















*p < .05.     **p < .01.      ***p <.001
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5.2.3 Quit attempts 
A comparison of the pre- and post-assessment performance for the PS and FC intervention 
groups for smoking outcomes is presented in Table 20. Table 21 presents the multi-level model 
controlling for clinic- and provider-level variance as well as baseline difference between groups for 
smoking abstinence. 
5.2.4 Smoking abstinence 
Contrary to the study hypothesis, a higher and statistically significant 7-day point prevalence 
abstinence (OR 6.8, 95% CI 2.1-21.7; p= <0.01) and continuous abstinence (OR 13.7, 95% CI 2.1-
128.3; p= <0.05) rate was observed in the PS group compared to the FC group at the 16-week follow-
up. The extremely large confidence interval indicates significant uncertainty surrounding the point 
estimate. It should be noted that the 7-day point prevalence abstinence rate was significantly greater in 
the FC group compared to the PS group at the pre-intervention assessment; 2.1% for the PS group, and 
14.8% for the FC group (p= <0.01). Although the post-intervention assessment documented a higher 
quit rate in the FC group, the overall change scores (pre-post) was greater in the PS group. There were 
no differences in quit attempts documented between intervention groups.  
The ICC for 7-day point prevalence abstinence was also consistent with my estimates; 
however, both quit attempts and continuous abstinence had larger ICC than originally estimated, 
indicating a greater degree of clustering. Intra-provider ICC values ranged between 0.04 to 0.14, 
indicating most of the variation observed was between individual providers within a clinic.
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Table 20: Smoking abstinence by intervention group at the pre- and post-intervention assessments 
 
Parameter PS Group 
 
FC Group ∆FC - ∆PS 
Pre Post 
 
∆ Pre Post ∆  
Full Sample - Patients Reached  
Continuous Abstinence 
Prolonged Abstinence 







  9/210 (  4.3) 








14/168 (  8.3) 




   9/147 ( 6.1) 











Full Sample - Self-reporteda 
Continuous Abstinence  












14/183 (  7.7) 
27/183 (14.8) 
 








Full Sample - Bio-chemically Validated a 










13/183 (  7.1) 
 


















a Patients who were not reached were classified as smokers. 
ppa=point prevalence abstinence 
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Table 21: Outcome estimates for smoking abstinence and quit attempts for the multi-level models examining differences 
























































































Controlling for clinic and provider level factors. 
CI = Confidence Interval.*p < .05.     **p < .01.      ***p <.001.  
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5.3 Comparison between pre- and post-intervention assessments  
5.3.1 Changes in provider performance in 5As delivery  
Figure 7 presents a comparison of rates of provider performance in the delivery of each of the 
5As at the pre- and post-intervention assessment points. For this analysis, pre-post assessment data for 
both intervention arms was combined in order to estimate the associated benefits derived from the 
multi-component intervention program implemented. Following implementation of the intervention 
program, 80% of patients reported they were advised to quit by their physicians in the last 12 months 
compared to 70% at the pre-assessment. On the day of their last visit to clinic, 62% of respondents 
reported that they were asked about their smoking status, 56% reported receiving advice to quit, 52% 
were asked if they were asked about their readiness to quit smoking, and 47% received assistance with 
quitting. Table 22 presents the outcome estimates generated from the multi-level analysis comparing 
5As delivery and smoking outcomes for the pre- and post-assessments. The multi-level analysis 
documented a significant increase in provider performance in the delivery of smoking cessation 
treatments at the post-intervention assessment for each of the 5As with the exception of setting a quit 
date and prescribing medications. The point estimates and 95% CI were: ask (OR 1.5, 95% CI 1.1-
2.0); advise (OR 2.0, 95% CI 1.5-2.7); assess (OR 2.1, 95% CI 1.6-2.9); assist (OR 2.30, 95% CI 1.70-
3.12); discuss medications (OR 1.8, 95% CI 1.3-2.5; provide self-help material (OR 4.0, 95% CI 2.6-
6.3); and arrange (OR 1.9, 95% CI 1.2-3.0).   
Table 22 also presents the ICC for intra-provider and intra-clinic variation. The ICC was 0.01 
for “discuss medications” and “arranging follow-up”, indicating less clustering of final results than 
had been expected. A slightly larger ICC value of 0.05 was calculated for “prescribing medications” 
component of “assist”. The majority of variability observed was between providers within clinics. 
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Figure 7: Provider performance in 5As Delivery Pre- and Post-Implementation for all study participants  
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Table 22: Provider performance in 5As delivery pre- and post-intervention  
 


























52.2 62.3 10.1 1.50 1.12 2.00 ** 0.41 0.15 7.6 0.00 0.04 
Advise 
 
39.2 56.4 17.2 2.02 1.53 2.67 *** 0.70 0.14 24.2 0.00 0.04 
Assess 
 
34.5 52.3 17.8 2.13 1.59 2.85 *** 0.76 0.15 25.8 0.00 0.04 
Assist 
 
28.7 46.9 18.2 2.30 1.70 3.12 *** 0.84 0.16 29.0 0.00 0.05 
Assist – Quit Date 
 
33.6 46.1 12.5 1.23 0.77 1.95  0.21 0.24 0.8 0.00 0.13 
Assist – Self-help 
 
8.1 25.2 17.1 4.02 2.56 6.33 *** 1.39 0.23 36.3 0.00 0.11 
Assist – Discuss Medications 
 
23.6 34.8 11.2 1.78 1.29 2.46 ** 0.58 0.17 12.2 0.01 0.07 
Assist – Prescribe Medications 
 
14.5 17.6 3.1 1.25 0.86 1.83  0.23 0.19 1.4 0.05 0.05 
Arrange 
 
8.9 15.3 6.4 1.94 1.23 3.04 ** 0.66 0.23 8.3 0.01 0.12 
Controlling for clinic and provider level variance between clusters.   
CI = confidence interval. 
ICC = Intra-class correlation coefficient. 
aBased on self-report data. All patients lost to follow-up were categorized as smokers. 
*p < .05.     **p < .01.      ***p <.001.    
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5.3.2 Other clinic staff 
Data on the rates at which other clinic staff (i.e., nurse, pharmacist, reception) delivered 5As is 
presented as Table 23. A large (19.6%) increase in the involvement of staff in screening for smoking 
status (i.e., “ask”) was documented. Small but statistically significant increases were also observed for 
the involvement of other clinic staff members in the “advise”, “assess”, and “assist” domains of 5As 
delivery on the day of the patient’s clinic appointment.  
5.3.3 Assistance with quitting reported at the 4-month follow-up assessment 
Table 24 presents responses collected at the 4-month follow-up telephone interview regarding 
the delivery of supplemental smoking cessation advice, counselling and pharmacotherapies. A 
statistically significant increase in both the rates of advice and recommendations regarding 
pharmacotherapy were documented. No differences were observed in the number of patients who 
reported receiving smoking cessation counselling from their primary care physician’s office between 
the pre- and post-assessment. 
5.3.4 Comparison of pre- and post-assessment data by study clinic 
Table 25 provides a summary of provider performance in 5As delivery across intervention 
clinics. Change scores for performance in 5As delivery by intervention clinic between the pre- and 
post-assessment are presented in Table 26. Significant variability was observed in provider 
performance for 5As delivery between clinics with change scores ranging from a reduction of 12.7% 
to an improvement of 43%.  
 
    
96 
Table 23: Performance of Other Staffa in the Delivery of Tobacco Treatment Strategies (5As)  
 
Parameter  
Pre Post ∆ 
Ask  
Today’s Visit  












Today’s Visit   




 60/349 (17.2) 
  






Today’s Visit   






 44/396 (11.1) 
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Post ∆ P= 
Has your family doctor or another member of the clinic staff advised you 





202/258 (78.3) +8.2 .027 
Have you sought/received counselling for smoking cessation from your 










In the last 12 months has your doctor or another member of the clinic 




149/309 (48.2) 158/255 (62.0) +13.8 .001 
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  9/54 (16) 
25/50 (50) 
 













































 4/60 ( 7) 
 
5/58 (9) 





































































































  6/56 (11) 
11/52 (21) 
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35.8 34.7 12.3 39.9 33.3 16.9 9.9 -8.4 10.1 13.2 
Clinic 2 
 
1.8 15.8 17.0 10.5 5.2 0.0 3.5 4.9 -5.8 1.4 
Clinic 3 
 
6.2 14.7 2.9 6.0 10.5 12.8 -1.2 -0.4 18.5 9.9 
Clinic 4 
 
-12.7 0.5 9.3 3.0 -2.7 -4.9 -2.9 -1.6 15.8 5.0 
Clinic 5 
 
16.2 12.6 8.6 10.5 15.8 22.8 11.6 10.5 15.6 0.7 
Clinic 6 
 
10.6 24.3 18.2 22.5 22.7 6.3 -0.7 2.8 25.1 -0.6 
Clinic 7 
  
13.5 20.4 5.3 33.1 42.9 27.4 6.5 4.8 38.5 15.2 
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5.3.5 Patient quit attempts 
Table 27 presents data for the number of patients who made a quit attempt between the exit 
interview and 4-month follow-up interview at the pre- and post-assessment. Table 28 presents the 
outcome estimates generated from the multi-level analysis comparing smoking outcomes for the pre- 
and post-assessments. A statistically significant increase was documented for the number of patient 
quit attempts between the pre- and post-assessment (31% to 37%, p<0.001; OR 1.42, 95% CI 1.04-
1.94).   
5.3.6 Smoking abstinence 
A small increase was documented in the 7-day point prevalence abstinence at the post-
assessment (7.7% vs. 11.5%; OR 1.5, 95% CI 0.94-2.5); however, observed differences were not 
statistically different (Table 27 and Table 28). No significant increase was documented between 
assessment points for continuous abstinence. Bio-chemically validated smoking abstinence was 3.6% 
vs. 5.5% at the pre- and post-assessments, respectively. Observed differences were not statistically 
significant. All biochemical samples returned confirmed smoke-free status of patients. The differential 
between the self-reported and bio-chemically validated rates reflects the large number (45%) of 
patients who did not return the biochemical sample and were coded as active smokers. The intra-clinic 
ICC for 7-day point prevalence abstinence was also consistent with a priori estimates. However, ICCs 
for both quit attempts and continuous abstinence were larger than the a priori estimates, indicating a 
greater degree of clustering. Intra-provider ICC values ranged between 0.04 to 0.13 indicating most of 
the variation observed was between individual providers within a clinic. Smoking outcomes by study 
clinics are presented as Table 29). Clinics 3 and 5 documented the largest increases in smoking 
abstinence between the pre- and post-assessment (~+15%). Clinic 7 documented an increase of 5%, 
and no changes were documented in the remaining clinics. This data should be interpreted with 
caution given the small sample size at each clinic.
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Table 27: Smoking abstinence and quit attempts reported at the 4-month follow-up pre- and post-intervention for all 
smokers and smokers ready to quit in next 30 days 
 
Parameter All Smokers Smokers Ready to Quit 
Pre Post 
 
∆ Pre Post 
 
∆ 
Participants Reached – Self-reported 
Continuous Abstinence 





















Full Sample – Self-reporteda 
Continuous Abstinence  





















Full Sample - Bio-chemically validated  


















136/370 (36.8) +6.3 58/126 (46.0) 71/120 (59.2) +13.2 
aAll patients lost to follow-up were categorized as smokers. 
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Table 28: Quit attempts and smoking abstinence reported at the pre- and post-intervention assessments  
 
Parameter % 














































3.6 4.1 0.5 1.23 0.61 2.49  0.21 0.36 0.3 0.05 0.05 
Quit attempts 
 
30.5 36.8 6.3 1.42 1.04 1.94 ** 0.35 0.16 5.0 0.02 0.04 
Controlling for clinic and provider level variance between clusters.  
CI = confidence interval. 
ICC = Intra-class correlation coefficient. 
aBased on self-report data. All patients lost to follow-up were categorized as smokers. 
*p < .05.     **p < .01.      ***p <.001.  
 
    
103 


















   20/49 (40.8) 





















































  8/52 (15.4) 
 
18/43 (41.9) 




























Reported as n/N (%). 
aBased on self-reported data for full study sample. Patients lost to follow-up were categorized as smokers. 
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5.3.7 Reasons for returning to smoking  
The reason for returning to active smoking was recorded for patients who reported having made a 
quit attempt between the exit interview and 16-week follow-up interview (Table 30).  The most commonly 
reported factor that contributed to relapse was stress (39.4%), death or illness in the family (15.6%), and 
habit (12.5%).  
 
Table 30: Patients self-reported reason for returning to smoking following unsuccessful 
quit attempt  
 
Reason n % 
Stress 63 39.4 
Death or illness in the family  25 15.6 
Habit  20 12.5 
Social environment/gathering 12 7.5 
Cravings 9 5.6 
Nerves/Emotional problems 8 5.0 
Enjoyment/Relaxation 6 3.8 
Boredom 4 2.5 
Spouse 4 2.5 
Drinking 3 1.9 
Medication side effect 3 1.9 
Lack of motivation/willpower 3 1.9 
Other 8 5.0 
No reason 5 3.1 
Don’t know 13 8.1 
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5.4 Fidelity of intervention implementation 
5.4.1 Implementation of intervention components 
Implementation results are shown in Table 31 for the pre- and post-assessment periods.  At 
baseline, most clinics had very few supports in place to assist with the delivery of evidence-based 
smoking cessation services. The majority of study clinics formed a multi-disciplinary task force, and 
all of the study clinics developed their own clinic-specific tobacco use protocol and received a training 
workshop on smoking cessation; however, the proportion of the overall physician providers who 
attended the training session varied by clinic. Two of the study clinics were no longer using the 
tobacco use survey at the post-assessment consistently (i.e., used in modified manner with subset of 
patients).    
Table 32 presents information on the proportion of providers in each clinic that completed the 
training as well as the model used to deliver the quit plan visits. Sixty-three percent of all providers 
attended the 3-hour continuing medical education workshop on smoking cessation best practices that 
was offered to both intervention groups as part of the study. Significantly more providers in the PS 
group attended the training workshop (p=0.039). Providers in clinics 1 and 7 who were not able to 
attend the workshop met one-on-one with a representative from the clinic task force to review the 
clinic tobacco control protocol.  
Three of the seven clinics had an existing staff member to whom physicians could refer 
patients who smoke for support with quitting and follow-up. At post-intervention, all seven clinics had 
identified staff trained in smoking cessation and available to be referred to for smoking cessation 
consults. Half of the clinics used front-line staff to deliver all program elements including the quit plan 
visit at the end of the patient appointment or via appointment. One clinic was not able to identify any 
non-physician staff to complete these consults and physicians delivered all program elements. The 
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other half of clinics chose to identify a dedicated staff member(s) who served as the clinic’s smoking 
cessation counsellor by appointment. These staff received smoking cessation referrals from all clinic 
physicians and conducted 10- to 30-minute visits to develop a personalized quit plan with patients 
ready to quit smoking in the next 30 days. The majority of clinics used nursing staff (RN or NP) to 
conduct the quit plan visits.  The remaining clinics used pharmacists (n=2) or physicians (n=1) in this 
role.  
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Table 31: Implementation of intervention program activities pre- and post-intervention 
 
 
Practice Implementation Activities  
 
Time Clinic Overall 
PS Group FC Group 
2 3 5 7 1 4 6 
1. Clinic task force formed   Pre - - - - - X - 1/7 
Post  X X X X X - X 6/7 
2. Clinic tobacco control protocol developed Pre - - - - - - - 0/7 
Post X X X X X X X 7/7  
3. Tobacco use queried and documented for all 
clinic patients 
Pre - - - - - - - 0/7 
Post - X X X X - X 5/7 
4. Training tobacco dependence treatment offered 
to health care providers in last year  
Pre - - - - - - - 0/7 
Post X X X X X X X 7/7 
5. Dedicated staff to provide tobacco dependence 
treatment 
Pre X X - - - X - 3/7 
Post X X X X X X X 7/7 
6. Tobacco use survey in use  Pre - - - - - - - 0/7 
Post - X X X X - X 5/7 
7. Consult form  in use  Pre - - - - - - - 0/7 
Post  X X X X X - X 6/7 
8. Process to follow-up tobacco users for at least 
one month after clinic visit in place 
Pre X - - - - X - 2/7 
Post  X X - X X X X 6/7 
9. Process to evaluate quality or program 
implementation in place 
Pre - - - - - - - 0/7 
Post  X - - X X - X 4/7 
10. Process to provide feedback to clinicians about 
performance in place 
Pre - - - - - - - 0/7 
Post X X X X X X X 7/7 
Total Pre-Assessment  2/10 1/10 0/10 0/10 0/10 3/10 0/10  
Total Post-Assessment  8/10 9/10 8/10 10/10 10/10 6/10 10/10  
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Table 32: Attendance at training workshop and service delivery model used by study clinics, study group, and overall 
















































































aProviders from clinic 1 and 7 who were not able to participate in the CME training had a brief orientation to the clinic’s tobacco control protocol conducted one-on-one by a member of 
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5.4.2 Patient participation in telephone follow-up program 
A total of 1140 referrals were received to the telephone-based follow-up system between the 
launch of the pilot program and the end of the data collection period in December 2009, including 425 
patients who were embarking upon a quit attempt. The 60-day quit rate among the patients referred for 
follow-up was 41.6%. In the calculation of quit rates, patients who could not be reached were coded as 
active smokers.  
Among patients in the FC group who took part in the study assessments 31/175 (17.7%) at the 
post-assessment agreed to be enrolled in the telephone follow-up program (see Table 33).  Among 
patients who reported they were ready to quit in the next 30-days, 32.6% were referred to the 
telephone follow-up program and 31.2% were abstinent at the end of 4 months.  
 
 
Table 33: Patients who agreed to receive the adjunct telephone follow-up support 
 










31/175 (17.7) 4/16 (25.0) 8/31 (25.8) 
Ready to Quit in Next 30 days 
 
 
7/62 (11.3) 16/49 (32.6) 2/7 (28.5) 5/16 (31.2) 
 
Sixteen patients from the FC pre-intervention assessment sample who had received a quit plan 
session were referred to the telephone-based smoking cessation program. This data indicates that 
patients were seen in the clinic again after the smoking cessation intervention was instituted at the 
clinic and were exposed to the intervention. Data was re-analyzed to remove those participants who 
were referred to the telephone-based follow-up program for whom exposure to the intervention 
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condition was known to have occurred (see Table 34). Removing these participants partially explained 
the higher quit rates observed in the FC group at baseline relative to the PS group; however, 
significant differences still remained between groups even after these cases were removed. It should be 
noted that three patients in the PS group who did not have access to the telephone follow-up program 
were referred for IVR follow-up (2/233 at baseline and 1/241 at the follow-up) indicating some cross-
over between groups.    
 
Table 34: Smoking abstinence rates overall and by study group at the pre- and post-
intervention assessment when patients who were exposed to intervention were 
removed from the analysis 
 












5/233 (2.1) 23/167 (13.8) 28/399 (7.0) 
Post  
 
25/242 (10.3) 23/177 (13.0) 48/419 (11.5) 
Δ  
 
8.1% -0.8% 4.5% 
 
 
5.5 Examination of mediating and moderating variables  
Multi-level modelling was used to examine the influence of clinic, provider, and patient 
characteristics on study outcomes.   
5.5.1 Smoking abstinence and quit attempts  
Table 35 presents the final models for smoking abstinence and quit attempts. There were no 
clinic- or provider-level characteristics that were found to be significantly associated with patient 
smoking abstinence or quit attempts. Assignment to the PS group remained a significant factor in 
predicting smoking abstinence at the post-assessment. At the level of the patient, self-reported 
readiness to quit in the next 30 days was associated with higher rates of continuous abstinence (OR 
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3.09, 95% CI 1.49-6.40). High self-efficacy defined as confidence of 7 or greater on a 10-point scale 
was found to be a modest, however statistically significant, predictor of 7-day point prevalence 
abstinence. It should be noted that both readiness to quit and self-efficacy were moderately correlated 
in models for both continuous and point prevalence abstinence and could potentially be used 
interchangeably as predictors of smoking abstinence (r=.334, p=0.01). Not having made a previous 
quit attempt in the past year was significantly associated with reporting a quit attempt at the 16-week 
follow-up.  
5.5.2 Provider performance in 5As delivery 
Tables 36 and 37 present the final models for provider performance in each of the 5As 
strategies. No significant relationship between clinic characteristics and provider performance in 5As 
delivery was documented. At the level of the provider, provider age was found to have a small but 
statistically significant association with the rates at which self-help materials were provided to patients 
and medications discussed. Female providers and non-physician staff members (i.e., residents or nurse 
practitioners) were more likely to arrange follow-up appointments for patients to discuss smoking 
cessation. No other relationship between provider characteristics and outcomes was found.   
 




Table 35: Final model for the multi-level analysis of clinic, provider, and patient characteristics related to smoking  
cessation outcomes 
 










   
Patient Characteristics           
Confidence 1= greater than 7/10    1.10 (1.01, 1.20)*     
Ready to quit in next 30 days 1=yes 3.09 (1.49, 6.40)**       
Previous quit attempt in last year 1=yes     0.43 (0.31, 0.60)***   
Provider Characteristics            
-           
Clinic characteristics           
-           
Intervention            
Group  1= FC Group 0.06 (0.01, 0.45)** 0.16 (0.06, 0.41)*** 0.71 (0.52, 0.98)*   
Time  1=Post Assessment         
Interaction Effects           
Group x Time   9.19 (1.17, 72.4)* 4.95 (1.85, 13.25)**     
CI = confidence interval. 
*p < .05.     **p < .01.      ***p <.001.   
Note: Continuous Abstinence (1=32, 0=803), 7-Day Point Prevalence Abstinence (1=80, 0=755), Quit Attempt (1=249, 0=491). 
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At the level of the patient, having fewer years of formal education was associated with higher 
rates of being asked about smoking status, advised to quit, prescribed quit smoking medications, and 
receiving follow-up. The presence of a smoking-related illness was associated with increased rates of 
asking and advising but not with any of the other 5As strategies. One of the most significant factors 
associated with 5As delivery was the nature of the clinic encounter on the day of the assessment. 
Patients who were seen in clinic for an annual exam were more likely to be asked about smoking 
status (OR 8.2, 95% CI 4.6-14.6), advised to quit (OR 4.7, 95% CI 3.0-7.5), assessed for readiness to 
quit (OR 5.3, 95% CI 3.4-8.3), receive assistance with quitting (OR 4.8, 95% CI 3.1-7.4), receive self-
help materials (OR 2.1, 95% CI 1.2-3.6), discuss medications (OR 3.0, 95% CI 1.8-4.9), and receive a 
prescription for a quit smoking medication (OR 1.9, 95% CI 1.1-3.5) compared to patients who were 
seen for a follow-up appointment or other appointment. As would be expected, patients who were 
ready to quit in the next 30 days reported receiving self-help material, setting a quit date, discussing 
medication, and receiving a prescription for a quit smoking medication statistically more often than 
patients who were not ready to quit. A small relationship between time to first cigarette in the morning 
(a predictor of nicotine addiction) and rates of advising, assessing, and prescribing medications was 
documented. Having had at least one unsuccessful quit attempt in the last year was also associated 
with receiving a prescription for a quit smoking medication. Patients were more likely to have had set 
a quit date on the day of their visit if they were ready to quit in the next 30 days and had high levels of 
self-efficacy as well as those patients who ranked importance of quitting as high (7 or more on a scale 
of 1 to 10). Within the final models, the time variable (post-intervention period) remained a significant 
factor, predicting rates of asking, advising, assisting, providing self-help materials, discussing 
medications, and arranging follow-up. As was documented in the main multi-level model, the time 
(pre vs. post) variable was not significantly associated with setting a quit date or prescribing 
medications in the final models.  
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Table 36: Final model for the multi-level analysis of clinic, provider, and patient characteristics related to rates of provider  
delivery for ask, advise, assess and assist  
 
Parameter Response OR (95% CI) 
Asking Advising  Assessing Assisting  
 
Patient Characteristics           
Education 1% for every year 0.93 (0.88, 0.98)** 0.94 (0.88 . 0.99)*     
Smoking-related illness 1=yes 1.70 (1.22, 2.37)** 1.64 (1.18, 2.29)**     
Purpose of Clinic Visit  1=annual exam  8.18 (4.6, 14.6)*** 4.74 (3.01, 7.47)*** 5.3 (3.4, 8.3)*** 4.78 (3.09, 7.40)*** 
Time to first cigarette 1=within 30 mins   1.64 (1.17, 2.30)** 1.87 (1.33, 2.64)***   
Readiness to Quit  1=Ready   1.65 (1.18, 2.32)**    
Cigarettes/day 1% for every cigarette       1.03 (1.01, 1.05)** 
Years smoking 1% for every year       1.01 (1.00, 1.03)* 
Quit Attempt in Last Year 1=Yes         
Other smokers in home 1=yes 1.60 (1.16, 2.22)**       
Confidence  1=greater than 7/10     1.07 (1.01, 1.14)* 1.09 (1.02, 1.16)** 
Importance 1= greater than 7/10  1.10 (1.04, 1.15)**   1.09 (1.03, 1.15)** 1.12 (1.1, 1.2)** 
Intervention            
Time  1=Post Assessment 1.4 (1.01, 1.95)* 2.22 (1.60, 3.09)*** 1.90 (1.38, 2.62)*** 2.20 (1.55, 3.12)*** 
Group           
Interaction Effects           
Group x Time           
Random  variance (SE) 
Clinic            
Provider           
OR = Odds Ratio; CI = confidence interval; SE = Standard error.   
*p < .05.     **p < .01.      ***p <.001.   
Note : Ask (1=465,0=348), Advise (1=386,0=420), Assess (1=349,0=456), Assist (1=304,0=501). 
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Table 37: Final model for the multi-level analysis of clinic, provider, and patient characteristics related to rates of delivery 
for the provision of self-help materials, setting quit date, discussing and prescribing medications, and arranging follow-up 
 
Parameter Response OR (95% CI) 





Patient Characteristics             
Education 1% for every year       0.88 (0.81, 0.96)** 0.90 (0.83, 0.98)* 
Smoking-related illness 1=yes           
Purpose of Clinic Visit  1=annual exam  2.06 (1.17, 3.63)**   2.98 (1.8, 4.9)*** 1.91 (1.06, 3.45)*   
Time to first cigarette 1=within 30 mins       2.11 (1.21, 3.68)**   
Readiness to Quit  1=ready 2.41 (1.47, 3.94)** 4.10 (2.20, 764)*** 2.45 (1.6, 3.7)*** 1.91 (1.12, 3.27)*   
Cigs/day 1% for every cigarette     1.03 (1.0, 1.1)*     
Years smoking 1% for every year           
Quit Attempt in Last Year 1=yes       2.01 (1.17, 3.44)**   
Other smokers in home 1=yes           
Confidence  1=greater than 7/10   1.17 (1.05, 1.29)**   1.20 (1.09, 1.33)***   
Importance 1= greater than 7/10    1.32 (1.12, 1.55)**     1.48 (1.30, 1.68)*** 
Provider Characteristics              
Provider Age 1% for every year 1.03 (1.0, 1.07)*   1.03 (1.01, 1.06)*     
Provider Gender 1=male         0.37 (0.16, 0.87)* 
Health Professional  1=physician         0.53 (0.30, 0.93)* 
Intervention              
Time  1=post-assessment 5.46 (3.1, 9.7)***   1.94 (1.27, 2.96)**  1.81 (1.10, 2.99)* 
Group            
Interaction Effects             
Group x Time             
Random  variance (SE) 
Provider   0.21 (0.187) 0.526 (0.284) 0.135 (0.128)   0.215 (0.204) 
OR = Odds Ratio; CI = confidence interval; SE = Standard error.  
*p < .05.     **p < .01.      ***p <.001.     
Note: Self-help material (1=135, 0=673), Set Quit Date (1=88, 0=739), Discuss Medication (1=234, 0=569), Prescribe Medication (1=129, 0=674), Arrange (1=101, 0=729). 
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5.5.3 Patients ready to quit smoking in the next 30 days 
Participants who reported they were ready to quit smoking in the next 30 days on the exit 
survey were more likely to receive “assistance” with quitting and be “prescribed a quit smoking 
medication” than the overall study sample (see Table 38). However, only about half of participants 
ready to quit smoking reported receiving assistance with quitting at the exit survey. It should be noted 
as per above that several of the 5As areas assessed (i.e., “set quit date”, “prescribe medications”) 
would likely have been delivered at a separate clinic appointment (quit plan visit) and, as such, not 
captured as part of the exit survey. At the post-assessment, participants were twice as likely to have a 
follow-up appointment arranged to discuss smoking cessation than at the pre-assessment.  
Among patients ready to quit smoking in the next 30 days, a significant increase in the number 
of quit attempts was documented between the pre- and post-assessment (46% to 59%, p=0.04; OR 1.7, 
95% CI 1.03, 2.8). This is a greater increase than that observed in the overall sample. A 7% increase 
was documented in the 7-day point prevalence abstinence at the post-assessment (11% vs. 18%, 
p=.074; OR 1.9, 95% CI 0.94, 3.8); however, observed differences were not statistically different. 
There were no changes documented between assessment points for continuous abstinence.   
5.5.4 Type of clinic visit  
The evaluation found patients at both the pre- and post-assessment were significantly more 
likely to be “asked” about smoking status if they were scheduled for an annual physical compared to 
other types of clinic appointments. A similar pattern was observed for each of the 5As at both the pre- 
and post-assessment (see Figure 8), with the exception or “quit date”, and “prescribe medication”, for 
which a small decline was documented between the pre- and post-assessment. Interestingly, patients 
who were surveyed following their annual exam did not report as many quit attempts at the 16-week 
follow-up assessment.
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Table 38: Provider performance in 5As delivery and smoking outcomes pre- and post-intervention for participants who are 
























Provider Performance                     
Ask 73/138 86/130 52.9 66.2 13.3 1.74 1.06 2.85 ** 0.554 0.25 4.8 
Advise 61/136 81/128 44.9 63.3 18.4 2.11 1.29 3.47 *** 0.751 0.25 8.9 
Assess 51/136 76/126 37.5 60.3 22.8 2.53 1.54 4.17 *** 0.930 0.25 13.4 
Assist  51/137 68/125 37.2 54.4 17.2 2.01 1.28 3.30 *** 0.699 0.25 7.7 
Assist – Quit Date 31/141 37/128 22.0 28.9 6.9 1.44 0.83 2.51   0.367 0.28 1.7 
Assist – Self-help 19/137 40/129 13.9 31.0 17.1 2.79 1.51 5.14 *** 1.026 0.31 10.8 
Assist – Discuss Medications 46/137 58/125 33.6 46.4 12.8 1.71 1.04 2.82 * 0.538 0.26 4.46 
Assist – Prescribe Medications 33/138 40/126 23.9 31.7 7.8 1.48 0.86 2.54   0.392 0.28 2.0 
Arrange 20/141 38/131 14.2 29.0 14.8 2.47 1.35 4.53 ** 0.905 0.31 8.6 
Smoking Outcomes, 16 weeksa                    
7-day point prevalence 15/141 24/131 10.6 18.3 7.7 1.88 0.94 3.77   0.633 0.35 3.2 
Continuous abstinence 11/141 12/131 7.8 9.2 1.4 1.19 0.51 2.80   0.175 0.44 0.2 
Quit attempts 58/126 71/120 46.0 59.2 13.1 1.70 1.03 2.82 * 0.530 0.26 4.2 
 
Controlling for clinic and provider level factors.          
CI = confidence interval.             
*p < .05.     **p < .01.      ***p <.001.    
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Figure 8:  Comparison of provider delivery of 5As at the pre- and post-intervention for those patients screened  
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Chapter 6 Discussion 
6.1 Summary and interpretation of the findings   
6.1.1 Incremental value of extended adjunct telephone-based smoking cessation 
counselling  
The primary objective of this study was to compare the incremental impact of delivering 
adjunct telephone-based follow-up counselling as part of a multi-component intervention in primary 
care practice. As hypothesized, improvements in provider delivery of evidence-based smoking 
cessation treatments were documented in both study intervention groups at the post-intervention 
assessment with no differences between groups. Contrary to the study hypothesis, FC clinics that had 
the ability to refer patients to a telephone-based smoking cessation counselling program did not 
document greater improvement in patient smoking abstinence at the 4-month follow-up compared to 
baseline. Moreover, a higher and statistically significant increase in 7-day point prevalence abstinence 
(OR 6.8, 95% CI 2.1, 21.7; p= <0.01) and continuous abstinence (OR 13.7, 95% CI 2.1, 128.3; p= 
<0.05) was observed in the PS group compared to the FC group at the 4-month follow-up. These data 
should be interpreted in light of the large confidence intervals surrounding this point estimate, which 
indicates significant uncertainty.  
The results of the present study are in contrast to a study by Borland and colleagues (2008), who found 
that the referral of primary care patients who smoke to a quit line doubled quit rates compared to the 
standard in-clinic primary care treatment (Borland et al. 2008, 382-389). A 2006 study by An et al. 
also found that telephone-based behavioural counselling delivered over a 2-month period was effective 
in increasing smoking abstinence at the 12-month follow-up [OR 3.50; 95% CI 1.99, 6.15] (An et al. 
2006, 536-542). These studies compared adjunct counselling delivered in isolation to no intervention 
in a primary care setting. In the present trial, a multi-component intervention program providing 
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practice and provider-level supports was used as the comparator. Five previous studies of multi-
component interventions have included extended adjunct counselling in addition to practice and 
provider-level intervention strategies; each trial was able to document a positive impact on smoking 
abstinence (Grandes, Cortada, and Arrazola 2000, 803-807; Pieterse et al. 2001, 182-190; Katz et al. 
2002, 293-301; Young, D'Este, and Ward 2002, 572-583; Katz et al. 2004, 594-603). However, this 
data is confounded by the fact that cost-free pharmacotherapies were also provided to patients in four 
of the five trials. A recent study by Rothemich and colleagues (2010) found that an expanded tobacco 
use vital sign combined with fax referral to a quitline, and provider feedback on quitline referrals 
increased the number of patients who reported receiving cessation support compared to a traditional 
tobacco use vital sign (Rothemich et al. 2010, 367-374). This study did not report on the subsequent 
impact on patient smoking abstinence. To my knowledge, the current study is the first randomized 
control trial that attempts to isolate the value of patient-level follow-up counselling in the primary care 
setting when delivered as part of a multi-component intervention on patient smoking abstinence.  
The study hypothesis that adjunct telephone-based counselling would increase smoking 
abstinence was based on previous work that has documented a relationship between extended 
counselling and improved patient smoking outcomes (Fiore et al. 2008; Stead, Bergson, and Lancaster 
2008b, CD000165; Papadakis et al. 2010, 199-213). Given the time and  
resource constraints reported in the primary care setting for delivering such follow-up support, it was 
hypothesized that linking patients to adjunct follow-up counselling conducted by individuals external 
to the practice could serve as a feasible method to “extend treatment” when delivered in conjunction 
with initial intervention provided by primary care providers (Zhu et al. 2002, 1087-1093; Smith et al. 
2009, 47-53). A crude assessment of the study data would lead one to conclude that the multi-
component intervention program tested, which included practice and provider-level supports, was  
more likely, to increase smoking abstinence than providing access to a telephone-based smoking 
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cessation follow-up program for patients. However, a closer examination of the data suggests that 
factors related to program implementation may have confounded study outcomes. The lack of a 
significant increase in smoking abstinence at the 4-month follow-up needs to be examined in light of 
the significant differences in rates of smoking abstinence documented between intervention groups at 
the pre-assessment: 2.1% vs. 14.8% in the PS and FC group, respectively. Data indicates that 16 
patients from the FC group pre-intervention assessment were seen at the clinic again after the smoking 
cessation intervention was instituted at the clinic and were exposed to the intervention. It appears 
likely that exposure to the intervention may in part explain the larger quit rate observed among 
patients in the FC group prior to the program being implemented. Removing these participants 
partially explained the higher quit rates observed in the FC group at baseline relative to the PS group; 
however, significant differences still remained between groups even after these cases were removed. It 
is not possible to determine if patients from the pre-intervention sample, other than those referred to 
the telephone follow-up system, received support from the clinic as a result of the intervention 
program, which may have affected study outcomes.        
Patients sampled at the PS group post-assessment reported receiving both prescriptions for 
first-line quit smoking medications and follow-up support more frequently than participants in the FC 
group. For example, a 16% increase in the number of patients who were recommended 
pharmacotherapy was documented in the PS group compared to a 10% increase observed in the FC 
group. The higher rates at which assistance and follow-up were provided to patients may explain the 
observed improvement in smoking abstinence in the PS group relative to the FC group. This data also 
suggests that it may be feasible for some primary care clinics to deliver follow-up support to patients 
with existing resources, at least as part of a research study.   
Other factors that may have contributed to the larger increase in quit rate observed in the PS 
group following implementation of the program may include differences in the characteristics of 
 
    
122 
patients sampled between groups. Significantly more patients in the PS group compared to the FC 
group reported being depressed at both the pre- and post-intervention assessment periods. Although 
the presence of anxiety or depression was not found to be significantly associated with smoking 
abstinence in the final study models, the known association between anxiety and depression and 
smoking abstinence may offer insight into the observed differences documented at baseline in quit 
rates between groups.   
Another factor to be considered in the interpretation of outcomes related to smoking 
abstinence is the possibility that the implementation of the telephone follow-up program was not 
executed as planned. Data suggests that not all patients who were ready to quit in the FC group were 
referred to the telephone follow-up program. Among all patients screened at FC clinics at the post-
assessment, only 17.7% agreed to be enrolled in the telephone follow-up program. The proportion of 
patients who were referred to the telephone follow-up program increased to 33% when only the subset 
of patients who were ready to quit in the next 30-days was examined. Patients who were referred for 
telephone follow-up were more likely to be ready to quit smoking and to have been seen by a provider 
who reported lower self-efficacy to deliver smoking cessation counselling. Among those patients who 
were referred to the telephone follow-up program, the rate of 7-day point prevalence abstinence at the 
4-month follow-up was 31.2%.   
It is also possible that the mode of delivery and/or schedule of contacts used in the telephone-
based counselling program tested in the present study was not acceptable to some patients identified in 
the clinic setting and contributed to lower levels of uptake by patients. Other authors have reported 
that patient attitudes towards smoking cessation program supports are poor, and that these attitudes 
may impede patient interest in these services (Vogt, Hall, and Marteau 2010, 160-166). Given that the 
follow-up counselling intervention tested in the present study used an IVR system to deliver follow-up 
telephone calls to patients, the system was able to triage people who were in need of smoking 
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cessation counselling to a smoking cessation specialist for more specialized counselling and support. 
The IVR system has the potential to be a cost-effective method for intervening with large volumes of 
patients who smoke. There has been limited research on the acceptability of IVR-mediated telephone 
follow-up supports among patients who smoke. Only one study in the primary care setting has looked 
at the use of IVR for smoking cessation; in this study, IVR was used solely to assess the smoking 
status and readiness to quit of clinic patients prior to their quit appointment (McDaniel et al. 2005, 
S57-66). Outside of the primary care setting, IVR-mediated telephone follow-up counselling for 
smoking cessation has been evaluated in a pilot study of hospitalized patients who smoke with 
coronary artery disease (Reid et al. 2007, 319-326). The study found the system was an acceptable 
modality for delivering smoking cessation follow-up support to smokers. Due to the sample size, the 
increase in 12-month smoking abstinence favouring the IVR group that was documented was not 
statistically significant. A second study, which combined IVR-mediated calls with web and text 
message communication to deliver smoking cessation interventions to smokers recruited via the 
Internet in Norway, found a statistically significant increase for the IVR intervention compared to 
controls (Brendryen and Kraft 2008, 478-84). Data regarding personal preferences of patients in regard 
to the mode of delivery of follow-up support was not examined in the present study.  
 
6.1.2 Comparison of pre- versus post-intervention data   
The secondary objective of this study was to examine whether the introduction of a multi-
component intervention in primary care clinics is associated with higher rates at which evidence-based 
smoking cessation treatments (5As) are delivered to patients and, subsequently, to increased quit 
attempts and smoking abstinence among patients.   
In regard to 5As delivery, although the present study lacks an untreated control group, the 
results of the pre vs. post assessment provides evidence that the implementation of the multi-
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component intervention program, which combined outreach visits with practice supports, provider 
training, and performance feedback, was associated with a significant increase in the rates at which 
most evidence-based cessation treatments are delivered by primary care practitioners. These findings 
are consistent with previous research, which has shown multi-component intervention programs to be 
effective in improving primary care provider performance in 5As delivery (Kottke et al. 1992, 701-
708; Grandes, Cortada, and Arrazola 2000, 803-807; Grimshaw et al. 2001, II2-45; Pieterse et al. 
2001, 182-190; Young, D'Este, and Ward 2002, 572-583; Anderson and Jane-Llopis 2004, 299-312; 
Katz et al. 2004, 594-603; Unrod et al. 2007, 478-484; Fiore et al. 2008; Papadakis et al. 2010, 199-
213;). Table 39 provides a comparison of the odds ratios (OR) documented in the present study for the 
pre- and post-intervention assessments and the pooled OR for previously published multi-component 
interventions conducted in the primary care setting (Papadakis et al. 2010, 199-213). Observed 
increases in the present study for “ask”, “advise”, and “assess” are of a comparable magnitude to that 
of published research studies. However, increases observed following the introduction of the multi-
component intervention in the present study for “setting a quit date” and “prescribing medications” 
were lower rates than had been previously reported in the literature. Only one previous study has 
reported on the impact of a multi-component intervention on the rates at which follow-up support was 
arranged in primary care settings (Unrod et al. 2007, 478-484). Unrod and colleagues (2007) reported 
a large effect estimate, which was not achieved in the present study.   
Data gathered in the present study should, however, be interpreted with caution, given that 
many study clinics scheduled a separate quit plan appointment for patients who were ready to quit in 
the next 30 days. At this quit plan visit, clinicians would set a quit date, discuss medications, and 
arrange for supplemental follow-up support. The exit survey was limited to capturing information 
regarding activities that occurred on the day the patient was originally seen in the clinic. As such, it 
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may only be appropriate to compare data from the exit survey to rates at which patients were “asked”, 
“advised”, and “assessed” from previous trials.  
 
Table 39: Comparison of odds ratio for the pilot study and published trials of multi-
component interventions in primary care setting 
 
Outcome  Pilot Study  
Pre vs. Post 
Published Multi-component 
Interventions 
OR [95% CI} # Trials Pooled OR [95% CI]  
Ask 1.50 [1.12, 2.00]  6 1.79 [1.6, 2.1] 
Advise 2.02 [1.53, 2.67] 7 1.60 [1.4, 1.8] 
Assess 2.13 [1.59, 2.85] 3 1.92 [1.4, 2.7] 
Assist 2.30 [1.70, 3.12] 1 1.22 [0.8, 1.9] 
Assist – Set Quit Date 1.23 [0.77, 1.96]  5 3.45 [2.8, 4.2] 
Assist – Prescribe Medications 1.25 [0.86, 1.83] 4   9.29 [6.8, 12.8] 
Arrange 1.94 [1.23, 3.04] 1  8.53 [5.1, 14.2] 
Smoking Abstinence 1.52 [0.94,2.46] 7 2.19 [1.7, 2.8] 
 
In regard to the impact of the multi-component intervention program on the number of 
patients who made a quit attempt, patients from the post-intervention assessment sample reported 
making a quit attempt more often than the baseline sample, with an overall increase in quit attempts of 
7% documented. Among patients who reported they were ready to quit smoking in the next 30 days, 
there was a 13% increase in the number of quit attempts made by patients between the pre- and post-
assessment samples. Patients who received advice to quit at the time of their visits were more likely to 
report making a quit attempt at the 4-month follow-up. These data lend support to the hypothesis that 
the intervention program was associated with increased patient motivation to quit as well as with 
accelerating a quit attempt among patients who had been contemplating quitting. A significant 
increase in patient self-efficacy was documented at the post-assessment compared to pre-intervention.  
 
    
126 
There was a 3.8% improvement in self-reported 7-day point prevalence smoking abstinence 
between patients sampled at the pre- and post-assessment; however, observed differences were not 
statistically significant. For the respondents who reported a readiness to quit in the next 30 days, a 
7.7% increase in 4-month point prevalence smoking abstinence was documented following the 
implementation of the intervention program. Previous evaluations of multi-component interventions 
reported increases in smoking abstinence that ranged between 3.8% and 15%. For example, in a 
randomized controlled trial conducted by Katz et al. (2004) that involved eight primary care clinics 
and 2163 patients, an adjusted OR of 1.7 [95% CI 1.2, 2.6] was reported for smoking abstinence 
measured at 6 months of follow-up, representing a 5% increase in patient quit rates between the 
intervention and control group (15.4% vs. 9.8%) (Katz et al. 2004, 594-603). The intervention 
program tested by Katz and colleagues (2004) involved: (1) physician tutorial in delivery of 5As; (2) 
real-time provider reminders using a modified vital signs stamp applied to progress notes with 
questions to stratify a  
patient’s stage of readiness; (3) an 8-week supply of NRT patches and self-help material; (4) telephone 
counselling for eligible patients, which involved telephone counselling via a centralized cessation 
counselling service prior to and one week following the patient’s quit date; and (5) feedback to intake 
clinicians on performance of guideline recommended activities delivered at baseline and interim. A 
second, by Grandes, Cortada and Arrazolla (2000), tested a multi-component intervention program 
using a before-after controlled trial design involving 10 primary care clinics and over 1700 patients, 
reporting a 5% increase in smoking abstinence compared to control group [2.1% vs. 7.1%; OR 3.50, 
95% CI 1.90, 6.47] at 12 months of follow-up. The multi-component intervention program tested 
included development of a therapeutic plan for patients (i.e., setting quit date and prescribing NRT), 
follow-up calls placed by physicians on the quit day and 15 days following the patient’s quit day, and 
in-person follow-up consultation at 4 and 8 weeks (Grandes, Cortada, and Arrazola 2000, 803-807). 
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Given that smoking abstinence in the present trial was assessed at the end of 4 months, the increases 
documented are slightly lower than that reported in previously published studies, which report 
outcomes after at least 6 months of follow-up (see Table 39).  
There are several conclusions that can be drawn regarding the non-significant increases in 
smoking abstinence observed between the pre- and post-assessments in the present study. The first is 
that the documented 4% increase in smoking abstinence is an important population-level association; 
however, limitations related to the sample size were not sufficient to appropriately power the study. It 
was known a priori that the study was not powered to detect differences of less than 10%. A larger 
trial would therefore be required to provide more conclusive evidence regarding the value of the 
program in improving patient smoking abstinence. Another possibility is that the changes observed in 
provider behaviours do not consistently translate into changes in patient smoking abstinence. The so- 
called “hardening” hypothesis has been previously discussed in the literature (Warner and Burns 2003, 
37-48). The hypothesis suggests that relative to earlier generations of smokers many individuals who 
smoke today may have specific needs and challenges that make them less willing to make a quit 
attempt as well as make it more difficult to modify long-term smoking behaviours. A recent Canadian 
study estimated that the prevalence of “hardcore smokers” in Ontario ranges from 0.03% to 13.77% 
(Costa et al. 2010, 860-864). This suggests that people who are considered to be “hardcore smokers” 
constitute a relatively small fraction of the population (Augustson and Marcus 2004, 621-629). The 
present study had limited ability to evaluate social variables and their role in predicting outcomes. It is 
possible that social context and other factors play a larger role than the intervention itself in 
determining smoking outcomes and may assist with explaining the observed impacts on smoking 
abstinence in the present trial. Stress was the most common reason patients reported relapse to active 
smoking in the present trial.  
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6.1.3 Multi-level modelling of patient, provider and clinic-level variables in predicting 
study outcomes 
Although several published studies of multi-component interventions in primary care settings 
have controlled for clinic-level variation in outcome estimates using hierarchical modelling, few have 
reported on clinic and provider characteristics that are associated with outcomes of interest (Quinn et 
al. 2005, 77-84; Ulbricht et al. 2006, 232-238; Bentz et al. 2007, 341-349). The present study was able 
to examine a sub-set of provider and patient-level factors that were hypothesized to mediate and/or 
moderate the association between intervention and outcomes of interest. As has been reported in the 
literature, the presence of smoking-related illness was predictive of patients being asked and advised to 
quit; however, having a smoking-related illness did not increase the likelihood that patients would 
receive assistance with quitting or follow-up support to address smoking ( Wynn et al. 2002, 997-999; 
Martinson et al. 2003, 125-132; Steinberg et al. 2006, 405-412; Azuri et al. 2009, 710-717). In contrast 
to previous research (Lucan and Katz 2006, 16-23; Browning et al. 2008, 55-61), which has reported 
that patients with higher education are more likely to be advised to quit, the present study found that 
participants with fewer years of formal education were more likely to be asked about their smoking 
status, advised to quit, prescribed a quit smoking medication, and have a follow-up appointment 
arranged. Further research is required to understand the possible explanation of this previously 
unreported finding.   
The type of patient visit had a significant influence on the rate at which smoking cessation 
treatment was delivered to patients. Patients were eight times more likely to be asked about smoking 
status, five times more likely to be advised to quit or report receiving assistance with quitting, and 
twice as likely to receive self-help materials and discuss medications if the purpose of their visit was 
for an annual exam compared to other types of appointments. The higher rates at which smoking 
cessation treatments are delivered at appointments for annual exams is likely related to the fact that 
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these visits are typically longer in duration, therefore making intervention more feasible. Annual 
health exams are also typically the time during which preventative health issues are raised with 
patients in primary care, and higher rates of cessation interventions at the annual health exam have 
been previously documented in the literature (Litaker et al. 2005, 556-563).   
Participants who reported they were ready to quit in the next 30 days were three times more 
likely to be abstinent at the follow-up after controlling for other variables. Being ready to quit in the 
next 30 days made it more likely that a patient received advice to quit, “assistance” with quitting, and 
were “prescribed a quit smoking medication” on the day of his or her visit to the clinic when compared 
to those not ready to quit in the next 30 days. However, only about half of patients who were ready to 
quit smoking reported receiving assistance with quitting at the exit survey. Moreover, although a two-
fold increase was observed in the number of patients ready to quit smoking with whom a follow-up 
appointment was arranged, two thirds of participants who were ready to quit were not scheduled for a 
follow-up appointment at the post-assessment, thereby indicating a missed opportunity to provide 
evidence-based care to patients interested in quitting.   
Interestingly, study participants who had not made a quit attempt in the last year were more 
likely to report making a quit attempt between the exit survey and telephone follow-up assessment 
four months later. This finding is contrary to a study by Browning and colleagues (2008) that reported 
higher quit rates among individuals who made at least one prior quit attempt in the last year 
(Browning et al. 2008, 55-61).   
The present study found moderate provider-level variation in the rates at which asking, 
advising, and assessing was delivered to patients with ICCs values ranging between 0.04-0.05. 
However, the study did document larger intra-provider variability (ICC between 0.07 to 0.14) in the 
rates at which patients received self-help materials, set a quit date, discussed medications, and had 
follow-up support arranged, as well as for 7-day point prevalence abstinence. In all cases, intra-
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provider variability was larger than the intra-clinic variability observed. In the final models, female 
providers were significantly more likely to refer patients for follow-up support, a finding that has been 
previously reported in the literature (O'Loughlin et al. 2001, 627-638; Schnoll et al. 2006, 233-239). In 
addition, nurse practitioners were more likely to arrange follow-up support than physicians, with no 
other differences observed between providers and nurse practitioners or medical residents in 5As 
delivery. These provider-level factors, however, only partially explain the observed differences 
between providers; further investigation is required to better understand important factors associated 
with intra-provider variation in 5As delivery.    
The multi-level analysis documented minimal clinic-level variance in 5As delivery, and in 
some cases, no variance was found between clinics. It is likely that the lack of documented variance is 
a result of the limited number of clinics involved in the pilot study. The present study did, however, 
document trends that may be used to generate hypotheses regarding possible clinic-level factors that 
influence outcomes. A large range was documented for change scores between study clinics for 5As 
delivery between the pre- and post-intervention assessments, with change scores ranging from a 
reduction of 12.7% to an improvement of 43%. Clinics can be categorized into three groups according 
to documented increases in 5As delivery: high performers, moderate performers, and poor performers. 
The largest improvements in 5As delivery were noted in clinics 1, 6, and 7. Clinics 2, 3, and 5 showed 
moderate improvements at the post-assessment. The poorest performance was documented in clinic 4, 
for which performance declined from the pre- to post-assessment in several domains of the 5As. 
Examination of the data related to program implementation suggests that factors such as baseline rate 
of 5As delivery were low and that having both a nurse and physician champion may be associated 
with greater improvements in 5As delivery.  
The fidelity of the intervention’s implementation among participating clinics was also 
examined as part of this study. There was variation between clinics in the implementation of the 
 
    
131 
intervention program. Trends were observed between the number of intervention activities in place at 
the post-assessment and the overall improvements in 5As delivery documented among study clinics. 
The failure of some clinics to implement intervention activities may explain the lack of observed 
changes in study outcomes. For example, clinic 4, which had the fewest number of intervention 
activities implemented at the follow-up, also had the lowest overall changes in study outcomes at the 
post-assessment. This finding emphasizes the importance of high quality implementation of future 
programs.   
6.1.4 Who did the intervention reach? 
The rationale for intervening in primary care settings is that  this setting offers the opportunity 
to interact with large numbers of smokers during a potentially teachable moment; intervention should 
result in more smokers making a quit attempt.  It may be useful as such to examine the potential reach 
of smoking cessation programs delivered in primary care and any potential biases in the population of 
smokers reached. Thirteen per cent of patients screened in the study smoked daily and consumed an 
average of 15.6 cigarettes per day, which is consistent with the overall population of smokers in both 
Ontario and Canada (CTUMS 2010; Ontario Tobacco Research Unit 2010). Smoking prevalence rates 
varied significantly between study clinics, ranging from 12% to 29%. The highest rate of smoking was 
documented in the single rural clinic. This pattern is consistent with previously reported rates of 
smoking for sub-regions within the Champlain District, which range from 14.1% in the City of Ottawa 
to 26% in surrounding public health regions (Statistics Canada 2009). Data from the present study 
suggests that the primary care setting is well suited to supporting interactions with patients 45 to 64 
years old which represents the largest group of smokers in Canada. However, relative to the known 
population of people who smoke in Canada, fewer younger men (aged 20 to 34) participated in the 
present study. This finding supports previous reports that primary care settings may not be well suited 
to reaching the young males who smoke (Jaakkimainen et al. 2006). It would be important to note that 
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a significant proportion of patients from the pre-post assessment samples reported the presence of 
anxiety (29%) or depression (27.5%). While these rates are large, they are lower than the rates of 
anxiety and depression that have been reported for the general population of people who smoke in the 
United States (Lasser et al. 2000, 2606-2610). Only limited comparable data is available for smokers 
in Canada. The single paper to report rates of major clinical depression in Canada suggests the overall 
rate is 10% and 19% for high-dependence smokers (Khaled et al. 2009, 204-208). 
In regards to the ability of a primary care visit to serve as a teachable moment for patients, 
almost 60% of respondents indicated the advice of their primary care physician was either an 
“extremely important” or “important” factor in motivating them to quit smoking at the baseline 
assessment. In the present study, almost 70% of participants who smoke reported they were interested 
in quitting smoking in the next 6 months, and one third of all participants reported they were ready to 
quit in the next 30 days. Readiness to quit in the next 30 days was higher among study participants 
than that which has been reported nationally, and patients were also more likely to have made a quit 
attempt in the last year. These data suggest that respondents may represent a sub-set of patients with 
greater readiness to quit than the overall population of smokers in Canada.  
A comparison of participants in the present study to those in a recent evaluation of the Ottawa 
Model for Smoking Cessation in the hospital setting indicates overall prevalence of smoking is similar 
in both clinical settings (15% vs. 19.8%) (Reid et al. 2010, 11-18).  Participants sampled were almost 
10 years younger (45.8 ± 14.6 years vs. 55.6 ± 17.4 years) than the hospital sample with a smaller 
proportion of men sampled (41% vs. 60%). Patients from the present study reported similar levels of 
nicotine dependence with 54% smoking within 30 minutes of waking versus 58% in the sample of 
hospitalized smokers.  
Comparison of the characteristics of smokers from the present study with that reported in a 
large trial of a multi-component intervention conducted in primary care settings showed the samples 
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were similar. The mean age of participants in a study by Katz et al. (2004) was 42 years and 45% of 
participants were male who smoked an average of 17 cigarettes per day (Katz et al. 2004, 594-603). 
The mean years of formal education for participants in the present study was higher than in the study 
by  Katz et. al..  
6.2 Study limitations and generalizability  
The study findings should be interpreted in the context of the study’s limitations. There are 
several factors that may undermine the study’s internal validity; that is, the ability to make correct 
inferences about the relationship between the independent variable and the outcome of interest as well 
as the ability to generalize the study findings to other populations, settings, and treatments. Potential 
threats to the study’s internal and external validity are examined here (Shadish, Cook, and Campbell 
2002). 
6.2.1 Threats to statistical conclusion validity  
The most obvious threat to validity was the limitations imposed by the study’s sample size. 
Given that the number of intervention practices was fixed at seven, the study was not adequately 
powered to examine differences in the rates of delivery of evidence-based smoking cessation 
treatments and quit-smoking rates of less than 10%. Based on the observed increase in self-reported 7-
day point prevalence abstinence (7.7% pre-assessment, 11.5% post-assessment) and ICC value 
observed (0.01) documented in the present study, a total of 20 practices (10 practices per group) and 
70 patients per practice would have been required to detect a difference of 4% in the rate of smoking 
abstinence. The number of clinics involved in the present study meant there was also limited power to 
examine clinic-level variables, which may be predictive of 5As delivery or smoking outcomes as part 
of the multi-level analysis. A larger pool of clinics would be required to allow for adequate statistical 
examination of clinic-level variability.   
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The broader context in which data collection activities occurred is also important to consider 
when reporting on the gaps in 5As delivery by providers. Post-assessments took place during H1N1 
influenza outbreak in the fall of 2009.  The outbreak was declared a pandemic by the World Health 
Organization (World Health Organization 2009b). Six of the seven clinics involved in the study had 
post-intervention assessment activities taking place during the peak of the H1N1 pandemic. Many of 
these clinics reported significant disruptions to normal clinic routines and the need to alter in-take 
processes to manage patient volumes and patient exposure. In addition, patients seen in clinic during 
the H1N1 outbreak may have been more likely to present with acute symptoms, which may have 
resulted in smoking cessation being made a lesser priority at the visit for both patient and provider. 
Although the study protocol aimed to exclude urgent care visits, it is possible that the H1N1 influenza 
negatively affected the rates of 5As delivery documented at study clinics during the post-assessment 
data collection period. The largest increases in provider delivery of smoking treatments was observed 
in clinic 1, which was also the only clinic in which post-assessment activities were completed prior to 
fall 2009. It is possible that the H1N1 influenza pandemic limited the ability to accurately document 
increases in 5As delivery resulting from the intervention program. Reports from participating clinics 
also suggest that some clinics were affected to a larger extent than others by the H1N1 outbreak. 
Clinic 4 informed study investigators that workload related to H1N1 had required the clinic to 
temporarily discontinue tobacco use screening and distribution of the tobacco use survey. Clinic 4 is 
the only clinic to document at the post-assessment rates of 5As delivery that were lower than those 
documented at the pre-assessment. Although it seems likely that H1N1 negatively affected study 
outcomes, it is not possible to quantify the magnitude of this impact. 
Multiple outcome measures were examined in the present study that may introduce error rate 
problems. No correction was made to p-values to adjust for the multiple ends points and, as such, it 
may be argued that there is a possibility that statistical significance may be artificially inflated. 
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Concern regarding the lack of corrected p-values should be considered in light of the fact that study 
outcomes were reported as odds ratios bounded by confidence intervals so that the magnitude of the 
co-variation and precision of the point estimate could be used to better reflect uncertainty versus an 
emphasis on significance testing based on p-values alone. 
6.2.2 Threats to internal validity  
The lack of a control-group comparison arm limits the study’s ability to exclude maturation as 
a threat to internal validity. Given the robust literature regarding multi-component interventions, it was 
felt that a comparison of two active intervention groups would make a larger contribution to 
addressing knowledge gaps in the field. It is possible that secular trends towards increasing rates of 
preventative service delivery during the study timeframe could explain the increase observed in 5As 
delivery during the pre- and post-assessment periods. However, the likelihood of secular trends 
explaining outcomes is considered minimal given the relatively short time period (less than 6 months) 
between the pre- and post-intervention assessments.   
Another limitation of this study is the use of a cross-sectional sample of patients versus 
within-participant design. The cross-sectional sample design introduces the possibility of patient level-
factors affecting study outcomes. There were differences documented between treatment groups at 
baseline, as well as differences in the pre-post intervention samples, which may have affected study 
outcomes. Adjustment for the covariation observed in the present trial was addressed in the multi-level 
analyses techniques employed.   
6.2.3 Threats to construct validity  
Treatment diffusion, or exposure to the intervention, was documented among the pre-
intervention sample in the FC group, thereby making differentiation between the pre- and post-
assessment samples challenging. In addition, it appears possible that compensatory equalization may 
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have occurred in the PS group, in which providers may have delivered compensatory services to 
support patient follow-up that they might not have otherwise provided if they had not participated in 
the present study.   
The possibility of reporting bias should also be considered given that patient self-report is 
used to assess rates at which smoking cessation services were delivered by providers. Although 
patients were instructed at both the exit survey and telephone interview to be honest with their 
responses, it is possible that patients were over-reporting rates of provider delivery of smoking so as 
not to have their physician rated unfavourably. Previous research has shown patient exit survey data 
regarding 5As delivery to be reliable; however, when a discrepancy occurred it was generally a patient 
over-reporting of intervention (Pbert et al. 1999, 183-188). In addition, both readiness to quit and 
smoking abstinence are subject to social desirability bias in that patients are more likely to report 
being ready to quit and being successful in a quit attempt because they perceive this to be a more 
socially favourable response. The proportion of patients who report a readiness to quit in the pilot 
study at the pre-intervention assessment was higher than other national survey data, which may 
support the possibility that patients are over-reporting their readiness to quit smoking. Although bio-
chemical validation was used to validate self-report smoking abstinence, the biochemical samples 
were completed by only 53% of patients, therefore making the possibility of self-report bias a 
potentially important threat to study validity. Numerous studies have reported poor return rates with 
respect to biochemical samples such as that observed in the present study (Etter, Perneger, and Ronchi 
1998, 141-146; SRNT 2002, 149-159; Katz et al. 2004, 594-603). The Society for Research on 
Nicotine and Tobacco (SRNT) subcommittee on Biochemical Validation recommends that self-
reported abstinence be used in the evaluation for low to moderate intensity interventions such as that 
delivered in the present trial (SRNT 2002, 149-159).  
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In the present study, it was not feasible to blind investigators or clinic staff to the outcome 
assessment or intervention group assignment, nor to when data collection activities were occurring. It 
is possible that clinics and individual providers engaged in behaviours that they would not have 
normally as a result of their knowledge that their performance was being measured. The ability of 
providers to maintain such behaviours over the duration of the four- to eight-week data collection 
period seems unlikely. It should be noted that the study investigator was involved in the delivery of the 
intervention, which may have biased the intervention support provided to clinics to favour the 
hypothesized study outcome. Experimenter expectancies may have also introduced biases in the 
questionnaire design. Given the study findings did not support the study hypothesis, it seems unlikely 
that this occurred.    
There is also a possibility that the measurement tools used in the present study did not 
adequately capture rates of “assist” and “arrange” that were delivered to patients at the post-
assessment. As noted previously, several study clinics developed protocols that involved the 
scheduling of a separate appointment in which a physician or non-physician staff member met with 
patients to develop a quit plan. As such, the exit survey may not have adequately captured activities 
that would occur at this follow-up visit, including providing self-help materials, setting a quit date, and 
discussing and prescribing medications. Although it is very likely that such a measurement error 
occurred, it seems unlikely that this measurement bias would have occurred disproportionately in one 
of the two intervention groups. It is more likely that the post-assessment data may underestimate rates 
at which the “assist” outcomes were documented by limiting the measurement to a fixed date when the 
actual delivery of these intervention components would occur over a wider window of time.  
Another limitation of the present study was the timeframe over which outcome data was 
collected. Due to constraints with study funding, a limited timeframe was available to complete the 
study; smoking abstinence was assessed 4 months after a patient’s visit to the clinic. The gold-standard 
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measure of long-term smoking abstinence is a minimum of 6 months, and ideally the assessment of 
smoking abstinence would be measured at 12-months follow-up (West et al. 2005, 299-303).  
6.2.4 Threats to external validity 
An effort was made to maximize generalizability of the study findings by including clinics 
from both urban, suburban, and rural settings, including several types of primary care practices models 
(e.g., family health groups, teams, and networks), as well as including all patients who consume 
greater than one cigarette per day, rather than simply those who are ready to quit, as is often the case 
in clinical trials. Despite efforts made to increase the study’s generalizability, the ability to generalize 
findings from the present study to a broader population of people who smoke should be examined in 
light of potential threats to the study’s external validity.  
The method of recruitment may potentially be a significant threat to the study’s 
generalizability. In the present study, the recruitment of clinics was limited to practices with five or 
more physicians from three sub-regions in the Champlain District. The response rate among invited 
clinics was 54% (7/13 clinics). It is possible that the eligibility criteria as well as the enrollment rate 
achieved in the present study would limit the ability to generalize findings to a broader group of 
primary care clinics. Clinics that chose to participate in the study might have been more motivated 
compared to those that declined participation in the study, which may bias results towards greater 
improvements than what might otherwise be expected if the intervention program was disseminated to 
all primary care clinics. Clinics which choose to participate in the present study may have also been 
higher performing clinics and as such reduced the ability to detect differences between the pre and 
post assessment. The pre-intervention rate at which physician advice to quit was delivered in the last 
12 months was similar to reported rates of advice in Ontario and 15% higher than rates reported 
nationally based on data gathered from the Canadian Tobacco Monitoring Survey (CTUMS 2006). 
This may suggest that clinics sampled as part of the present study are similar to the broader primary 
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care community in Ontario with respect to the delivery of smoking cessation treatments, but may be 
higher performers than primary care clinics nationally.   
Perhaps the most serious limitation to generalizability was the rate of participation amongst 
eligible smokers in the clinic setting. Fifty-four percent of eligible patients screened agreed to 
participate in the study and completed the exit survey. This recruitment rate is lower than that reported 
by previously published studies (Katz et al. 2004, 594-603). It is possible that the sample recruited 
may be biased and, as such, limit generalizability to the broader population of patients who smoke 
seen in primary care settings. Limited information was available on the demographic profile of non-
respondents to assess the potential impact of such biases. As such, the study is limited in regards to 
reporting on how the study sample may differ from the overall population of patients who smoke in 
primary care settings. The loss to follow-up rate in the present study was very low at less than 11%, 
therefore minimizing concern that sample attrition may have biased study findings.       
Another potential threat to the study’s generalizability is that the recruitment of practices was 
limited to clinics from one geographic region in Eastern Ontario. It will be important, as such, to 
replicate the study findings in other practice types and geographic settings in order to address this 
limitation.  Finally, the present study tested a multi-component intervention program that included 
four intervention components to intervene at the level of the provider and practice. It is possible that 
another combination of sub-components may yield different results. Moreover, the telephone-based 
follow-up support program offered to patients in the FC group was one potential format to deliver 
extended follow-up support to patients identified in primary care. Other follow-up programs may 
produce different results than those observed in the present trial. A recent study found a dose response 
effect in the delivery of behavioural counselling to patients who smoke identified in the primary care 
settings (Secades-Villa et al. 2009, 747-758). The present study also recommended an intra-
disciplinary model to support the diffusion of the 5As model in which members of the clinic staff 
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(physicians, nurses, allied health) shared the responsibility of delivering components of the 5As. It is 
possible that a different type of intervention model, which for example emphasized physician delivery 
of 5As, may yield different results.   
6.3 Implications to policy and practice 
The decline in the overall prevalence of smoking in Canada has been the result of progressive 
policies and programs such as smoke-free spaces legislation, taxation of tobacco products, warning 
labels on cigarette packaging, and social marketing campaigns (McIvor 2009, 21-26). Today in 
Canada, the majority of people who smoke want to quit, and many are actively making quit attempts 
(CTUMS 2005; Ismailov and Leatherdale 2010, 282-285). Unfortunately, the vast majority of people 
who smoke are not accessing evidence-based supports that may increase the likelihood of long-term 
abstinence (Hammond et al. 2004, 1042-1048; McIvor 2009, 21-26; Ismailov and Leatherdale 2010, 
282-285). Our ability to motivate a cessation attempt among the remaining population of residents 
who smoke, as well as increase the use of evidence-based cessation treatments, will be important if we 
are to further impact on smoking outcomes in Canada.   
Health care delivery systems may be a potentially important component of a comprehensive 
tobacco control system. Several authors have reported encouraging improvements in the rates at which 
primary care providers are documenting smoking status and providing cessation advice over the last 
decade (CTUMS 2006; Curry et al. 2006, 269-272; Schnoll et al. 2006, 233-239; Curry et al. 2008, 
411-428; McIvor 2009, 21-26; CTUMS 2010; Szatkowski 2010). In the present study, prior to the 
introduction of the intervention program, 70% of patients reported they were advised to quit by their 
physician in the last 12 months at the baseline assessment. However, on the day of their last visit to the 
clinic, only 39% of patients reported receiving advice to quit. Given that clinical practice guidelines 
recommend that all patients be asked about their smoking status and advised to quit at every clinic 
visit, data from the pilot study suggests that despite the observed improvements following the 
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intervention program there continues to be a large number of patients who are not regularly advised to 
quit smoking (Fiore et al. 2008). 
In the present study, it was rare for non-physician health providers working in primary care 
settings to deliver any of the 5As at the pre-intervention. This observation has been previously 
reported in the literature (Dosh et al. 2005, S50-2). The present study found a multi-component 
intervention that seeks to involve an inter-disciplinary team and simplify the role of physician 
providers increased the likelihood that 5As treatments were delivered to patients.  
Although there is clear evidence regarding the cost-effectiveness of smoking cessation 
interventions, there is a lack of implementation knowledge to inform the design and delivery of these 
interventions into routine clinical practice. In this pilot study, best available evidence from the world 
of tobacco control, health systems, and health behaviour change was used to design an intervention 
program aimed at increasing the likelihood family doctors deliver evidence-based treatments. The 
intervention program aimed to address many of the barriers that are hypothesized to have limited 
widespread delivery of cessation intervention to date.  
This pilot study offers policy-makers evidence to support the feasibility and efficacy of multi-
component intervention programs to support the delivery of smoking cessation services within busy 
primary care practices in Canada. Given that ministries of health in Ontario, Alberta, British 
Columbia, and Quebec have made significant investments to support the delivery of preventative 
interventions in primary care settings, this information would seem particularly important. It will be 
important for system-level supports to be introduced to support the delivery of smoking cessation 
treatments in primary care. This would include ensuring adequate supports such as those provided in 
the present multi-component program are available to primary care providers and are delivered as part 
of a comprehensive quality improvement program rather than in isolation (i.e., training, provider 
prompts) which has typically been the case in Canada. The multi-component intervention program 
 
    
142 
tested is scalable for implementation in primary care settings across Canada. Examples of similar 
programs for other disease prevention and management areas such as diabetes, asthma, and 
hypertension can be found in Canada (Ontario Ministry of Health and Long-Term Care). Most 
provinces have not included smoking cessation as a key preventative target and, as such, a significant 
opportunity to impact a major risk factor for chronic disease is being missed. Many provinces, like 
Ontario, have the necessary infrastructure in primary care settings to allow intra-disciplinary teams to 
deliver cessation interventions to large numbers of patients who smoke using similar approaches to the 
one tested in this pilot study.   
This study offers several insights for primary care practitioners who are interested in 
implementing smoking cessation programs within their clinical settings. In the present study, the well-
known 5As model was modified for use in a multi-disciplinary clinic environment by defining roles 
and responsibilities for reception, nursing, allied health professionals, and physician providers based 
on time available and access to patients, which may assist with addressing the feasibility of 
intervention delivery when physician time is limited. Although the present study was not specifically 
designed to test the value of specific implementation factors, the following activities were undertaken 
as part of this study to support the implementation of a smoking cessation program in primary care 
settings: formation of a multi-disciplinary task force at the clinic; developing a detailed tobacco 
control protocol for the clinic; using a multi-disciplinary team to deliver the intervention program with 
clear roles and responsibilities assigned for each of the 5As strategies; frequent screening of patient 
smoking status and readiness to quit; real time provider prompts created and embedded into existing 
clinic routines; and performance metrics collected and reported regularly. Given that many primary 
care clinics use electronic medical records, attention should also be given to strengthening the design 
of electronic medical records to cue providers in the assessment of smoking status, delivery of strong 
advice, and the simplification of the referral process to designated staff within the clinic who will 
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provide supplemental support to patients (Cantrell and Shelley 2009, 81). The experience developed as 
part of the present study supports the need for practitioners to pay careful attention to issues related to 
program implementation as the quality of implementation appears to be associated with larger 
improvements in 5As delivery. 
In the present study, a higher rate of 5As delivery was documented for visits scheduled for 
annual health exams. However, only 16.2% of appointments in the present study were for annual 
exams. Evidence-based guidelines emphasize the importance of assessing smoking status at every 
visit. A study by Jaén et al. (2001) suggested that tobacco-specific discussion is appropriate in 
approximately three fourths of primary care visits by patients who smoke (Jaén et al. 2001, 859-863). 
It will be important for clinicians to ensure patients are asked, advised, and offered assistance with 
making a quit attempt regularly, and that trained staff are available to support patients with making a 
quit attempt using evidence-based supports. If proven efficacious in a larger trial, the telephone-based 
counselling intervention evaluated within the present study could potentially be delivered by existing 
quit lines (e.g., smoker’s helpline), therefore making the larger scale rollout of the intervention model 
feasible within Ontario and Canada. Creating stronger links to cessation interventions outside of the 
primary care setting, as part of a systems approach to cessation, may serve to increase the reach of 
evidence-based cessation interventions and address barriers faced by busy primary care practitioners.   
 
6.4 Implications for future research  
The results of the present study also have implications for future research. Given the 
limitations related to sample size, a larger trial involving a greater number of primary care clinics is 
recommended to strengthen the evidence base regarding the effectiveness of the multi-component 
intervention program in primary care settings. A larger trial would assist with addressing two 
significant areas of research that were not addressed in the pilot study. The first is the ability to 
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adequately examine the impact of the multi-component intervention on patient quit rates between the 
pre- and post-assessments periods as well as between group differences. The second relates to the 
ability to examine clinic-level factors that are associated with high and low performance with respect 
to the delivery of evidence-based smoking cessation treatments.  
Replicating the study would also enable the opportunity to re-examine outcome estimates that 
would be expected for 5As delivery in the absence of the disruptions encountered in the present trial as 
a result of the H1N1 pandemic. It is recommended that future trials strengthen the intervention design 
so as to: 1) measure smoking abstinence at 6 months of follow-up or longer; 2) limit the potential of 
intervention diffusion in the pre-assessment sample; and 3) ensure measurement of 5As accounts for 
the possibility that intervention may be delivered over multiple clinic appointments. It may be 
important for future research to also consider intra-provider variability when calculating sample size. 
In the present study, intra-provider ICC values were found to be larger than that observed for intra-
clinic variability. Finally, the inclusion of a no-intervention control group may be valuable to provide 
gold standard evidence regarding the multi-component interventions efficacy.     
  Additional research is also required to better understand important clinic-level factors that are 
associated with improved program implementation, 5As delivery, and smoking outcomes. For 
example, it would be important to know precisely what types of clinic environments are most 
conducive to the successful delivery of multi-component programs such as that tested in the present 
study. In addition, given provider-level variability observed in the present trial, it may be important to 
pay more attention to provider-level variation. Mixed methods approaches may offer value in further 
understanding the clinic and provider-level factors influencing outcomes, variation in program 
implementation activities, and program sustainability. 
It would also seem important to develop and test new instruments for assessing variables 
hypothesized to mediate 5As delivery at both the level of the clinic and the provider. At present, tools 
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available to meaure changes in attitudes, knowledge, and self-efficacy, as well as other variables that 
may mediate the relationship between the intervention and study outcomes, are rudamentary and have 
not been well validated. A recent study by Delucchi, Tajima, and Guydish (2009) used exploratory 
factor analysis to identify five factors that are associated with provider delivery of smoking cessation 
services including a single “knowledge” factor, three “attitude” factors (“treatment barriers”, 
“counsellor self-efficacy”, and “counsellor attitudes”) and a single “practices” factor (Delucchi, 
Tajima, and Guydish 2009, 347-364). Supplemental work to refine our knowledge and ability to 
measure these underlining factors is required.  
Many providers continue to report modest levels of self-efficacy in setting a quit date, 
recommending medications, and providing extended counselling even after training. The highest 
scores for provider self-efficacy were documented for: advising patients to quit, the provision of brief 
counselling, and prescribing of medications (all mean scores were greater than 8 on a 10-point scale). 
These are arguably the simplest intervention strategies to deliver. Slightly lower levels of self-efficacy 
were documented for other activities, such as setting a quit date with patients, the provision of 
extended smoking cessation counselling, and arranging follow-up. This data suggests that providers 
continue to lack confidence in their ability to adequately counsel patients who smoke in more 
complicated aspects of 5As delivery. Additional research is required to understand how best to address 
provider self-efficacy for the delivery of smoking cessation treatments. Intervention strategies that are 
hypothesized to modify provider self-efficacy, such as performance feedback, may be a practical area 
of future research. The present study offered a fairly low intensity intervention related to performance 
feedback with data provided to the clinic’s smoking cessation task force at three different time-points 
during the study. Previous research has reported that the more intensive the feedback, the greater its 
effect on outcomes (Jamtvedt et al. 2006, CD000259). A recent study found a one-time individualized 
audit and feedback session with providers resulted in an increase in the documentation of tobacco 
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dependence counselling from 7.5% to 46.5% (p<0.0001) and the appropriateness of NRT dosing from 
26% to 64% (p<0.001) following the intervention in hospital settings (McKay-Brown et al. 2008, 4). 
Gaining a better understanding of the value of a more intensive performance feedback protocol on 
provider self-efficacy and 5As delivery would also seem to be an important area for additional 
research.   
The present study tested one possible patient-level intervention strategy (i.e., extended adjunct 
telephone counselling). Future research should examine other possible patient-level intervention 
strategies for supporting long-term abstinence among patients identified in primary care settings when 
delivered as part of multi-component interventions. One such strategy is the provision of cost-free quit 
smoking medications to patients. Cost-free pharmacotherapy was included in 50% of the multi-
component interventions that were included in the meta-analysis of primary care intervention 
strategies (Papadakis et al. 2010, 199-213). The most impressive increases in smoking abstinence were 
reported by Twardella and Brenner (2007), in which practice-level supports were combined with the 
provision of cost-free pharmacotherapy (Twardella and Brenner 2007, 15-21; Salize et al. 2009, 230-
5). Supplemental research would assist with understanding the incremental impact of cost-free 
medications when delivered in combination with multi-component interventions, as well as the 
effectiveness of combining both adjunct counselling and cost-free medications. 
The pilot study examined 5As delivery two months following implementation of the multi-
component intervention program. The ability of clinics and providers to maintain rates at which 5As 
treatments are delivered over an extended period of time was not examined. Previous authors have 
reported that intervention programs that result in improved outcomes may revert to baseline after the 
intervention stimulus ends. Moreover, it has been shown that initial implementation success does not 
predict institutionalization of outcome changes (Stange et al. 2003, 296-300). Future research should 
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aim to examine the rate at which interventions are maintained over the long term as well as factors 
predictive of long-term maintenance of such programs in real-world settings.  
Investment in intervention strategies designed to reach the population of hard-to-reach patients 
may also be required if we are to continue to have an impact on smoking prevalence in the population. 
Possible segmentation strategies for motivating and supporting quit attempts in sub-populations of 
people who smoke would also appear to be an important area for future research. 
Finally, it will also be important to continue to monitor current practice trends and practice 
gaps in the delivery of cessation services in primary care settings. Several studies have noted 
improvements in the last five years in the rates at which patients are asked and advised to quit; 
however, much lower rates are reported for the delivery of the remaining 5As (CTUMS 2006; Schnoll 
et al. 2006, 233-239; CTUMS 2010). Changes in practice behaviours over time would affect the 
relative benefit derived from some interventions strategies. As such, having adequate information to 
monitor trends in provider behaviours will be important.  
 
6.5 Conclusions 
This is the first study to evaluate a multi-component intervention program in primary care 
practices within the Canadian health care system. It is also the first study to examine the incremental 
value of adjunct telephone-based smoking cessation counselling when delivered as part of a multi-
component intervention program. The strengths of the present study include the use of a cluster-
randomized control trial design, the evaluation of both rates of evidence-based smoking cessation 
treatment delivery and smoking abstinence, and low rate of patient loss to follow-up. The study builds 
on existing knowledge regarding the value of interventions that combine practitioner-, practice-, and 
patient-level intervention components.  
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This study documents three new pieces of information. First, a multi-component intervention 
tested in primary care clinics in Canada is associated with enhanced provider performance in the 
delivery of evidence-based smoking cessation treatments to patients, as well as a higher proportion of 
patients who make a quit attempt 4 months following their visit to clinic. Second, making adjunct 
telephone-based follow-up support available to patients identified in primary care clinics who have 
implemented a multi-component program does not necessarily lead to improved patient smoking 
outcomes; however, smoking abstinence tended to be greater among those patients who are referred to 
the telephone follow-up support program. Third, patient, provider, and possibly clinic-level factors 
may influence the rates at which smoking cessation treatments are delivered to patients in primary care 
settings. These findings will assist with informing future policy, practice, and research in regards to 
the design, implementation, and evaluation of intervention programs for improving the delivery of 
smoking cessation treatments to patients identified in primary care settings.     
Study data suggests that both clinic and implementation factors have significant influence on 
the improvements achieved following implementation of a multi-component smoking cessation 
program in primary care. However, due to the number of clinics involved in the present trial, it was 
not possible to adequately examine clinic-level factors, which may influence success achieved using 
multi-level modelling techniques. It was also not possible to adequately explain the observed 
differences in provider and clinic level variation. Finally, this study does not rule out the possibility 
that a different type of telephone counselling program may have yielded different results. A larger trial 
is recommended to conclusively determine the impact of the intervention program on rates at which 
providers are delivering cessation treatments, long-term smoking abstinence, and the characteristics of 
clinics, which are required to support successful implementation of the intervention.  
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Appendix A– Systematic review and meta-analysis of strategies to increase the 
delivery of smoking cessation treatments in primary care setting 
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Appendix B- Provider Recruitment Letter 
DATE  
INSERT NAME  
INSERT ADDRESS 
 
RE: ADDRESS SMOKING CESSATION WITH PATIENTS IN PRIMARY CARE  
 
Dear Dr. (Insert Name), 
 
Over the past three years we have been working on creating a network of hospitals in Eastern Ontario that 
are using a common approach to systematically identify and intervene with all smokers while they are in 
hospital. We have referred to this approach for intervening with smokers in clinical settings as the 
“Ottawa Model for Smoking Cessation”.  Seventeen of the hospitals in our region are implementing the 
“Ottawa Model for Smoking Cessation” and we have seen a significant increase (15% to 25%) in the 
number of smokers who quit smoking following visit to hospital as a result of the program.  
 
We believe that the systematic approach for addressing tobacco use in hospital also has application in the 
primary care setting.  We would like to conduct a study to evaluate a version of the Ottawa Model for 
Smoking Cessation that has been adapted for use in busy primary care practices. We are hoping to 
evaluate the program in a group of 6 to 8 primary care group practices in Ottawa and the surrounding 
area.   
 
We would like to invite your practice to take part in the study.  Participation in the study will offer your 
practice with specialized onsite training in smoking cessation and support with implementing simple tools 
within your practice for identifying smokers and providing brief assistance with quitting.  Half of the 
practices involved in the study will also have access to a specialized follow-up telephone counselling 
program which will provide follow-up support to smokers from your practice who are ready to make a 
quit attempt for a period of two months.  
 
This study is being conducted by the University of Ottawa Heart Institute in collaboration with an 
investigator from the University of Waterloo, Sophia Papadakis. We look forward to the involvement of 
local primary care clinicians in the evaluation of this new approach for addressing smoking in clinic 
settings.  I would greatly appreciate hearing back from you on your interest in participating in the pilot 
study.  Please contact Sophia Papadakis at SPapadakiS@ottawaheart.ca or at 613-761-5489 to discuss the 





Andrew Pipe     Sophia Papadakis 
Medical Director    Ph.D. Candidate 
Prevention and Rehabilitation Centre  Health Studies and Gerontology  
University of Ottawa Heart Institute  University of Waterloo  
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Appendix C - Program Summary 
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Student Investigator: Sophia Papadakis, MHA, PhD candidate,  
    Health Studies and Gerontology, University of Waterloo 
Faculty Supervisor:   Paul McDonald, PhD, Associate Professor,  
    Health Studies and Gerontology, University of Waterloo 
Co-Investigators:  Roy Cameron, PhD, University of Waterloo   
    Robert Reid, PhD, MBA, University of Ottawa Heart Institute   
    Andrew Pipe, MD, University of Ottawa Heart Institute   
    Stephen Brown, University of Waterloo      
 
Please read this Information Sheet and Consent Form carefully and ask as many 
questions as you like before deciding whether to participate. 
    
You have been asked to participate in a research project entitled: “Comparative evaluation of two 
interventions for integrating smoking cessation into routine primary care practice: A cluster-randomized 
trial.”   
Introduction: 
 
The purpose of this study is to determine if adjunct telephone-based smoking cessation counselling 
increases the rate at which evidence-based smoking cessation treatments are delivered to patients and 
smoking abstinence among smokers identified in family doctors offices. We hope this study will inform 
the design and delivery of smoking cessation interventions within primary care practice settings.   
 
What is involved in this study?  
All providers (physicians and nurses) in the practices will be asked to complete a provider survey at 
baseline and 4-months later.  The survey will take approximately 10 minutes of your time to complete. 
The survey will ask about your attitudes, knowledge and confidence with delivering smoking cessation 
interventions.   
 
Your practice will be randomly assigned to either the practice supports (PS) intervention group or the 
follow-up counseling (FC) group.  If you are assigned to the PS group you will receive a 3-month practice 
level intervention designed to integrate evidence-based smoking cessation practices into your daily clinic 
routines including training, a waiting room screener, consult form and a quit plan for smokers ready to 
quit in the next 30 days.  If you are assigned to the CF group you will receive the same intervention as the 
PS group plus your patients will have access to a quit smoking follow-up counseling program. 
 
Patient Information Sheet & Consent Form 
 
Comparative evaluation of two interventions 
for integrating smoking cessation into routine 
primary care practice: A cluster-randomized 
trial  
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The researchers also wish to approach a cross sectional sample of 55 consecutive eligible patients 
attending your clinic for a non urgent medical appointment to participate in this study pre and post 
implementation of the intervention. The purpose of the assessment is to determine if the intervention 
assisted with the delivery of evidence-based smoking cessation strategies and helped more patients quit 
smoking. 
 
A total of six to eight practices will be involved in this research study.  We request that all practices 
identify a contact person who can work with study staff in implementing the study protocol.  All clinics 
who agree to take part in this study are expected to provide reasonable assistance in the implementation of 
the study protocol.  The study has been designed to provide minimal disruption to your clinic.    
Procedure: 
 
Baseline Exit Survey and Telephone Follow-up  
We will survey a sample of 55 eligible smokers from your practice prior to the delivery of the study 
intervention to establish a pre-intervention rate of evidence-based smoking cessation treatment delivery 
for your clinic as well as smoking abstinence.  The baseline assessment will begin on a mutually agreed 
upon start date.  Upon check to the clinic patients will be asked to review an Information Sheet and 
Consent Form about their participation in the study.  Consenting patients will be asked to complete a 
patient exit survey.  The exit survey will take 5-10 minutes for patients to complete and will ask about 
smoking habits and their encounter with clinic staff.  Your clinic will be provided with a research 
assistant on site to assist with data collection activities pre and post intervention.  
 
Patients will also be asked to complete a follow-up telephone interview 4-months following their clinic 
visit. During the interview patients will be asked about their smoking status and experience with smoking 
over the past 4-months.  Because this is a research study we may ask patients who have been able to quit 
smoking to provide a saliva sample to prove they have been able to successfully quit.  Patients will be 
selected at random to provide a cotinine sample.  If they are selected we will mail a home cotinine saliva 
test to the participant’s home at the time of the 4-month follow-up telephone call.  Patients will be asked 
to return the kit in a pre-paid return envelope within 48 hours.  Patient participation is completely 
voluntary and patients may choose to skip questions on the survey or telephone interview if they do not 
wish to answer them.   
 
Randomization 
Your practice will be paired with another practice in the Eastern Ontario region who performed similarly 
on baseline rates of screening for smoking and rates of advising smokers to quit.  One practice from each 
of the pairs will be randomly assigned to the PS group of CF group. Your practice will have a 50/50 
chance of being assigned to either intervention group.  
 
Practice Support (PS) Group 
If your practice is assigned to the PS Group, your practice will receive feedback on the results of the 
baseline practice audit, a 1-hour training workshop will be provided to all professional and administrative 
staff working in intervention clinics. Your practice will be supported with implementing: (a) a waiting 
room screener, (b) smoking cessation consult form, and (c) patient quit smoking plan to assist with the 
integrating evidence-based cessation strategies into your practice routine.   
 
Follow-up Counselling (FC) Group 
If your practice is assigned to the CF Group your practice will receive the same smoking cessation 
training and practice support tools delivered to the PS group (as described above).  In addition, patients in 
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the FC group who are smokers and are willing to set a quit date within the next 30 days will be enrolled in 
an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR 
system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 
days after their TQD to check the patients’ smoking status, potential concerns, and their risk of relapse. 
During the calls, the IVR system will pose a series of questions concerning current smoking status, 
confidence in staying smoke-free over the time period until the next planned call, and the use of 
pharmacotherapy, self-help materials and other forms of cessation support.  If patients identify that they 
have resumed smoking but want to make another quit attempt soon or indicate that their confidence in 
remaining smoke-free is low (less than 7 on a 10-point scale), the IVR system will flag the patient in a 
software interface in order to ensure that they are contacted by a smoking cessation specialist.  The 
smoking cessation specialist will provide additional assistance, consisting of up to three 20-minute 
telephone counselling sessions over an 8-week period. For participants who were not smoking but whose 
confidence in remaining smoke-free was low, the nurse-specialist will assist them to identify tempting 
situations that were undermining confidence.  The smoking cessation specialist and the participant will 
then work to develop strategies to deal with these situations using cue control, healthful alternatives, 
pharmacotherapy, and/or social support.  Patients who are not ready to quit in the next 30 days but report 
a willingness to quit smoking in the next 6-months will receive two IVR follow-up telephone calls 30 and 
60 days following their clinic visit to reassess readiness to quit.  If patients report at the 30 or 60 day call 
a readiness to quit smoking in the next 30 days, they will receive a 10-20 min counselling session with the 
smoking cessation specialist to set a quit date and develop a quit plan.   The participant will then be 
enrolled in the 60-day IVR mediated telephone follow-up and counselling program as described above.  
 
Post-Implementation Follow-up Assessment  
Following a three month implementation phase a follow-up assessment will be conducted.  The methods 
described in the baseline survey will be repeated in a second sample of 55 patients from your practice in 
order to establish the interventions effectiveness. 
 
All practices participating in this study will receive specialized training in smoking cessation, practice 
based support tool and patient self-help materials.  If your practice is randomized to the CF group your 
patients will also have access to follow-up smoking cessation counselling program. You may not receive 
any additional direct benefit from your participation in this research. Your participation in this research 
may allow the researchers to evaluate and refine an approach to integrating smoking cessation assistance 
into routine primary care practice among practices in our region. 
Benefits of Participation: 
 
The risks and discomforts of participation are minimal.  Your clinic will be asked to identify the smoking 
status of all persons scheduled for a non urgent follow-up appointment at your clinic. There is a time 
commitment involved for members of the clinic staff to complete the smoking cessation training and 
integrate the practice support tools into your practice routines.  There may be some minimal disruption to 
your clinic during the collection of pre and post intervention data.  To minimize this burden your practice 
will be provided with the support of a research assistant during the data collection period.   
Risks and Discomforts of Participation: 
 
There will be no financial remuneration for participation in this study.  By participating in the study 
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All data gathered, including responses to questionnaires and interviews will remain confidential. 
Only the Principal Investigator and research staff will review survey and interview responses 
provided by consenting provider and patients.  All personal information will be coded, then it will be 
stripped of identifiers, and will be assigned a research ID number.  Paper copies of surveys and 
interviews will be kept in a locked filing cabinet.  We will also use a secure electronic database that 
is password protected and only accessible by the Investigators and our research staff to store 
electronic copies of data.  The data will be destroyed fifteen years following their publication. Your 
practice and patients will remain anonymous in any publications or reports on the results of this 




This project has been reviewed and received ethics clearance through the Office of Research Ethics 
(ORE) at the University of Waterloo.   If you have any comments or concerns resulting from your 
involvement in this study you may contact the Director of the ORE at 519-888-4567 Ext. 6005.   
  
 
Participation in research is completely voluntary.  You are free to choose to participate or not to 
participate in this research study.  If you agree to participate in this study, you may choose to 
withdraw your participation at any time by providing written letter to the Principal Investigator. You 
may also choose not to answer any specific questions. 
Participation: 
 
Should you require any additional information about the study, you may contact Sophia Papadakis, 
Student Investigator at 613-761-5489 or by mail at H-2300, Ottawa Heart Institute, 40 Ruskin Street, 
Ottawa, ON, K1Y 4W7.  
 




I agree to participate in a study being conducted by the Department of Health Studies and Gerontology at 
the University of Waterloo and the University of Ottawa Heart Institute titled “Comparative evaluation of 
two interventions for integrating smoking cessation into routine primary care practice: A cluster-
randomized trial”.  I have made this decision based on the information I have read in the information 
letter.   
 
As a participant in this study, I realize that I am being asked to complete a brief questionnaire prior to and 
following the implementation of the intervention in my clinic, that my practice will be randomized to one 
of the two intervention groups, and that a sample of my consenting patients will be surveyed by research 
staff upon exit from their clinic appointment and by telephone 4-months following their visit to clinic.  I 
may decline answering any of the questionnaire items, if I so choose.  All information which I provide 
will be held in confidence and neither I nor my patients will not be identified in any way in the final 
report. I understand that I may withdraw this consent at any time.  
 
I also understand that this project has been reviewed by and has received ethics clearance through the 
office of Research Ethics at the University of Waterloo and that I may contact this office if I have any 




Provider’s Name (Please Print) 
 
 
    




Name of Investigator/Delegate (Please Print) 
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Appendix E - Provider Survey  
 
 
On a scale of 1 to 10, how would you describe your confidence in the following areas: 
(1 being not very confident and 10 being extremely confident) 
  
QUESTION  RESPONSE 
 
Advising patients to quit smoking 
 
   1     2     3     4     5     6     7     8     9     10 
Providing brief smoking cessation counselling (<3 
minutes) 
 
   1     2     3     4     5     6     7     8     9     10 
Prescribing quit smoking medications 
 
   1     2     3     4     5     6     7     8     9     10 
Setting a quit date with patients 
 
   1     2     3     4     5     6     7     8     9     10 
Providing smoking cessation counselling 
 
   1     2     3     4     5     6     7     8     9     10 
Arranging timely follow up for patients planning to quit 
 
   1     2     3     4     5     6     7     8     9     10 











Have you previously completed smoking cessation training? 
  Yes 
  No   
 
How would you describe the importance placed on 
smoking cessation within your clinic setting? 
  Extremely important  
  Very important 
  Important   
  Somewhat important  
  Not important  
 
As a practitioner, how would you describe 
the importance you place personally on 
helping your patients quit smoking? 
  Extremely important  
  Very important  
  Important  
  Somewhat important  
  Not important  
 
Are the following practice supports in place in your clinic? (check those which are in place) 
  Formalized process to screen for smoking status  
  Consult forms to guide you through quit smoking counselling  
  Self-help materials for smokers 
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Appendix F -  Sample Tobacco Use Survey 
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Appendix G – PS Group Sample Provider Consult Form  
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Appendix I- Sample Clinic Poster  
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Insert Clinic Name 
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SUMMARY  
Smoking is the most preventable cause of death and disability in our region.  
Helping a patient who smokes quit is perhaps the most important preventative 
intervention clinicians can offer to patients.    
 
Most patients who smoke want to quit.  A health professional’s advice to quit can 
play a powerful role in motivating a patient to make a quit attempt.   
 
Quitting isn’t easy.  However, providing patients with strategic guidance and 
support will increase the odds a patient will be successful with quitting. 
 
As part of the Ottawa Model for Smoking Cessation a partnership was established with the 
<Insert Clinic Name>.  The program involved ensuring the clinic processes and health 
professionals were using state of the art approaches to addressing smoking with patients.  
 
The program involved:  
• An assessment of current processes 
• Support implementing best practices for smoking cessation  
• Practice tools to systematize the delivery of smoking cessation treatments   
• Training for all providers in smoking cessation  
• Specialized training for dedicated counselors at the clinic 
• Access to the smoker’s follow-up system  
• Collection of baseline and follow-up evaluation data 
 
We are pleased to be collaborating with <Insert Clinic Name> in improving the delivery of 
smoking cessation in our region and are committed to continuing to work together to ensure 
there are systems and supports in your setting to help your patients and the residents in this 
region – QUIT.   
 
IN THIS REPORT  
 
In this report we present the results of the evaluation completed at the <Insert Clinic 
Name> as part of the implementation of the Ottawa Model for Smoking Cessation in 
Primary Care Pilot Program.  
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DATA COLLECTION METHODS 
 
Data presented in this report is based on the collection of data from two samples of daily 
smokers screened before and after the implementation of the Ottawa Model for Smoking 
Cessation at the clinic.   
Baseline data collection occurred from XX to XX and included a sample of XX patients who 
smoked.  





• Two and a half times more patients had their smoking status assessed and were advised to 
quit at the follow-up compared to baseline.   
 
• There was a threefold increase in the number of patients who report they received 
assistance with quitting as well as a prescription for a quit smoking medication.  
 
• 16% of smokers reported that they had a follow-up appointment to discuss smoking 
arranged compared to 0% at baseline.   
 
• Among smokers who reported they were ready to quit in the next 30 days, a 37% increase 
in the rate advise to quit was provided was documented and a 31% increase in the number 





    208 
 
 
SMOKING PREVALENCE AT CLINIC 
 
PARAMETER BASELINE Jan 26 – Feb 28 2009 
FOLLOW-UP 














PROFILE OF SMOKERS 
 
PARAMETER BASELINE FOLLOW-UP ∆ 









23 (51.9%) -1 




15.6 (3.99) -0.5 
Mean Cigarettes/Day (SD); Range 
 
13.1 (9.2); 1-40 
 
14.2 (9.6); 1-45 +1.1 
Mean Years smoking (SD); Range 
 
16.4 (14.0); 0.4-57 
 
23.2 (14.6); 1-60 +6.8 
Time to First Cigarette 
   Smoke <30 mins of waking (%) 








Readiness to Quit  
   Next 30 Days 
   Next 6-months 
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PROVIDER PERFORMANCE OF TOBACCO TREATMENT 
STRATEGIES (“5A’S”) 
 









% ∆ P= 
Ask 
Today’s Visit (Doctor) 



























































































































REDUCTIONS IN QUIT DATES BEING SCHEDULED ARE EXPECTED GIVEN THIS ACTIVITY HAS NOW BEEN 
DESIGNATED TO SMOKING CESSATION COUSELLORS AT THE CLINIC 
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HOW WE DID WITH SMOKERS READY TO QUIT  
 









Today’s Visit (Doctor) 















































































Physician today  









































The smoking cessation pilot program evaluation has documented some important increases in 
rates at which patients are advised and assisted with quitting. Congratulations on the 
improvements made!  
 
We would like to recommend a couple of activities moving forward: 
 
• Communicate Results: Communicate results to all members of the clinical team.  
 
• Commit to continuing with the protocol as a new standard of care at the clinic: 
Ensure clinic staff remain committed to addressing smoking as a priority issue with 
patients.  
 
• Set Annual Targets: Determine what targets the clinic would like to achieve and if 
success should be measured on an annual basis or at each visit. We would recommend 
a target of 85% of smokers be advised about quitting at each clinic encounter and 85% 
of smokers receiving assisting ready smokers with quitting.  
  
• Quality Improvement Plan for Screening, Advising and Referring: Work 
collaboratively with the UOHI to identify challenges in systematizing the screening, 
advising and referring patients into clinic routines. Develop action plan for addressing 
these quality improvement areas. Careful monitoring of these changes.   
 
• Institute monthly quality audits to ensure the processes and systems developed are 
maintained over the next year.  I am attaching a template we would suggest using for 
conducting these quality audits. It will be important to identify a staff member responsible 
for this activity.  
 
• Consider Introducing New Program Components in the New Year: Discuss with the UOHI 
the clinics interest in introducing new supports for patients interested in quitting. This includes 
introducing the smoker’s telephone follow-up system which was tested as part of the pilot 
program in half of the pilot sites. The UOHI will also have $100.00 vouchers for smoking 
cessation medications available to distribute to patients as part of a new program through Health 
Canada over the next year. 
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Appendix L - Sample Clinic Implementation Workplan 
INSERT CLINIC NAME 
WORKPLAN FOR OTTAWA MODEL FOR SMOKING CESSATION PILOT STUDY 
 






PHASE 1: PROGRAM INTRODUCTION AND SIGN-ON 
1.1 Introductory meeting with management team    
1.2 Provider consent forms signed    
1.3 Assign primary contact for implementation activities (time limited role)    
1.4 Form smoking cessation task force to support program implementation    
1.5 Review work plan and implementation steps and identify timelines with task force    
1.6 Complete practice needs assessment (template provided)    
1.7 General information session with clinical team meeting AND/OR introductory information 
distributed to team members 
   
1.8 Designate clinic smoking cessation coordinator (ongoing role)    
PHASE 2: BASELINE ASSESSMENT    
2.1 Identify Preferred Start Date for Data Collection     
2.2 Identify process for distribution of baseline assessment     
2.3 Site Visit (Protocol, Logistics, Staff Roles)    
2.4 Assign contact for RAs (if different from lead)    
2.5 Identify designated location (locked cabinet) to store     
2.6 Collect data     
2.7 Complete telephone follow-up contacts    
PHASE 3A: PLANNING YOUR CLINIC TOBACCO CONTROL PROTOCOL   
3.1 Review OMSC standard processes Task Force    
3.2 Review of current clinic smoking cessation practices and patient flow   Task Force    
3.3 Determine and document required revisions to OMSC processes 
- Tobacco question  
- Collection of Smoking Profile  
- Consult Form 
- Electronic versus paper-based documentation 
- Registration of Patient (if required) 
Task Force    
3.4 Determine roles and responsibilities in program delivery 
- Clerks 
- Nursing staff  
- Smoking cessation resource person  
- Physicians 
Task Force    
3.5 Select date for training workshop (see Phase 4) Task Force    
3.6 Determine smoking cessation assistance for clinic staff Task Force    
3.7 Complete tool and processes modifications (as required)    
3.8 Identify ‘Go Live’ date for program  Task Force    
3.9 Prepare and print program materials     
3.10 Order supplemental materials (posters, samples, CCS Smoking Brochures)    
3.11 Designate staff person for reordering materials Task Force    
PHASE 3B: RANDOMIZATION TO INTERVENTION GROUP 
3.12 Obtain group assignment from Methods Centre    
PHASE 3C: IMPLEMENT IVR SYSTEM (FOR PRACTICES ASSIGNED TO FOLLOW-UP COUNSELLING ONLY) 
3.13 Designate staff person for data entry     
3.14 Train designated staff person on data entry and report generation     
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3.15 Run quality assurance check     
PHASE 4: TRAINING CLINIC STAFF   
4.1 Schedule Training workshop    
4.2 Determine if MANPRO credits are of interest     
4.3 Submit relevant information to College of Physicians    
4.4 Arrange Logistics (location, catering, equipment)    
4.5 Send communication to clinic staff with RSVP    
4.6 Prepare summary of data collected during baseline assessment    
4.7 Clinicians completes provider survey (1-page) at training session     
4.8 Conduct Training workshop    
4.9 Schedule Intensive training for smoking cessation coordinator(s)      
4.10 Incorporate training into employee orientation program    
PHASE 5: PROGRAM IMPLEMENATION  
5.1 Access to IVR system is activated    
5.2 Designate person for data entry of the Consult Form into web-based system      
5.3 Train designated person on accessing and using IVR system     
5.4 Begin screening patients with waiting room screener    
5.5. Implement new smoking cessation forms and protocols     
5.6 Place other materials in designated areas (posters, self help materials)    
5.7 Internal audit system established     
5.8 Quality assurance checks conducted bi-monthly      
5.9 Conduct follow-up clinic needs assessment    
5.10 Identify issues processes    
5.11 Resolve issues as required    
PHASE 6A: POST-ASSESSMENT  
6.1 Schedule date for post-assessment     
6.2 Identify staff contact for RAs    
6.3 Review baseline process and revise as required     
PHASE 7: PROGRM SUSTAINABILITY  
7.1 Conduct quarterly quality assurance checks     
7.2 Quarterly review of performance date by senior management/task force      
7.3 Problem solve as required to improve quality of implementation activities    
7.4 Annual quality improvement and training plan created  for clinic based on need    
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Appendix M - Needs Assessment 
The Needs Assessment Tool provides us with necessary demographic information regarding your clinic, 
such as the number of patients, staff… The Clinic Practices for Treating Tobacco Use and Dependence 
reflects your clinic practice for tobacco treatment before implementation of the “Ottawa Model.” It is not 
uncommon for most clinics to have few if any of these practices in place. 
 
Date of Completion:       Name of Clinic:  
Key Contact Person:     






Type of Clinic  (e.g FHT, FHN, FHG, FHO, other)  
Single Site or Multiple Sites (please identify all sites)  
Does Clinic Use EMR, Paper Charts, Both (Name of EMR System)  
Number of clinic visits annually  
Number of unique clinic patients seen annually  
Number of unique clinic patients (total)  
Proportion of patients who are smokers (if known)  
Teaching/Non-Teaching   
Chief Physician  
Director  
# Nurse Managers  
# Nurse Educators  
# Advanced Practice Nurses/Clinical Nurse Specialists  
# RN’s  
# RNA’s/RPN’s  
# Other Health Care Professionals (e.g., social workers, 
dieticians, occupational therapists) 
 
# Support staff (IT, administrative)  
# Physician Housestaff  
# Medical Residents  
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Best Practices for Treating Tobacco Use and Dependence  
(“The Ottawa Model”): Pre-Post Assessment 
 
Practice Yes  No Comments 
1. Clinic task force formed      
 
2. Clinic tobacco control protocol developed    
 
3. Tobacco use queried and documented for all clinic patients     
 
4. Training tobacco dependence treatment offered to health 
care providers in last year 
   
 
5. Dedicated staff to provide tobacco dependence treatment     
 
6. Documentation in place to gather information of smoking 
history from patients 
 
   
7. Consult form or other documentation in place to assess 5As 
delivery 
   
 
8. Processes to follow-up tobacco users for at least one month 
after clinic visit in place. 
   
 
9. Process to evaluate quality or program implementation in 
place  
   
 
10. Processes to provide feedback to clinicians about 
performance in place. 




Include Samples of the Following if applicable:  
 
 Current Questions for assessing smoking status of patients and other characteristics of smokers 
 
 Current Waiting Room Screeners/Questionnaires 
 
 Current Smoking Consult Forms 
 
 Current practices for addressing smoking with patients  
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Appendix N - FC Group Provider Consult Form  
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Appendix O – FC Group Quit Plan 
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Thank you for taking part in this survey.  Please read and respond to the questions below which 
relate to your smoking history and visit to the clinic today.  By responding to this survey you are 
in no way obligated to make any changes to your smoking habits.  We are simply conducting an 
assessment of how clinic staff address smoking with their patient’s before and after they receive 
training and implement new processes in the clinic.  Please be honest when answering the 
questions, it is the best way for us to evaluate the success of the program.  
 
The survey should take about 10-15 minutes to complete.  Please speak to the research 
assistant if you have any questions or concerns about any of the survey questions.  
 
Thank you for your assistance.  
 
ABOUT YOUR VISIT TO THE CLINIC TODAY  
 
1. Have you completed this survey before?  
  Yes 
  No 
  Don’t know 
 
2.   a) Did your doctor ask
 
 you about your smoking status? (This includes any surveys 
you may have filled out) 
 Today:    In the Last Year: 
 Yes    □   Yes 
 No    □   No 
 Don’t Know   □   Don’t know 
 
b) Did another member of the clinic staff ask
 
 you about your smoking status? (This 
includes any surveys you may have filled out) 
Today:    In the Last Year: 
 Yes    □  Yes   
 No    □  No 
 Don’t Know   □  
Don’t know 
3. a) Did your doctor advise
Today:     
 you to quit smoking? 
 Yes 
 No 
 Don’t Know  




SMOKING AND YOUR FAMILY DOCTOR STUDY 
PATIENT SURVEY 
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b) Did another clinic staff member advise
 
 you to quit smoking? 
Today:     
  Yes 
  No 
  Don’t Know 




4.  a) Did your doctor ask if you were interested in quitting smoking
 
? 
Today:     
  Yes 
  No 
  Don’t Know 
 





     b) Did another clinic staff member ask if you were interested in quitting smoking
 
?
Today:     
  Yes 
  No 
  Don’t Know 
 




5.  a) Did your doctor offer you assistance
 
 in quitting smoking? 
Today:     
  Yes 
  No 
  Don’t Know 
 
In the last year: 
  Yes 
  No 
  Don’t Know 
     b) Did another clinic staff member offer you assistance 
       
in quitting smoking? 
Today:     
  Yes 
  No 
  Don’t Know 
In the last year: 
  Yes 
  No 
  Don’t Know 
6.  How long did the doctor or nurse speak to you specifically about quitting smoking today
 
? 
 Not at all 
 Less then 2 minutes 
 2-5 minutes 
 5-10 minutes 
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7.  Did your doctor or other staff provide you with written materials about quitting smoking? 
 
Today:     
  Yes 
  No 
  Don’t Know 
 












9.  a) Did your doctor discuss with you available smoking cessation medications (like the 





 Don’t Know 
 




b) Did another member of the clinic staff discuss with you available quit smoking  
medications? 
 
Today:     
 Yes 
 No 









10. Did your doctor or another member of the staff provide you with a prescription or 
recommendation to use one of the smoking cessation medications listed above? 
 
Today:     
 Yes 
 No 














11. Did you schedule a follow-up appointment to discuss your smoking? 
  Yes, please indicate date:____________________________ 
  No 
  Unsure  
 
12. How important is your doctor’s advice to quit smoking in motivating you to want to 
quit?  
  Very important 
  Important 
  Somewhat important 
  Not at all important  
 
13. How important is the advice of other clinic staff (e.g. nurse) in motivating you to want 
to quit smoking?  
  Very important 
  Important 
  Somewhat important 
  Not at all important  
 
14. How satisfied were you with the support provided to you on smoking cessation while 
in clinic today
  Extremely satisfied 
? 
  Very satisfied  
  Satisfied  
  Somewhat satisfied 
  Not at all satisfied 
 
15. How helpful were the clinic staff to you today
  Extremely helpful 
 as it relates to addressing smoking? 
  Very Helpful  
  Helpful  
  Somewhat helpful 
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SOME INFORMATION ABOUT YOU  
 
16. How many years of formal schooling have you completed? (please circle the 
appropriate number)  
1    2    3    4    5   6    7   8            9   10   11   12   13            14  15  16   17   18   19   20   21   22    23 
      grade school                               high school                                       college/university 
  
17. Do you have any of the following conditions?:  
Heart Disease           Yes       No       Don’t Know  
Heart Attack            Yes       No       Don’t Know 
Heart Failure             Yes       No       Don’t Know 
Stroke or Transient Ischemic Attack       Yes       No       Don’t Know 
Diabetes           Yes       No       Don’t Know 
Cancer           Yes       No       Don’t Know 
Chronic Bronchitis          Yes       No       Don’t Know 
Chronic Obstructive Pulmonary Disorder      Yes       No       Don’t Know 
High Blood Pressure         Yes       No       Don’t Know 
High Blood Cholesterol          Yes       No       Don’t Know 
Depression            Yes       No       Don’t Know 
Anxiety            Yes       No       Don’t Know 
Mental Illness       Yes       No       Don’t Know    prefer not to answer      
HIV/AIDS                     Yes       No       Don’t Know     prefer not to answer 
 
18.  What was the purpose of your visit today? 
  Annual visit    
  Follow-up 
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YOUR SMOKING HISTORY  
 
Age:     _______________years 
 
Your Sex:       Male          Female 
 
On average how many cigarettes do you smoke per day? ___________cigs/day 
If you do not smoke daily provide cigarettes you smoke per month _________cigs/month 
 
How many years have you been smoking? _____________years 
 
How soon after you wake up do you smoke your first cigarette? 
  After 60 minutes  
  31-60 minutes  
  6-30 minutes  
  Within 5 minutes 
 
How many quit attempts (lasting >24 hours) have you made in the past year? 
    No attempts 
    1-2 attempts 
    3 or more attempts 
 
Do others smoke in your home? 
  Yes  
  No  
 
Are you exposed to second-hand smoke in your home or another place where you  
      spend a lot of time? 
  Yes  
  No  
 
Which of the following best describes your feelings about smoking right now? 
 I would like to quit in the next 30 days 
 I would like to quit in the next 6 months 
 I am not planning on quitting in the next 6 months 
 
On a scale of 1 to 10 how confident are you that you would be able to quit smoking at 
this time? (1=not at all confident, 10=extremely confident) circle your response 
1 2 3 4 5 6 7 8 9 10 
 
On a scale of 1 to 10 how important is it to you to quit smoking at this time?  
(1=not important at all, 10=extremely important) circle your response 
1 2 3 4 5 6 7 8 9 10 
 
Thank you very much for taking the time to complete this survey.  Please return the 
survey to the research assistant.  Have a good day! 
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CONTACT INFORMATION SHEET 
 
 
In order for us to contact you in four months time for the brief telephone interview, 
please provide us with the following information.   
 
The best number to contact you is: (           )  _____________________________ 
 
This is your number at:   home    work    cellular 
 
An alternate telephone contact is: (             )______________________________ 
 




Please indicate the best time to contact you: 
 




Please indicate the best day of the week to contact you:  
 




Your Mailing Address:  
 
Street:______________________________     Apt:________________ 
 
City:_______________________________      Province: ___________ 
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Appendix R - 16-week Telephone Interview Script and Log Form 
 
PRACTICE ID NUMBER:  ______________ 
 
STUDY ID NUMBER:  _____________ 
 





  Not Completed 
  Partially Completed 
  Completed  
 
 
TELEPHONE SCRIPT AND RESPONSE LOG  
 
“Good Morning/Afternoon/or Evening. My name is ________________ and I am calling from the 
University of Ottawa Heart Institute. May I please speak with Mr/Mrs/Ms X?” 
 
If patient not at home
“Thank you.  We would like to reach Mr/Mrs/Ms X.  We will try again later.  If Mr/Mrs/Ms X 




Once patient is on the phone
“Good Morning/Afternoon/or Evening Mr/Mrs/Ms X.  This is _________ calling from the 
University of Ottawa Heart Institute in follow-up to the survey you completed in Dr. <insert 
doctors name> __________ office OR/ at the <insert clinic name>_________________back in 
_____________(state month).  Thank you again for participating in our study which will help us 
evaluate a new program being implemented at your family doctors office / <insert clinic name>.  
It has been 16 weeks since you helped us with completing the written survey in the waiting room 
of your family doctors office and we are calling to complete the follow-up survey.  This will take 
about 5-10 minutes of your time to complete.  
: 
 
Is this a good time for you to complete the survey?   
  Yes - If Yes: Complete remainder of survey  
  No - If No: No problem.  Perhaps you could let me know what would be the best time to 
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SECTION 1:  SMOKING STATUS 
 
“I have a series of questions for you related to your smoking habits.  There are no right or wrong 
answers.  In order to properly evaluate the program it is most helpful if you can be honest with 
your answers.  All the responses you provide to us will be kept confidential.”   
 
1. “Have you smoked any form of tobacco in the last 12 weeks?”  The response options 
are:  
  A) No not a puff 
  B) 1 to 5 cigarettes 
  C) More than 5 cigarettes  
 
2. “Have you smoked any form of tobacco (even a puff) in the last 7 days?” 




SECTION 2 – NOT SMOKING  
That’s great to hear you have been able to quit.   
 
3. “Do you recall the approximate date that you quit smoking?”  
      Day _____________________    Month __________________ 
 
4. “Did you use a quit smoking medication like the nicotine patch or varenicline or 
bupropion to help you quit smoking?” 
  Yes 
  No – Skip to question 6  
 
5.  “Which medication did you use?” 






6. “Have you sought/received counselling for smoking cessation from your primary  




7. “Have you attended any other smoking cessation program?” 
  Yes - Specify: ______________________________  
  No  
 
 
“Because this is a research study, it would be very much appreciated if you could provide us 
with a saliva sample to document that you are not currently smoking.  We would mail you a test 
kit to your home. Which only requires a few minutes to complete and we will provide you with a 
package to return the test to us at no cost to you.”    
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8. Are you okay with us mailing you the test kit and have you return it to us by mail?” 
  Yes  




 Provide instructions about mail-out of NicAlert test to participant’s home.  
Confirm mailing address and prepare kit to be mailed. 
Great.  I will be sending you the Saliva Sample Kit by mail. Instructions will be included – the 
test will take only a few minutes of your time to complete.   
 
9. Can you confirm that you are not presently using a nicotine patch, gum or inhaler.   
  ⁯Yes  
  No  
 
If yes, I see, because the saliva test will pick up on the nicotine in the product we would prefer 
to collect a breath sample from you. .  To take the breath sample we have you blow into a 
carbon monoxide machine and the machine gives us a reading.  The test takes less than a 
minute to complete. To obtain the breath sample we could have you come into the Heart 
Institute at the time of your choosing or we could arrange to have a staff member come to a 
public place in your community if that is easier for you.  
 
10. Are you okay with us arranging to take a breath sample? 
  Yes  
  No  - Skip to Question 20.  
 
11.  Can I also confirm that we have the correct mailing address – repeat address from 
contact sheet.  Is this correct:  
  Yes  
  No  
 
If NO: “May I have the correct address”.   
 
Mailing Address: _____________________________________ 
   _____________________________________ 
   _____________________________________ 
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SECTION 3:  FOR CURRENT SMOKERS 
 
(RESPONDED YES TO QUESTION 2)  
“We know quitting smoking can be difficult. I have a couple of questions for you about what’s 
happened since we last saw you at the clinic.”   
 
12.  Have you attempted to quit smoking since your clinic appointment on (indicate date            
of appointment)? 
  Yes  
  No – SKIP TO QUESTION 17 
  
13. “How soon after your quit date did you resume smoking?” 
      Date:________________  Month: _________________ 
 
14. “What would you say was the primary reason you went back to smoking?” 
      Answer: _______________________________________________________ 
 
15. “Did you use a quit smoking medication like the nicotine patch or varenicline or 
bupropion when attempting to quit?” 
  Yes 
  No – SKIP TO QUESTION 17  
 
16.  “Which medication did you use?” 
  Nicotine patch  
  Nicotine gum 




17. “How many cigarettes per day are you currently smoking?”  #:______________ 
     
18. “How would you describe your feeling about quitting smoking right now. Do you want 
to quit smoking in the next?” 
  7 days 
  30 days 
  6 months or  
  would you say you don’t want to quit smoking  
 
If patient enquires about support with quitting:  
If you are interested in assistance with quitting there several programs available to 
help you.  Please don’t hesitate to call the Smoking Cessation Counsellor at any time 
should you feel you need support or information at 613 761-4866. 
 
19. “Have you sought/received counselling for smoking cessation from your primary  








My final questions for you relate to your primary care doctor.  
 
20. Have you had an appointment with your doctor in the last 12-months? 
  Yes  
  No – SKIP TO QUESTION 24 
 
21. Has your family doctor or another member of the clinic staff advised you to quit 
smoking in the last 12-months? 




22. In the last 12-months has your doctor or another member of the clinic staff 
recommended to you about available quit smoking medications? 




23. In the last 12-months, has your doctor or another member of the clinic staff written 
you a prescription for a quit smoking medication? 




24. On a scale from 1 to 10 (where 1 is not at all important and 10 is very important) how 
important is your doctor’s advise and support in motivating you to want to quit smoking? 
 ANSWER:  _______________ 
 
25.  Are you satisfied with the support you receive from your doctor as it relates to 
smoking?  
  Yes 
  No  
  Unsure 
 
“That concludes the interview.  On behalf of the Heart Institute and Dr. <family doctor’s name> 
thank you again Mr/Mrs/Ms (last name) for participating in our smoking cessation program. 
 
IF WE ARE COLLECTING A CO TESTING: We appreciate your assistance with collecting the 
breath sample.  A reminder that we will <review details agreed to for sample collection including 
location, date, time.>” 
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Appendix S - Power Calculations 









0.3643 0.01 0.05 4/55 4/55 0.05 0.10 0.05 
0.8156 0.01 0.05 4/55 4/55 0.05 0.15 0.10 
0.9760 0.01 0.05 4/55 4/55 0.05 0.20 0.15 
0.9985 0.01 0.05 4/55 4/55 0.05 0.25 0.20 
1.00 0.01 0.05 4/55 4/55 0.05 0.30 0.25 
0.2495 0.01 0.05 4/55 4/55 0.10 0.15 0.05 
0.6670 0.01 0.05 4/55 4/55 0.10 0.20 0.10 
0.9258 0.01 0.05 4/55 4/55 0.10 0.25 0.15 
0.9919 0.01 0.05 4/55 4/55 0.10 0.30 0.20 
Grey highlight = power > 80% 
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Appendix T - Effect estimates of published multi-component intervention studies 
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ppa 12 - Training 
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-  Cost-Free 
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>100 cigs in 
lifetimes 
irrespective of 
intentions to quit 
Not 
reported 
















appa = point prevalence abstinence; co = continuous abstinence 
bFollow-up reported in months
 
    243 
 
Appendix U - Patient Invite Letter and Eligibility Screener 
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Student Investigator: Sophia Papadakis, MHA, PhD candidate  Tel. 613-761-5489 
University of Waterloo Health Studies and Gerontology: 
 Paul McDonald, PhD          Tel. 519-888-4567 ext. 35839
  
    Roy Cameron, PhD.           Tel. 519-888-4567 ext. 84503
  
    Stephen Brown, PhD           Tel. 519-888-4567 ext. 35500
  
University of Ottawa Heart Institute Minto Prevention and Rehabilitation Centre:   
Andrew Pipe, MD            Tel. 613-761-4756 
    Robert Reid, PhD, MBA          Tel. 613-761-5058  
 
Please read this Information Sheet and Consent Form carefully and ask as many 
questions as you like before deciding whether to participate. 
 
You have been asked to participate in a research study being conducted by the University of Waterloo 
and the University of Ottawa Heart Institute with the support of your family doctor’s office.  The 
purpose of this study is to document how often your family doctor addresses smoking with his/her 
patients and the smoking status of patients in the 4-month period following their visit to the clinic.  We 
are surveying smokers who attend this clinic before and after implementing an intervention program.  
The intervention program is designed to help clinic staff with assisting patients who smoke with 
quitting. We hope this study will provide valuable information about how best family doctors can help 
their patient’s with quitting smoking.   
Introduction:   
 
If you agree to participate in the study you will be asked to complete the two phases of the study.  
Procedure: 
Phase One involves the completion of a brief survey following your visit with your family doctor.  
The survey will take approximately 5-10 minutes to complete.  The survey will collect information on 
whether or not your family doctor or another member of the staff provided information to you about 
smoking and if they offered you assistance with quitting.  Phase Two of the research involves a 
telephone interview in 4-months time.  The interview will take 5 to 10 minutes to complete and will be 
scheduled on a date and time that is convenient for you.  You will be asked about your smoking status 
Patient Information Sheet & Consent Form 
 
Comparative evaluation of two interventions 
for integrating smoking cessation into routine 
primary care practice: A cluster-randomized 
trial  
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and experiences with smoking over the past 3-months.  Because this is a research study we may ask 
patients who have been able to quit smoking to provide a saliva sample to confirm they have been able 
to successfully quit smoking.  To do so we would mail home saliva test kit to you along with return 
packaging at no cost to you.  The kit simply requires you to spit into a container and mail it back to us.   
You are under no obligation to quit smoking as part of this study.  
 
There are no risks associated with your participation in this study.  The time required to complete the 
10 minute survey and complete the 10 minute telephone follow-up interview may be an inconvenience 
to you.    
Risks and Discomforts of Participation: 
 
You may not receive any direct benefit from your participation in this research. Your participation in 
this research will allow the researchers to evaluate and refine a program for assisting family doctors in 
our region help their patients to quit smoking which may be of benefit for future patients.    
Benefits of Participation: 
 
There will be no financial remuneration for participation in this study.  By participating in the 




As part of this research protocol, the Investigators and their clinical research staff will have access to 
your survey and telephone interview responses.  Your responses may also be reviewed by 
representatives of the Heart Institute Human Research Ethics Board under the supervision of the 
Investigator.  You will not be identifiable in publications or presentations.  
Confidentiality: 
All information you provide will be considered confidential unless release is required by law.  Your 
survey and interview responses will be identified only by the study code you have been assigned.  The 
data collected will be kept in a secure location and confidentially disposed of in fifteen years time.  
Your individual responses will not be shared with your family physician or the clinic staff, so please 
feel free to be honest with your responses. 
 
Ethics:
This study has been reviewed and received ethics approval through the Office of Research Ethics 
(ORE) at the University of Waterloo and the Human Research Ethics Board (HREB) of the University 
of Ottawa Heart Institute.   These bodies consider the ethical aspects of research projects involving 
human subjects.  If you have any questions about your right as a research subject you may contact Dr. 
Susan Sykes, Director of the ORE at 519-888-4567, Ext. 36005 or the Chair of the Human Research 
Ethics Board at the University of Ottawa Heart Institute at 613-798-5555, extension 19865. 
  
 
Participation in research is completely voluntary.  You are free to choose to participate or not 
to participate in this research study.  If you agree to participate in this study, you may choose to 
withdraw your participation at any time by contacting the investigator at the telephone number 
provided.  This will not affect your present or future care.  You may also choose not to answer 
any specific questions. 
Participation: 
 













I understand that I am being asked to participate in a research study about the delivery of smoking 
treatments by staff working in my family doctors office.  This study has been explained to me by 
__________________________________.  
Consent to Participate in Research 
 
I have read and understood this two page Patient Information Sheet and Consent Form.  All my 
questions at this time have been answered to my satisfaction.  If I or any of my family members have 
any further questions about this study, we may contact Sophia Papadakis at 613-761-5489.   
 
I also understand that this project has been reviewed and received ethics clearance through the Office 
of Research Ethics (ORE) at the University of Waterloo and the University of Ottawa Heart Institute 
Research Ethics Board.  I may contact these office/boards with any questions or concerns. 
 
I will receive a signed copy of this Patient Information Sheet and Consent Form.  
 




























Consent Form  
 
Comparative evaluation of two 
interventions for integrating smoking 
cessation into routine primary care 
practice: A cluster-randomized trial 
  
 
 
 
